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Abstract 
Pulmonary vein isolation (PVI) is a recommended treatment for drug-refractory paroxysmal atrial 
fibrillation. However, success rates remain around 50-70% for a single procedure despite advances in 
mapping and ablation technologies. PV reconnection is found in almost all patients with AF 
recurrence and therefore improving lesion durability is the focus of technological developments such 
as robotic manipulation. We demonstrated that robotic-assistance improves catheter stability 
compared to manual catheter guidance during AF ablation, resulting in greater electrogram 
attenuation at matched RF settings. However, this has not translated into improved outcomes in 
recent non-randomised trials, which may reflect that we only studied acute lesions. Several recent 
studies suggest that late-gadolinium enhancement cardiac magnetic resonance imaging (LGE-CMR) 
can be used for studying chronic ablation lesions. We developed an automated LGE-CMR method to 
detect left atrial ablation scar and validated the technique by comparing co-located electrogram 
amplitude. A significant correlation between scar and endocardial low voltage was demonstrated. 
Interestingly, higher levels of pre-existing atrial scar were associated with lower success rates 
following ablation. Furthermore, whilst veins found to be isolated at the redo procedure had greater 
levels of ostial scar than reconnected veins, there was no difference in the amount of ostial scarring 
or the number of circumferentially scarred veins between patients with and without AF recurrence. 
This finding is in keeping with invasive studies which suggest that there is a significant degree of 
reconnection in asymptomatic patients and highlights inconsistencies in our understanding of PV 
mediated ectopy. It has been suggested that PVI inadvertently damages upstream regulators such as 
the atrial ganglionated plexi (GP) of the intrinsic cardiac autonomic nervous system and animal 
studies indicate that these may be potential targets for ablation to prevent AF. Continuous high 
frequency stimulation (HFS) of GPs produces AV block and this phenomenon has been used to 
identify and ablate the GPs as putative autonomic triggers for PV ectopy. However, animal studies 
have revealed a complex network of autonomic connections and these have not been investigated in 
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detail in humans. We found that the right lower GP is the final common pathway to the AV node and 
must remain intact if all other GPs are to be identified and ablated. Heart rate variability has been 
suggested as a potential endpoint for autonomic modification. Using a novel intraprocedural, short-
segment HRV tool, we found that the reduction in HRV following AF ablation occurs only after 
ablation of the right upper GP and therefore does not reflect the inputs from any other left atrial GP, 
precluding its use as an endpoint for left atrial denervation. Furthermore, it would seem logical to 
target the parts of the network that trigger PV ectopy rather than targeting GP sites that produce 
effects at the sinus node and AV node.  We developed a technique to identify sites initiating ectopic 
triggers and found that the response could be abolished either by achieving PVI or by targeted RF 
ablation to the site. This raises the possibility of targeted autonomic denervation of culprit sites of 
atrial ectopy as an alternative strategy to PVI. These findings should now be applied prospectively to 
assess their impact on outcomes from AF ablation. 
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1 Background 
1.1 Introduction 
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice and causes a 
significant burden of morbidity and mortality.1 Ectopic activity originating within the pulmonary 
veins is a widely recognised trigger for paroxysmal AF2, whilst electrical, contractile and structural 
remodelling of atrial myocardium are each important contributing factors to the arrhythmogenic 
substrate in persistent AF.3 The relative contributions of these mechanisms, the presence of 
additional foci, and the optimal therapeutic strategy across a spectrum of AF phenotypes has yet to 
be fully elucidated.  
The AFFIRM4 trial confirmed that maintenance of sinus rhythm with anti-arrhythmic drugs provided 
no mortality benefit over the use of rate controlling medication and anticoagulation. Catheter 
ablation, primarily targeting the ectopic triggers within the pulmonary veins, has since been 
developed as an alternative treatment strategy to maintain sinus rhythm. Whilst a recent expert 
consensus stated that pulmonary vein isolation (PVI) is the cornerstone of AF ablation, success rates 
from PVI are only 35-70% for a first procedure and 65-90% after multiple procedures.5 Furthermore, 
patients maintaining atrial fibrillation for more than 7 days (persistent AF) have success rates for 
catheter ablation that are almost invariably lower.  
Additional ablative targets have been attempted by many centres in an effort to “target atrial 
substrate” in these patients. However, lack of procedural endpoints, varied and complex anatomical 
navigation and a narrow window between durable myocardial destruction and unintentional extra-
cardiac damage, remain significant clinical challenges. Pulmonary vein reconnection after ablation is 
thought to contribute to the majority of recurrent episodes of AF in paroxysmal AF. Whether this is 
due to lack of transmural lesion creation, lack of contiguous lesions placement around the veins or 
other theoretical mechanisms such as myocardial re-growth has not yet been determined. 
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It has been suggested that “preoccupation with methods for eliminating or isolating the PV triggers 
in the clinical laboratories has diverted attention from the mechanisms triggering AF in the PVs and 
the substrate for sustaining AF”6 and that “whether the PVs are responsible for the duration of 
paroxysms is less certain. To better understand the electropathology of paroxysmal AF, we must 
determine whether a patient primarily has a trigger problem, a substrate problem, or both”.7 
This thesis was initiated on this background to re-evaluate the relationship between the technical 
challenges of PV isolation and the mechanisms of AF initiation and substrate. 
 
1.2 The Electrophysiological Mechanisms of Atrial Fibrillation  
1.2.1 Historical concepts 
The first description of atrial fibrillation was made by Harvey in 1628, who described the undulation 
of the right auricle (atrium) in a dying horse heart, long after all normal beating has ceased.8 In 1876, 
Nothnagel published arterial tracings typical of this irregular heartbeat and introduced the term 
“delirium cordis”, which he described as a state of anarchy of the heart akin to delirium of the brain. 
In 1894, MacKenzie studied the character of venous pulse with the aid of the polygraph and showed 
that the initial wave was secondary to atrial contraction whilst the second resulted from ventricular 
contraction.9 During later studies, he demonstrated, in patients with severe mitral stenoses, when 
the irregular pulse supervenes, no signs of atrial activity could be detected in the venous pulse which 
subsequently returns when the pulse becomes regular again.10 These observations were 
corroborated by publication of electrocardiographs of AF and led to the additional diagnostic criteria 
of AF as the presence of an irregular baseline on the surface electrocardiogram, occasionally 
demonstrating irregular f-waves, but without organised atrial activity and irregularly timed QRS 
complexes, as demonstrated in Figure 1.1.11 12  Early in vitro and animal studies proposed a number 
of mechanisms for the clinical state of atrial fibrillation as described in the following sections. 
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Figure 1.1  The first electrocardiograph of AF, showing the presence of f-waves and absent p waves.  
Adapted from Herring 
 
The Multiple Heteropous Theory 
In 1914, Garrey made the observation that the ease with which a chamber could fibrillate was 
proportional to its mass. Large mammal ventricles would fibrillate with considerable ease and rarely 
spontaneously terminate, whereas small mammal ventricles or the smaller “auricular” chambers of 
large mammal hearts would rarely fibrillate and often stopped fibrillating spontaneously.13 Studies 
investigating the pathophysiology of atrial arrhythmias began in the late 19th century. Based on 
experiments of electrical currents on strips of myocardium, the earliest concept proposed to explain 
the nature of AF was the multiple heteropous centres theory.14 This states that each cardiac fibre 
could become independently rhythmic, forming a focus with its own impulse formation as a result of 
increased excitability. Such activity from one or more heterogeneous centre would be able to 
account for premature beats and regular tachycardias, as well as the completely in-coordinate 
activity seen in AF.15, 16  
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Mother wave theory 
During canine studies of induced atrial flutter, Lewis observed a group of atrial tachyarrhythmias he 
termed “impure flutter” with flutter-like p-waves on the surface ECG but with a variable cycle length 
and p-wave axis. Some “impure flutters” with the most variable cycle lengths resembled AF on 
surface ECG.17 Combined with earlier work demonstrating that myocardial conduction and refractory 
period were rate dependent, Lewis proposed a model of AF based on a meandering central or 
mother wave, moving in multiple directions and emitting centrifugal or daughter waves along its 
course dependent on local tissue excitability.18 This remained the dominant theory underlying the 
mechanism of AF for many decades. 
 
Multiple wavelet hypothesis 
In 1959, Moe developed a canine model of AF using a combination of atrial pacing and simultaneous 
vagal stimulation, which could sustain AF for much longer periods. He demonstrated that the atria 
continued to fibrillate despite termination of atrial pacing as long as vagal stimulation was 
maintained.19 Although this did not disprove the Mother wave hypothesis, Moe argued that since 
vagal stimulation significantly increases the dispersion of refractoriness in the atria, a single large 
wave of excitation would be unlikely to remain intact. Instead, he hypothesised that a central wave 
of activation was likely to fragment into multiple wavelets and, provided a sufficient number of 
wavelets were present, then the atria would continue to fibrillate.  Enlarged atrial chamber size and 
heterogeneous atrial refractoriness were therefore identified as characteristics predisposing to the 
maintenance of AF.  
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1.2.2 Current mechanistic understanding of atrial fibrillation 
 
 
 
Figure 1.2 Summary of our current understanding of the combined mechanisms leading to atrial 
fibrillation. Taken from: HRS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial 
Fibrillation 
(A) Schematic drawing of the left and right atria as viewed from the posterior. Shown in yellow are 
the four major LA autonomic ganglionic plexi and axons (superior left, inferior left, anterior right, and 
inferior right). (B) Large and small re-entrant wavelets that play a role in initiating and sustaining AF. 
(C) Common locations of PV (red) and also the common sites of origin of non PV triggers (shown in 
green). (D) Composite of the anatomic and arrhythmic mechanisms of AF.20 
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1.2.3 Arrhythmogenicity of pulmonary veins 
In 1998, Haissaguerre reported the seminal observation that early, spontaneous depolarisations 
originating from within the left atrial pulmonary veins initiated AF in humans. Patients with drug-
refractory AF and frequent paroxysms of AF were enrolled for electrophysiological studies to 
determine the mode of AF initiation.2 Roving quadripolar catheters were placed via patent foramen 
ovale or transeptal catheterisation, up to 4cm within the PVs. AF was initiated by single ectopic foci 
in a minority of patients, and a short burst of 2 or more repetitive focal discharges or both 
mechanisms, in the majority. 
Haissaguerre, was able to demonstrate that ectopic foci were travelling in a distal to proximal 
direction in relation to the mapping electrodes placed within the veins, whereas during normal sinus 
rhythm the same region of PV musculature could be seen to activate passively, from proximal to 
distal.2 Myocardial sleeve length and thickness measured in all pulmonary veins in patients with AF 
and controls were found to be greater in the superior and left-sided PVs compared to the inferior 
and right-sided PVs, with no difference noted in these measurements between AF patients and 
controls.21 However, electrophysiological properties of PVs in patients with AF were found to be 
significantly different from those of the PVs in control patients. Shorter effective refractory periods 
(ERP) were found in the PVs in patients with AF compared to the PVs in control subjects. The PV ERP 
was also found to be shorter than the LA ERP in patients with AF, whereas in the control group it was 
found to be longer in the PV. Greater decremental conduction from the PV to the left atria was 
noted in patients with AF compared to controls, along with a greater propensity for pulmonary 
venous extra stimuli to initiate AF.22  
It is not clear from these studies, whether these changes applied to all PVs in patients with AF or 
whether some veins exhibited these changes whilst others did not. Haissaguerre defined 
arrhythmogenic PVs on the basis of documented ectopy: single or multiple, isolated or initiating AF, 
with or without conduction to the left atrium, observed spontaneously or after provocative 
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manoeuvres.23 He also noted that patients with single arrhythmogenic PVs were a younger age,  had 
a smaller LA size and a shorter history of AF compared to patients with multiple arrhythmogenic PVs, 
however this observation does not differentiate cause from effect.23 
During rapid ventricular and atrial pacing in animal models, pulmonary veins are seen to undergo a 
pro-arrhythmic process of remodelling, resulting in an increase in automaticity and triggered 
activity.24, 25 Cardiomyocytes from the pulmonary veins of rapid atrially paced dogs exhibit a shorter 
action potential duration (surrogate for effective refractory period) and an increased incidence of 
spontaneous tachyarrhythmias compared to controls, suggesting that the arrhythmogenicity of the 
PVs may have been increased by prolonged atrial pacing.26, 27  
The exact mechanism of pulmonary vein arrhythmogenicity in humans however remains to be 
elucidated. Furthermore it is not clear whether arrhythmogenic pulmonary veins cause sustained 
atrial fibrillation or whether a susceptible substrate is required for ectopic firing within PVs to lead to 
sustained paroxysms of AF, which in turn may lead to electrical remodelling within the pulmonary 
veins.  
1.2.4 The Atrial Substrate for maintenance of Atrial fibrillation 
Allessie and co-workers proposed that fibrillation itself may cause progressive changes to the atria 
which promote the perpetuation of the arrhythmia. This was based on observations that up to one 
third of patients have no apparent underlying structural heart-disease, a high proportion of patients 
progress from paroxysmal to persistent AF and AF termination is harder to achieve in patients who 
have been in AF for a long time.3 This hypothesis was elegantly demonstrated during a series of 
experiments in goats in which progressively longer periods of atrial fibrillation were maintained 
artificially with rapid atrial pacing, leading to an increased susceptibility of the animals to AF 
induction and maintenance. These findings were associated with a number of electrophysiological 
properties which were termed “electrophysiological remodelling” including shortening of the atrial 
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effective refractory period and loss of the normal adaptation of refractoriness to changes in heart 
rate. These changes were found to be present after approximately 2-3 days of AF and were 
reversible within one week after restoration of sinus rhythm.  
Following the development of a chronic AF model in goats, the role of the following in the process of 
electrical remodelling was evaluated: (1) the autonomic nervous system, (2) ischemia, (3) stretch, (4) 
atrial natriuretic factor (ANF), and (5) rapid atrial pacing. Interestingly, it was found that electrical 
remodelling of the atria as a result of atrial fibrillation is not mediated by changes in autonomic 
tone, ischemia, stretch, or ANF. The high rate of electrical activation itself provides the stimulus for 
the AF-induced changes in AERP.28 Experimental evidence suggests that changes in AERP may be 
mediated in the short-term via functional changes such as Ca2+-induced inactivation of ICa, and that 
longer term changes may be mediated via down regulation of L-type Ca2+ channel proteins. 29, 30 
However, these findings remain to be confirmed in human AF. 
Nonetheless, there remained evidence of “structural remodelling” within the atria of the AF goats 
which lead to the induction of longer periods of AF, despite a period of 2-4 months in sinus rhythm, 
compared to goats that had always been in sinus rhythm. The structural myocardial changes 
included atrial myocyte hypertrophy, myocyte myolysis, loss of contractile apparatus, changes in 
mitochondrial shape and size and extra-cellular matrix protein deposition.31-33 Allessie noted that 
these structural changes lead to a loss of atrial contractility and transport function despite 
restoration of sinus rhythm and felt this may explain the increased clinical risk of atrial thrombus 
formation.3 
Similar changes have yet to be proven in humans, however electrophysiological properties have 
been studied in patients with lone PAF who had no arrhythmia in the week prior to the study, and 25 
control patients with left-sided accessory pathways. Patients with AF demonstrated larger atrial 
volumes,  longer ERP, longer atrial  conduction times, longer bi-atrial activation time, greater 
proportion of fractionated electrograms, longer corrected sinus node recovery time and lower atrial 
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voltage compared to controls.34These findings suggest that patients with lone PAF demonstrate 
structural myocardial changes, conduction abnormalities and sinus node dysfunction that likely 
predispose to the perpetuation of the arrhythmia. Clinical tools for identification and quantification 
of this underlying substrate are yet to be found, and would significantly enhance our understanding 
of the progressive nature of this disease. Such methods may have significant impact on the timing 
and success of interventional catheter ablation treatments. 
1.2.5 Fractionated atrial electrograms and the atrial substrate 
The presence of “complex fractionated atrial electrograms” (CFAE) during AF are thought by some to 
be reflective of an underlying arrhythmogenic atrial substrate. However their identification and 
electrophysiological basis remain unclear. Electrograms consisting of multiple “high frequency” 
components with low amplitudes and long duration, termed “fractionated,” were first recorded in 
patients with healed myocardial infarction during endocardial mapping.35 Several investigators 
thought these were artefactual due to movement between the catheter and myocardium. Although 
fractionated components may be caused by artefact, the majority of these electrograms are true 
reflections of underlying electrical conduction. Several theories have arisen around the 
pathophysiologic basis for CFAE and their role in the arrhythmogenesis of atrial fibrillation. These 
theories are based on a combination of observed spatial distribution, prevalence in different forms 
of AF, effect of autonomic modulation and most significantly the effect of ablation of CFAE on AF 
outcomes.  
 Konings et al were the first to describe fragmented atrial potentials in humans during unipolar 
mapping and demonstrate that they were present in regions of either slow conduction or areas 
where wavelets pivot. 36 Nademanee termed these signals complex fractionated atrial electrograms 
(CFAE) with an accompanying definition of low voltage atrial electrograms (ranging from 0.04 to 0.25 
mV) that are composed of two deflections or more, and/or have a perturbation of the baseline with 
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continuous deflection of a prolonged activation complex and/or have a very short cycle length (≤120 
ms) with or without multiple potentials.37  
Patients with long-standing PsAF were noted to have greater numbers and locations of CFAE than 
patients with PAF, however it is unclear whether this represents a cause or effect of PsAF.38-40 
Several studies have demonstrated that CFAE tend to localize in specific areas of the atria and do not 
meander, exhibiting temporal and spatial stability.41, 42 The development of an automated method 
for grading electrogram fractionation has facilitated investigation of the spatial distribution of 
different grades of fractionation.43 The following key areas appear to have a predominance of CFAE: 
proximal coronary sinus, superior vena cava-RA junction, septal wall anterior to the right superior 
and inferior PVs, anterior wall medial to the LA appendage, area between the LA appendage and left 
superior PV and postero-superior wall medial to the left superior PV.44  
High-density mapping of the dominant frequency (DF) and mean degree of CFAE similarly noted that 
86% of high DF recordings and 77% of continuous CFAE were located at the PVs or PV ostia. 
Interestingly, the majority of PVs associated with high DF or CFAE  were arrhythmogenic PVs 
(defined as PVs demonstrating ectopic foci or repetitive firing initiating AF).45 Further studies of the 
spatial distribution of CFAE with respect to the PV ostia have concluded that if ostial ablation lines 
were extended 10mm further into the LA then a significant majority of CFAE would be targeted, 
particularly in patients with PAF compared to PsAF. 
The combined use of heart failure models in sheep and computer simulated 2-D atrial models has 
suggested that the distribution of left atrial fibrotic tissue may influence electrogram fractionation in 
the left atrium.46 A study in a porcine model of AF went on to suggest that CFAE may be located at  
sites of underlying atrial fibrosis or areas of increased atrial muscle branching.47  However, there 
have been conflicting findings from a human studies demonstrating that CFAE areas were not within 
regions of low voltage during a paced rhythm, nor did they demonstrate any paced rhythm 
29 
 
fractionation or local conduction abnormalities, suggesting that CFAE may not localise to areas of 
atrial structural remodelling.48.  
A second theory for their existence and involvement in the pathogenesis of AF is that CFAE may be 
co-localised with autonomic ganglia. CFAE were found to be present at presumed GP sites in two 
thirds of patients compared with one third of patients with CFAE at other LA sites. The likelihood of 
finding CFAE at each of the 4 left atrial GP sites ranged from 30-60% with no significant differences 
highlighted between GP sites.49 However, this was not a functional study confirming the existence of 
active GPs at the presumed anatomical locations. 
During open-chested studies in dogs GP stimulation or myocardial “painting” with acetylcholine 
induced intermittent or continuous CFAE.50 Fast-fourier transform analysis identified that CFAE 
exhibited progressively decreasing incidence and dominant frequency with increasing distance from 
GP sites. Ablation of GPs markedly attenuated CFAE and eliminated these gradients, suggesting an 
autonomic basis for CFAE formation.51 
To further investigate this association, the prevalence of CFAE was measured in humans in the left 
and right atria in patients undergoing AF ablation. A significant decrease in the prevalence of CFAE 
was noted in patients with PAF but not PsAF following autonomic blockade with atropine and 
metoprolol, suggesting that CFAE in humans are at least in part influenced by the activity of the 
ANS.40  However this only appeared to be true for patients with a prolongation in the AFCL in 
response to autonomic blockade.52 The dependence of CFAE on atrial cycle length has been 
previously reported. The investigators noted that fractionated atrial electrograms demonstrated 
dynamic changes dependent on the local atrial cycle length, with shortening of the local AFCL 
frequently preceding the development of CFAE.53 The capability of the ANS to effect local changes in 
the atrial refractory period has previously been demonstrated in dogs54 and it may be via this 
mechanism that it influences the presence of CFAE.  
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Fractionated signals during sinus rhythm (SRF) have also been studied. Concomitant CFAE and SRF 
maps obtained in patients with AF, however, demonstrated that there was no correlation between 
these anatomical areas on the two maps. Furthermore, SRF maps were compared between patients 
with AF and control subjects, and the regions were found to be similar in the two groups, suggesting 
that the presence and distribution of SRF was unrelated to the appearance or maintenance of AF 
and therefore may not be a suitable target for ablation.55 However, one study performed in patients 
with PAF, found that sites of high-amplitude, fractionated electrograms in sinus rhythm (>4 
deflections and >40ms duration), were associated with parasympathetic responses to RF ablation, 
including atrial-His interval prolongation and slowing of the sinus rate.56. Evidently, the role of the 
autonomic nervous system in the generation of electrogram fractionation, both in AF and sinus 
rhythm, remains to be fully elucidated. 
 
1.2.6 The Role of the Autonomic Nervous System in the pathogenesis of AF 
Autonomically-mediated AF has been well described in the literature. Coumel described both vagally 
mediated AF, often among young males with structurally normal hearts who noted symptoms 
principally at night, after larger meals and during periods of relaxation, and adrenergically mediated 
AF, often seen in patients with structurally abnormal hearts and during periods of increased physical 
stress.57 It is not clear, however, what proportion of PAF is vagally mediated or whether progression 
to PsAF may also be influenced by the activity of the autonomic nervous system in humans. 
Adrenergic and cholinergic nerve fibres innervate the pulmonary veins terminating in autonomic 
ganglia (GPs) at each of the 4 PV-LA junctions.58  According to anatomical descriptions made by 
Armour et al the GPs are located as shown in Figure 1.3  Superior right atrial plexus (adjacent to the 
right upper pulmonary vein). Superior left atrial plexus (adjacent to the left upper pulmonary vein). 
Posterior right atrial plexus (in between the right sided pulmonary veins) Postero-medial left atrial 
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plexus (adjacent to the right lower pulmonary vein) Postero-lateral left atrial plexus (adjacent to the 
left lower pulmonary vein).59 For the purpose of this thesis the GPs will be referred to by the current 
most widely used nomenclature of right upper GP (RUGP), right lower GP (RLGP), left upper GP 
(LUGP) and left lower GP (LLGP). 
Figure 1.3 Anatomical locations of the epicardial ganglionated plexi. Adapted from Armour et al, 1997 59 
 
Vaitkevicius studied 35 intact human pulmonary vein–left atrial complexes stained for 
acetylcholinesterase to examine the patterns of autonomic innervation. He was able to demonstrate 
that epicardial nerves penetrated the pulmonary vein walls to form a network beneath the 
endothelium of the pulmonary veins.60 It was noted that the left and right superior pulmonary veins 
were innervated by a greater number of ganglia than the right and left inferior veins, which may be 
related to the clinical findings of Haissaguerre that the superior pulmonary veins exhibited a greater 
number of arrhythmogenic foci than inferior pulmonary veins.61  
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Autonomic nerve stimulation has been shown to produce both the trigger for AF and also promote 
atrial substrate changes which allow for the maintenance of sustained periods of AF in animal 
models. Local stimulation of nerve endings in the PV promoted both the release of acetylcholine 
which shortened the APD, and the release of adrenergic neurotransmitters which induced early after 
depolarisations (EADs) leading to rapid, triggered  firing within the PV. The underlying mechanism 
for the EADs relates to the temporal mismatch between the very short APD and the longer lasting 
calcium transient in the PV myocytes.62, 63  
Studies in dogs have subsequently shown that high frequency stimulation delivered to the GP 
adjacent to the left upper pulmonary vein can lead to heart rate slowing and initiation of atrial and 
pulmonary vein ectopic activity, resulting in the induction of AF.63, 64 Furthermore, stimulation of the 
vagus nerve shortens the action potential duration of atrial myocardium and increases the 
dispersion of atrial refractoriness. As a result premature atrial wave fronts fractionate and 
degenerate into multiple independent wavelets during vagal stimulation often generating AF from a 
single atrial premature stimulus65.  
Importantly, high rate atrial pacing, or pacing from within the PV to mimic PV ectopic activity did not 
result in sustained AF unless concomitant stimulation of the local GP was performed.66 AF induced 
during high rate atrial pacing ceased almost immediately with cessation of atrial pacing, whereas if 
simultaneous vagal stimulation was applied, AF continued after the high rate atrial pacing was 
stopped and was maintained until vagal stimulation was discontinued.19 Furthermore, local injection 
of a neuronal blocker inhibiting ganglionic function resulted in the loss of AF inducibility.64 
An experimental canine model of AF was used to identify whether elimination of the PVs whilst 
leaving the GPs intact, or ablating of the autonomic ganglia leaving the PVs intact, was more 
effective at preventing vagally induced AF. Carbachol induced AF was not prevented by excision of 
the PVs, however ablation of all 4 autonomic ganglia adjacent to the PVs was effective in abolishing 
atrial refractory period shortening and induction of AF in response to cervical vagal stimulation.67 
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These findings would suggest that an ablative strategy targeting the autonomic ganglia in humans 
may potentially have more success in preventing AF episodes than the strategy of pulmonary vein 
isolation. 
Direct evidence of autonomic nervous system activation provoking episodes of AF in humans is 
limited. Heart rate variability, an indirect measurement of autonomic activity, has demonstrated 
specific patterns of autonomic modulation immediately preceding the onset of AF on 24 hour Holter 
recordings.68 69 Our group has demonstrated in humans that endocardial stimulation of GP sites 
provoking a vagal response at the AV node also produced a reduction in the local AF cycle length. 
This effect was predominantly seen in the local PV, with a decreasing effect seen with increasing 
distance from the site of stimulation.70 These findings would suggest a role for the autonomic 
nervous system in producing a susceptible substrate for the maintenance of AF in humans. Similarly, 
it was demonstrated that ectopic firing within pulmonary veins could be triggered via short bursts of 
endocardial stimulation synchronised to the atrial refractory period. In some cases, PV ectopy led to 
the initiation of AF, which provides further evidence in humans that the ANS may play a role in AF 
initiation.71 However, the effect of endocardial ablation on these responses, and to AF initiation and 
maintenance, has yet to be determined. 
 
1.3 Current Ablative Treatment Strategies for Atrial Fibrillation 
Non-pharmacological curative therapies are being developed by both electrophysiologists and 
surgeons, targeting either the atrial substrate maintaining AF or eliminating the initiating trigger, 
primarily within the pulmonary veins. More than a decade ago, Haissaguerre commented that 
“complete elimination of AF is presently achieved in 70% of the patients. It is anticipated that 
continued technological development will improve and facilitate this technique for curative 
treatment of AF.” This section describes the evolution of the surgical and catheter ablation 
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techniques for targeting the trigger and substrate of AF, demonstrating that despite significant 
advances in technique and technology, the success rates appear relatively static. 
1.3.1 Pulmonary Vein Ostial Isolation 
Haissaguerre demonstrated that the application of localised radiofrequency ablation to the origin of 
ectopic foci at a point within the PV resulted in a decrease in the amount of ectopy on post-
procedural Holter recordings and eliminated AF completely in 62% of the cohort without the use of 
drug therapy.72 These success rates for focal PV ectopy ablation were independently replicated in 
1999, however it was noted that 42% of ablated PVs developed a focal stenosis.21 The significant side 
effect of pulmonary vein stenosis through ablation within the PV was also noted by several other 
centres.73, 74 
In view of this, Haissaguerre described electrophysiologically guided ablation of arrhythmogenic PVs 
in which a multi-polar, circular mapping catheter was placed within the pulmonary vein to record 
distal pulmonary vein potentials (PVPs).Radiofrequency ablation of distal PVPs was performed by 
targeting the earliest activating proximal PVP in sinus rhythm or pacing from the distal coronary 
sinus or left atrial appendage.23, 75 Subsequent RF applications were performed if necessary at 
contiguous sites showing synchronous PVPs. The end point was elimination or dissociation of distal 
PV muscle potentials and elimination of ectopic beats, spontaneous or induced by provocative 
manoeuvres (vagal manoeuvres, isoproteronol, adenosine and burst pacing). This endpoint 
predicted a more successful outcome than acute ectopy suppression. Interestingly, it was noted that 
the success rate decreased with increasing numbers of arrhythmogenic PVs identified. 23  
However, despite the use of provocative manoeuvres to initiate ectopic firing within the PVs, 
identification of arrhythmogenic pulmonary veins remained a significant and time consuming 
challenge. Groups moved towards empirical isolation of all 4 pulmonary veins, with similar success 
rates (70% AF freedom in PAF patients and 22% in PsAF). 76 In fact, it was demonstrated through a 
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randomised approach that there was no difference in outcome when a strategy targeting the 
arrhythmogenic PV was compared with ablation of all 4 PVs (71% vs. 75% AF freedom 
respectively)77. 
1.3.2 Wide Area Circumferential Ablation 
Pappone first described the method of circumferential pulmonary vein ablation in 2001. He 
described encirclement of pulmonary veins in pairs approximately 1-2cm outside the PV ostia. The 
end point of ablation was signal amplitude reduction by more than 80% and / or an absolute value of 
<0.1mV at ablation sites.  He described single procedure success rates of 85% for patients with PAF 
and 68% for patients with PsAF.78 Incremental success rates using this method versus PVI were also 
reported by other centres, albeit not to the same degree.79 Pappone proposed that the incremental 
success rates were due to additional electrical and structural remodelling within the atrial substrate, 
substantiated by evidence from his study that all patients without AF recurrence showed preserved 
and/or improved LA contraction, along with a significant reduction in post-ablation LA size versus 
pre-ablation.78 However it is not clear whether the remodelling is simply due to restoration of sinus 
rhythm following successful ablation, as a 10-20% reduction in left atrial size following successful 
ablation using the segmental ostial PVI approach has been reported by other centres.80-82 
Furthermore, the reduction in LA size following segmental PVI was correlated with the reduction in 
ostial PV diameter, therefore it is unclear whether LA shrinkage after ablation may also be attributed 
to contraction of scarred atrial tissue.81 On the other hand, there is evidence that in a mixed 
population of PAF and PsAF patients, CPVA is superior to PVI in patients with enlarged atria (left 
atrial volume index of >27cc/m2),83 which may support Pappone’s proposal. 
It is interesting to note that despite placement of apparently coalescent ablation lesions during CPVA 
(without additional ostial PV targeting) electrical pulmonary vein isolation is only achieved in 
approximately 50% of veins,84 with 80% of patients acutely having one or more PV with incomplete 
electrical isolation.85 It has also reported that freedom from AF following CPVA was not dependent 
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on the number of PVs with complete electrical isolation (determined acutely).85 Similar results were 
reported in a larger cohort of 643 patients (85% PAF) using a steerable sheath for completion of 
CPVA, without attempting to achieve electrical PV isolation. Again, the presence of complete PVI was 
not predictive of freedom from AF in this cohort.86 In a subsequent randomised study comparing the 
use of a steerable vs. non-steerable sheath, achieving complete PVI was one of several univariate 
predictors of AF freedom, however, on multivariate analysis, use of a steerable sheath was the only 
independent predictor of freedom from AF.87 They hypothesised that the quality of lesions created 
within a CPVA may have greater relevance than achievement of PVI at the time of the procedure. 
This hypothesis is supported by the findings of a study which compared achievement of PVI via 
aggressive CPVA with that of modified CPVA, in which additional ostial ablation of the PVs was 
performed to achieve PVI. They found a significantly greater freedom from AF in the aggressive 
CPVA group, again suggesting that perhaps the method of achieving PVI is more important than the 
endpoint of PVI.88  
However, there is no follow up data in either study at the redo procedures to identify whether 
patients in the steerable sheath group or the aggressive CPVA group were simply more likely to have 
durable PVI or whether the PV reconnection rates were similar between the 2 methods. When 
investigated prospectively, patients in whom electrical PVI was assessed using a circular mapping 
catheter with additional targeted ablation performed following CPVA, appeared to have greater 
freedom from AF compared to CPVA alone.89 It is not clear whether this improvement is due to a 
reduction in PV reconnection, or whether additional ablation around the PV ostia may provide 
benefit via another mechanism. Nonetheless, there remains the “second factor” hypothesis 
proposed to explain the improved success rates of CPVA over ostial PVI, namely that the CPVA may 
produce inadvertent local autonomic denervation given the overlap between the CPVA lesion set 
and recognised location of the left atrial autonomic ganglia. 
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This hypothesis was investigated in a prospective study that randomised patients to PVI or CPVA, 
with HRV parameters analysed on 24hr Holter recordings pre and post ablation proposed as a 
measure reflective of autonomic denervation. The number of reconnected PVs present in patients 
returning for repeat procedures were also investigated. Interestingly, no significant differences were 
noted in HRV parameter changes between the two techniques, however, they did notice a reduction 
in the number of reconnected veins identified at the repeat procedure in patients who had been 
treated with CPVA. On multivariate analysis, the CPVA technique, higher LF/HF ratio and lower HF 
parameters of HRV were independent predictors of AF freedom.90  The investigators concluded that 
vagal modification may prevent PAF recurrence independent of the technique used to achieve PVI. 
In this and Pappone’s study, a greater reduction in HRV parameters following ablation appeared to 
be predictive of freedom from AF, however, it is not clear what the role of left atrial GPs might be in 
producing this HRV change. If ablation of each GP had an incremental effect on HRV parameters 
then it would seem likely that a greater reduction in HRV would be seen following the CPVA 
technique compared with PVI.  
1.3.3 Linear Ablation within the Left Atrium 
Following the success of the surgical Cox Maze procedure, 91 several electrophysiology groups 
attempted to recreate this procedure using linear endocardial RF ablation. However, these 
procedures were long, achieved only moderate clinical success and suffered from a high rate of 
significant procedural complications.92 This strategy was largely abandoned by electrophysiologists 
following the discovery by Haissaguerre that ablation of the ectopic foci within the PVs was an 
effective strategy for preventing recurrent AF. However, as the success rates achieved by targeting 
the PVs alone remained approximately 50 -70% for PAF and lower for PsAF, some operators have 
gradually returned to the strategy of targeting additional areas within the LA in an attempt to 
improve procedural success. 
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A study by the Bordeaux group demonstrated that left atrial roof line ablation could achieve block in 
96% of cases and the addition of a roof line to PVI, in a randomised comparison of a mixed AF 
population, resulted in a greater freedom from AF (87% vs. 69% treated with PVI alone).93 Roof line 
ablation in this study resulted in an additional 19 ± 7 mins procedure time. However, it remains 
unclear whether patients with PAF alone benefit from the addition of a roof line, or whether this 
should be reserved for patients with PsAF.  
A further study by the same group demonstrated in patients with PAF that performing a mitral 
isthmus line and achieving conduction block, in addition to PVI and cavotricuspid isthmus ablation, 
resulted in an increased rate of freedom from AF.94  However, other groups have not been able to 
demonstrate any difference in success rates following the addition of a mitral isthmus line to CPVA.95 
In fact, one group found no difference in arrhythmia recurrence between PAF patients treated at 
their first procedure with segmental PVI alone compared with extensive ablation (CPVA +  roof + 
mitral line). In addition, the incidence of left atrial flutter was higher in the latter group.96 Certainly, 
if roof or mitral isthmus ablation is performed but permanent block is not achieved, then recurrent 
atrial flutter is more likely to occur than if linear ablation had not been attempted.97, 98 There is 
therefore no clear evidence that widespread use of linear ablation within the left atrium in patients 
with PAF provides benefit over PVI alone.  
 
1.3.4 Ablation of Complex Fractionated Atrial Electrograms 
Ablation of CFAE was first described by Nademanee, who achieved excellent clinical success rates in 
a study of 338 patients with either PAF or PsAF treated with CFAE ablation alone. 93% PAF patients 
and 87% PsAF patients were free from AF/AT after one or more procedures in this study. However, 
other centres have not been able to reproduce these results with CFAE ablation alone. One study of 
PAF patients achieved only a 9% success rate following ablation of CFAE alone, compared with 41% 
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success following CFAE + PVI.99 Interestingly, some studies have shown an additional benefit in PAF 
patients of a strategy of CFAE targeted ablation following PVI if they remain inducible for AF 
following PVI; 73% vs. 84% respectively.100 However, a meta-analysis of CFAE ablation in addition to 
PVI demonstrated that adjuvant CFAE ablation increases the success rate of AF freedom in non-
paroxysmal AF patients but does not provide additional benefit to in PAF patients.101 
However, significant interest in CFAE was generated when these regions were shown to be 
associated with AFCL prolongation or acute AF termination when specifically ablated.  AFCL has been 
shown to be associated with duration of the arrhythmia and ease of catheter ablation therapy to 
terminate AF. Furthermore biophysical computer simulation models have suggested an inverse 
relationship between the number of focal sources maintaining AF and the AFCL.102 However, 
whether there is a relationship between CFAE and focal sources of AF is not yet known.  
When electrogram characteristics associated with AFCL prolongation during CFAE ablation were 
analyzed,103 dominant frequency and electrogram amplitude appeared to have no effect, whereas 
fractionated activity for ≥70% of the recording was associated with AFCL prolongation. The effect of 
targeting the most or least complex electrograms first was also studied in a randomised fashion, and 
there appeared to be no difference in outcome between the two strategies. It was noted however, 
that following completion of the left and right CPVA, electrograms throughout the LA appeared to be 
less fractionated and the AFCL had prolonged. 104, 105  
The effect of CFAE ablation on outcomes, although mixed, does suggest that electrical isolation of 
the pulmonary veins may not be the only effective endpoint for ablation in PAF patients. Whether 
CFAE represent sites of autonomic innervation participating in the trigger and or substrate for AF, 
reflect areas of anisotropic muscle bundles, or are present due to areas of underlying scarred or 
fibrotic atrial myocardium contributing to heterogeneous conduction and non-uniform wave front 
activation, is not clear. However it is clear that ablation of these sites affects either the trigger or the 
substrate or both, as demonstrated by the prevention of recurrent AF episodes in previously 
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symptomatic patients. A clearer understanding of the mechanisms generating CFAE and more robust 
methods for their identification are likely to be required to achieve greater benefit from CFAE 
targeted ablation strategies. 
1.3.5 AF inducibility 
Ideally, if it were possible to identify patients with PAF in whom additional atrial substrate ablation 
may be beneficial, we could tailor our ablation strategies and improve procedural outcomes. 
Theoretically, the approach of performing AF inducibility testing following PVI would seem 
reasonable to predict those who had had sufficient ablation to prevent recurrent AF and those who 
had not. Several studies have investigated whether AF non-inducibility represents a suitable 
procedural endpoint in PAF patients and the results are conflicting. One study suggested that AF 
inducibility following CPVA was associated with both a lower bi-atrial voltage and an increased rate 
of recurrent AF.106 However, other studies conclude that although it can be associated with 
recurrent AF inducibility of an atrial arrhythmia following CPVA does not predict long-term 
procedural failure.107, 108 The low diagnostic accuracy of AF inducibility therefore suggests it is not a 
reliable procedural endpoint. This discrepancy may be due to the fact that successful PVI has the 
potential to result in atrial structural and electrical remodelling during a period of sinus rhythm 
which may prevent future AF recurrence, despite the substrate for AF maintenance remaining at the 
end of the ablation procedure. Therefore, at present, pre ablation investigations, including left atrial 
size109 and AF burden110, present the only clinical methods of identifying PAF patients with lower 
success rates following PVI. Whether these characteristics are sufficient to predict the efficacy of 
additional ablation targeting has yet to be studied.  
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1.3.6 Targeting Non-PV triggers 
The empirical use of pulmonary vein isolation to treat all patients with PAF perhaps ignores the 
potential for extra-pulmonary vein foci as the precipitant trigger for AF. Non-PV triggers responsible 
for initiating AF were identified in 28% of patients who were undergoing ablation for PAF in one 
study. Sites of non-PV triggers included the left atrial posterior free wall (LPFW) 38%, superior vena 
cava (SVC) 37%, the ligament of Marshall (LOM) 8%, the crista terminalis (CT) 4%, the coronary sinus 
os (CSO) 1% and interatrial septum (IAS) 1%. Ablation of these triggers alone (without PVI) resulted 
in complete freedom from AF off all AADs in 63% of patients.111 This success rate is remarkably 
similar to that of PVI as a treatment for PAF of suspected PV origin, with the efficacy of 
radiofrequency ablation perhaps being the common factor influencing long-term outcome. In a 
larger, retrospective cohort in 2008, 13% of patients with PAF or PsAF had non-PV triggers identified 
either with or without the use of isoproteronol.112 In patients undergoing redo AF ablation, the 
presence of non-PV foci was determined as the likely cause for recurrent AF in 18% of patients.113 
Non-PV triggers originating in the SVC were identified in 12% of a cohort of patients undergoing AF 
ablation. After performing SVC isolation (SVCI) in these patients they remained 100% arrhythmia 
free. In a further group of patients, empirical SVCI was performed. 96% of patients were noted to 
have electrical connection of the SVC and RA at baseline. 18% of patients demonstrated phrenic 
nerve capture with high output pacing, precluding safe SVCI. 16% of patients who underwent 
empirical SVCI had recurrent AF.114 A cohort of 6 patients out of approximately 2000 patients 
undergoing AF ablation (0.21%) were noted to have a persistent left SVC and documented of AF. 4 of 
the 6 patients had had at least one previous AF ablation in which the PVs were targeted and no PVR 
was identified as a source of recurrent PAF. Successful isolation of the persistent left SVC was 
performed in the 6 patients and all remained free from AF recurrence after 1 year follow up.115 
Although these results reflect a small, non-randomised cohort of patients, it would appear in both 
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studies that identification and targeting of the AF trigger has higher success rates than empirical 
ablation. 
In a large, prospective study of patients undergoing redo ablation for both PAF and PsAF, ectopy 
originating from the left atrial appendage (LAA) or LAA induced AF / AT was noted in 27% patients. 
Of note, 9% of these patients had no PV reconnection and the only source of recurrent AF / AT 
appeared to be the LAA. Patients were subsequently treated with one of three strategies; (1) the 
LAA potentials were not ablated, (2) focal LAA ablation was performed or (3) LAA isolation using a 
circular mapping catheter at the mouth of the LAA was performed. A significantly higher success rate 
was noted with the latter ablation strategy of isolating the LAA compared to either focal ablation of 
the LAA potential or no ablation; 25% AF recurrence vs. 68% and 74% respectively.116 However, the 
safety of LAA isolation, particularly in terms of thromboembolic risk, remains to be assessed in a 
multi-centre trial. 
One study investigated the association between CFAE and non-PV triggers. PV encirclement was 
performed in all patients. Non-PV triggers were subsequently identified either before or after 
extensive CFAE ablation. Non-PV triggers were identified in 38% of patients prior to CFAE ablation, 
with transient or stable CFAE found at 76% of the non-PV trigger sites. Non-PV triggers identified 
following extensive ablation of left and right atrial CFAE were found in only 20% patients. From these 
results the investigators deduced that CFAE ablation significantly reduces the number of non-PV 
triggers and they attributed this to the frequent co-location of these sites. This may suggest that the 
incremental success of CFAE ablation in addition to PVI seen in other studies may be due to the 
removal of non-PV triggers. The identification and targeting of non-PV triggers would appear to have 
a small but not insignificant effect on AF recurrence following ablation. Developing methods to 
identify and ablate all AF triggers in an individual patient, rather than performing extensive ablation 
of empirical targets including PVs, linear and CFAE ablation may allow us to improve our success 
rates without increasing the risk of the procedure. 
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1.4 Pulmonary Vein Reconnection 
Pulmonary vein reconnection (PVR) is hypothesised as the major cause for AF recurrence after 
ablation. Lack of contiguous, transmural ablation lesions around the pulmonary veins is proposed as 
the predominant factor leading to PVR. A recent surgical study, which took biopsies from patients 
with prior endocardial PVI, demonstrated full thickness myocardial scar in only 50% of biopsies. The 
other 50% had either partial thickness or fully viable myocardium, or both. Epicardial mapping 
performed prior to the biopsies demonstrated that transmural scar was more likely to be associated 
with PVs that remained electrically isolated, confirming that anatomic gaps or non-transmural 
lesions following catheter ablation were likely to be the cause of pulmonary vein reconnection.117  
Limited data is available on pulmonary vein reconnection rates in patients without recurrent AF, 
with far more data available describing the reconnection rates in patient with recurrent AF 
symptoms. This section describes studies investigating the relationship between PVR and AF 
recurrence, whether particular areas more commonly lead to PVR and whether there is value in re-
isolating PVs at the redo procedure.  
Several studies in the literature reported on rates of PV reconnection assessed at the redo 
procedure in patients with recurrent symptomatic AF. One study of 50 patients with recurrent AF 
found that 98% of patients had one or more reconnected PV.118 A smaller study of 14 patients noted 
that all patients had one or more PVR.119 70% and 60% of PVs had reconnected in these two studies 
respectively. Similarly, 2 larger studies found 97% of patients returning for a redo procedure had one 
or more reconnected PV,120 and that 91% of previously ablated PVs had reconnected.113 3% of 
patients had no PVR, 18% had 1 PVR, 41% had 2 PVR, 15% had 3 PVR and in 23% all 4 PVs had 
reconnected.  
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Of the studies which looked at a mixed group of symptomatic and asymptomatic patients, one 
included 26 patients with recurrent AF and 7 volunteers without AF recurrence at 3-4 months post-
ablation. No recurrence of PV conduction was found in the 7 asymptomatic volunteers, whereas 21 
of the 26 patients with recurrent AF had one or more PV reconnection121. In a larger cohort of 107 
patients, a restudy was performed approximately 6 months after the first procedure to identify rates 
of PVR in patients with and without recurrent AF. Group 1 did not have any recurrent symptoms off 
all anti-arrhythmic drugs and of these 81% of patients did not have any PVR and the other 19% of 
patients had 1 PVR. Group 2 had recurrent symptoms but were well controlled on anti-arrhythmic 
drugs and of these 5% of patients had no PVR, the other 95% had one or more PVR. Group 3 patients 
had recurrent symptoms refractory to anti-arrhythmic drugs and in this group all patients had one or 
more PVR.122 This data would suggest that if permanent pulmonary vein isolation is achieved in all 
veins then AF is unlikely to recur. However 19% of entirely asymptomatic patients had a single PVR 
at restudy suggesting that some PVs can reconnect without resulting in recurrent AF. 
Another study performed a repeat procedure in 40 patients 3 months post AF ablation, regardless of 
symptoms. In 8% of patients all 4 veins had reconnected, 18% had 3 PVR, 38% of patients had 2 PVR, 
15% had 1 PVR and 23% of patients had no PVR.123 In keeping with the results of the previous study, 
all patients with recurrent AF had at least two reconnected veins and patients in whom all veins 
remained isolated there was no evidence of AF recurrence without anti-arrhythmic drugs at 3 
months. Furthermore, both studies found that patients free from recurrent AF had lower PVR rates 
than patients with recurrent AF (1.4 vs. 2.5, p=0.006 124, 0.2 vs. 2.2, p=0.021122). However, in this 
study, an even greater number of patients without recurrent AF symptoms demonstrated PVR, in 
fact in 2 patients with no AF recurrence, all 4 veins had reconnected. This may be due to the fact 
that one study was performed at 3 months and the other 6 months after the index procedure, 
allowing less time for symptoms to recur, nonetheless, both studies identify patients in whom 
pulmonary vein reconnection does not result in recurrent AF.  
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The graph below summarises the data from the studies discussed in this section and demonstrates 
the number of reconnected veins compared for patients with and without recurrent AF. From this 
graph we can see that nearly all patients with recurrent AF have one or more reconnected 
pulmonary veins, which strongly supports the hypothesis that achieving lasting pulmonary vein 
isolation prevents recurrent AF. On the other hand, approximately one third of patients who are free 
from AF recurrence have one or more reconnected pulmonary veins.  
 
Figure 1.4 Pulmonary vein reconnection rates in patients with and without AF recurrence, combined 
results from 3 published series.120, 122, 124 
 
One could hypothesise that either significant pulmonary vein modification has occurred in these 
veins preventing the conduction of PV ectopy to the LA, or that not all pulmonary veins are culprit in 
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generating PV ectopy and therefore may not require isolation in the first place, as suggested by the 
findings of Dixit et al.77 
1.4.1 Re-isolation success rates 
Re-isolation of the pulmonary veins does appear to be effective in preventing further recurrences of 
AF with reported success rates ranging from 86-100%.113, 119, 122 This suggests that in the majority of 
patients with recurrence after the first procedure, the target remains the pulmonary veins. In fact, 
PVI appears to be more successful at the second attempt, as reported in a cohort of 161 patients 
with PAF over a 5 year follow up period, in which 53% of patients had AF recurrence after the first 
procedure compared to 18% of patients after the second. This may be due to the fact that repeat 
ablation commonly requires targeting of small gaps in previous ablation lines rather than full 
circumferential PV ablation. However, one study reported that 8 of 12 patients returning for a third 
procedure had evidence of recovered PV conduction, suggesting that despite 2 ablation attempts PV 
reconnection still occurs.125  
1.4.2 Reconnection patterns 
Reconnection patterns have been investigated and reported by several groups. Reconnection 
patterns compared between cryoballoon ablation and RF ablation found that reconnection sites 
were more common in the lower portion of all veins in cryoballoon cases compared to the RF group 
in which the majority were located in the mid or upper portion of all veins. Reconnection rates were 
similar between ablation modalities and did not appear to favour one particular vein.126 
Another study found that sites more likely to reconnect were the PV-LAA ridge and intervenous 
ridge (IVR) of the left sided veins, and the roof, floor and IVR on the right sided veins. Minimal PV 
reconnection occurred on the posterior wall.120 This latter study suggests that sites of PVR appear to 
occur more frequently at areas of increased thickness in myocardial tissue and are potentially due to 
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either a lack of transmurality achieved with ablation or due to the technical challenge of maintaining 
stability and producing contiguous lesions in these areas. 
 Given that the majority of patients in whom durable four vein isolation can be achieved 
demonstrate complete AF freedom, it is likely that addressing these challenges may result in 
improved outcomes from AF ablation. However, as discussed previously, some pulmonary veins can 
reconnect without leading to AF recurrence, suggesting that there may be “culprit” veins responsible 
for AF initiation. Therefore to improve the success rates for PVI as a treatment for PAF we either 
need to improve our rate of achieving permanent PV isolation in all 4 PVs, or we need to find a 
method to identify the culprit PVs and permanently isolate or eliminate the trigger from the 
identified PV, or extra PV source. 
PVR rates were reported in a randomised trial of general anaesthesia (GA) and conscious sedation. 
12% of patients who received their index AF ablation procedure under GA had recurrent AF 
compared to 31% of those under conscious sedation. At the redo procedure, patients from the GA 
group had fewer reconnected veins than in the conscious sedation group (19% vs. 42% 
respectively).127 This suggests that in a population with lower rates of PVR, the rate of AF freedom is 
higher. These findings would suggest that general anaesthesia improves ablation efficacy, and 
although the mechanism via which it does this has not been proven, it may be through improved 
catheter stability due to controlled breathing and lack of patient movement. On the other hand 
there have been reports in the literature that suggest general anaesthesia increases the procedural 
complication rate, for example increased oesophageal lesions have been noted following GA 
cases.128 This highlights the fine balance between improving procedural efficacy without 
compromising on patient safety and poses a significant challenge for the development of novel 
ablation technologies designed to achieve permanent pulmonary vein isolation.  
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1.5 Novel Ablation Technologies 
1.5.1 Robotically-assisted navigation and ablation 
To address some of the challenges of achieving durable pulmonary vein isolation, robotic 
technologies have been developed. These have been primarily designed to improve catheter 
stability, with the aim of delivering contiguous and transmural ablation lesions. Two systems for 
remote navigation of catheters within the heart have been developed; the first is based on a 
magnetic navigation system (Niobe, Stereotaxis, Saint-Louis, Missouri, USA), the second is based on 
a steerable sheath system (Sensei, Hansen Medical, Mountain View, CA, USA). Both robotic and 
magnetic navigation systems have proven to be feasible for performing ablation of both simple and 
complex arrhythmias, particularly atrial fibrillation.  
Both non-randomised and randomised comparative studies of robotic and manual AF ablation have 
reported a reduction in fluoroscopy time for robotic ablation compared to manual. The difference 
was noted to be most marked in the ablation part of the procedure using the instinctive navigation 
software (CohesionTM, Hansen MedicalTM) which intuitively integrates the 3D mapping system with 
the catheter steering console. The fluoroscopy time prior to ablation was similar between the 2 
modalities.129 Mean fluoroscopy time also reduced after the first 50 robotic procedures performed 
by a single operator, suggesting that fluoroscopy time reduced with increasing experience.130 
Further benefits of robotic navigation include the reduction in fluoroscopy exposure to the operator 
since the physician’s work station can be placed within the control room, where negligible radiation 
exposure has been recorded.131, 132 With long, complex ablation procedures becoming increasingly 
undertaken, chronic radiation exposure becomes a serious issue. Since the operator is able to sit 
down during robotic procedures and is not required to wear lead aprons for the majority of the 
procedure, there is a significant reduction in operator fatigue with the potential for greater career 
longevity.130  
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As previously alluded to, attempts to improve ablation efficacy may increase the risk of damage to 
structures neighbouring the left atrium and pulmonary veins. In the majority of reported 
experiences the occurrence of complications using robotically-assisted ablation has been greater 
during the learning curve for each centre and operator, and the incidence is greatly reduced in 
operators performing >30 cases per year.130, 133  
An early study reported 6 intraoperative, procedural related complications from a cohort of 76 
robotic AF ablation procedures; 4 vascular complications, one requiring iliac vein stenting, and 2 
cardiac tamponades, one related to a pop-phenomenon, both successfully treated by 
pericardiocentesis. 8 post-procedural complications were also reported which included delayed 
tamponade, pericarditis, pulmonary vein stenosis and gastroparesis. Several alterations in technique 
were made following these reports. The use of a longer sheath through which the robotic sheath 
could be more safely advanced, reduced power settings, particularly when ablating on the posterior 
wall, and the introduction of Intellisense to demonstrate the pressure recorded at the catheter tip 
were all recommended following this early study.133 
In a more recent study of 390 patients, 3 patients developed complications in during robotic ablation 
and 2 patients during manual ablation. In the robotic group, 2 patients had a tamponade requiring 
pericardiocentesis, one of which occurred during the manual transeptal puncture, and 1 had a groin 
haematoma. In the manual group, 1 patient had a tamponade and 1 patient had a groin haematoma. 
The complication rate did not differ between the manual and robotic ablation groups and is 
significantly lower than the rates quoted in earlier robotic studies.130 
To investigate the incidence of oesophageal damage a comparison between robotic and manual 
circumferential pulmonary vein ablation was performed. Robotic ablation was performed either a 
maximum power of 30 watts in all locations or a reduced power of 20 watts on the posterior wall 
and 30 watts elsewhere in the left atrium. Endoscopy was carried out 2 days post ablation. In the 
manual group no oesophageal lesions were seen in 60%, minimal lesions in 28% and ulcerations in 
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12% of patients. In the first robotic group, all patients had ulceration, one developed an oesophageal 
perforation requiring placement of a covered stent. In the robotic group with reduced power on the 
posterior wall, only a single minimal oesophageal lesion was found.134 In a similar study, endoscopy 
was performed in 42 patients within 24 hrs of robotic PVI in which powers had been limited to 25 
watts on the posterior wall. 14.3% of patients were found to have oesophageal lesions, all of which 
had healed at repeat endoscopy within 2 weeks. 135  
These studies therefore support the presumption that robotic ablation has the potential to produce 
greater lesion transmurality, hence the increase in damage to extracardiac structures. However, as 
yet, the increase in transmurality does not appear to translate into improvement in ablation 
outcomes. Several centres have undertaken non-randomised studies to identify the success rate of 
robotic ablation for atrial fibrillation. In an early study of patients with drug-refractory AF, all 
pulmonary veins were successfully isolated with Hansen system and at 1 year follow up 86% of 
patients were free from atrial arrhythmias off AADs.136 Similarly, in 2009 a study of mixed 
paroxysmal and persistent AF patients underwent robotic ablation achieving complete PVI in 95% of 
patients, with 73% of patients remaining free of any atrial tachyarrhythmia (76% for paroxysmal and 
68% for persistent).137 This is comparable to current quoted success rates for manual ablation.  
The largest comparative trial to date included 390 patients with symptomatic atrial fibrillation. 
Alternate procedures were performed using either robotic (Hansen) or manual ablation. The success 
rates were not significantly different; 85% for robotic ablation and 81% for manual.130 The only  
randomised comparison of robotic and manual AF ablation also reported similar success rates 
between the two modalities (73% vs. 77% respectively).129  
From the current literature, it is therefore not clear that robotically-assisted ablation produces an 
outcome advantage over manual ablation. Whether this is due to problems with robotically-assisted 
ablation efficacy, or whether it is due to the ablation strategy, common to both manual and robotic 
procedures, remains to be elucidated. 
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1.5.2 Circular ablation devices 
Given the approximately circular orifice to the pulmonary veins, many novel technologies for AF 
ablation have been designed to produce continuous circular lesions around the PV ostium, in the 
hope that gaps in ablation lines formed during point by point ablation could be avoided. However, a 
significant challenge posed to these technologies is that the anatomy of the PV ostia varies from 
patient to patient and is often oval rather than perfectly circular. This potentially leads to even larger 
gaps in ablation lines than using point by point ablation techniques, and acutely PVs frequently 
require additional point by point ablation to close these gaps. A comprehensive description of all 
circular ablation technologies is beyond the scope of this thesis, however, the following section 
includes a brief description of some of the more widely used circular ablation device.  
The PVAC™ (Medtronic Inc, Minneapolis) uses multiple electrodes around the circumference 
delivering phased unipolar and bipolar RF. This technology is potentially faster at delivering ablation 
lesions to the circumference of the PV ostium and requires significantly less operator hand-skill than 
point by point ablation. However, long-term success rates with this technology have at best been 
similar to conventional RF ablation 138, 139 and there are several reports in the literature of an 
increased risk of thromboembolic events compared to conventional ablation, potentially due to the 
lack of irrigation during ablation from the multi-electrode catheter.140  
Balloon based technologies have also been developed, including the cryoballoon which employs the 
cryo-energy of a nitrous oxide refrigerant to cool the balloon to around -80 °C. A detailed description 
of all balloon based ablation techniques and outcomes is beyond the scope of this thesis. However, 
again similar success rates are reported using the cryoballoon in patients with paroxysmal AF 141, 142 
and, although this has proven a fairly safe technology, it carries an additional risk of phrenic nerve 
palsy during ablation of the right sided veins.142    
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Figure 1.5 Illustrations of balloon-based ablation devices. 
 (left) Nitrous oxide-filled Arctic Front cryoballoon opposed to the pulmonary vein ostium. (right) 
Novel argon filled, compliant balloon with laser energy source emitted from the central lumen and 
focused at the point of contact between the balloon and the adjacent myocardium when placed at 
the pulmonary vein ostium. 
The recently developed technology of laser-balloon guided pulmonary vein isolation allows creation 
of point by point lesions around the ostia of each PV under visual guidance. Whilst this does not 
allow assessment of transmurality and it is difficult to visually differentiate tissue that has been 
effectively ablated from unablated tissue, the lesion playback feature facilitates contiguous lesion 
placement around the veins. Preliminary results both in animals and in humans have suggested that 
this is a highly effective method for producing acute PVI 143 and restudies in small numbers of 
patients have demonstrated a 90% rate of lasting electrical disconnection within the PVs.144  
Of particular relevance however, are the preliminary outcome results that, despite a significant 
decrease in the rate of PV reconnection with the laser balloon, only 60% of patients remain AF free 
following a single procedure. Although these are reports of small patient numbers and PV 
reconnection rates need to be confirmed in larger studies, this finding suggests that improving 
permanency of pulmonary isolation may not lead to an equivalent increase in AF freedom as may 
have been expected in this PAF population. Non-invasive assessment of the effects of ablation and a 
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method for identification of a pre-existing arrhythmogenic atrial substrate may provide important 
clues about likely success of ablation in patients with paroxysmal and persistent AF.  Delayed-
enhancement magnetic resonance imaging of the left atrium may be one such tool with the 
potential to assess both underlying atrial fibrotic change and iatrogenic scar formation. 
 
1.6 Late gadolinium-enhancement Magnetic resonance imaging of the left 
atrium 
1.6.1 Visualisation of ablation related atrial scar using LGE-MRI 
Histological evidence for the efficacy of current ablative techniques to produce permanent, 
transmural atrial scar is limited to post-mortem and animal studies. A non-invasive method for 
visualising atrial scar formation post-ablation may provide insights into the mechanisms of AF 
recurrence and facilitate improvements in ablation techniques. 
Late gadolinium-enhanced MRI (LGE-MRI) has clearly demonstrated its ability to delineate 
myocardial infarction scar in post-mortem animal studies 145 and has been utilised in canine models 
to characterise radiofrequency lesions in ventricular myocardium (as shown below). Following 
gadolinium-contrast injection, acute RF lesions were initially delineated as contrast-free areas of low 
signal intensity. Signal enhancement subsequently started in the lesion periphery and progressively 
extended towards the lesion centre, with eventual full delayed-enhancement of the lesion. DE-MRI 
correlated well with the pathological findings at each phase.146  
Importantly, the reproducibility of post-ablation atrial enhancement on LGE-MRI has been studied in 
humans with scans performed either 24hrs post and 3 months post, or 3 months post and 6 or 9 
months post conventional radiofrequency AF ablation. A poor correlation was demonstrated 
between delayed enhancement seen at 24hrs and 3 months post ablation. However, an excellent 
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correlation was found between LGE-MRI scans performed at 3 months and 6 or 9 months post 
ablation.147 The investigators concluded that permanent atrial scar had formed, and was 
reproducibly identified, on LGE-MRI 3 months post-ablation.   
 
 
Figure 1.6 Evaluation of discontinuous ablation line in canine ventricular myocardium 
Ablation lesions with gaps were placed on the epicardial surface of the right ventricle in an open-
chested canine study. Gadolinium enhanced magnetic resonance imaging of the ventricular 
myocardium was performed and correlated with histological section. A gap (dotted arrow) is 
demonstrated in the ablation line between two ablation lesions (solid arrows). A good correlation is 
seen between pathological specimen after chloraldehyde preparation (left panel) and gadolinium-
enhanced magnetic resonance imaging results (right panel).146 
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In order to identify whether regions of atrial enhancement were reflective of low-voltage 
myocardium, LGE-MRI scans were performed on 12 patients with prior LA ablation returning for a 
redo AF ablation and an endocardial voltage map was collected at the start of the procedure. The 
MRI segmentation displaying regions of “scar” and the electroanatomic (EA) voltage maps (un-
registered) were divided into 18 regions and scored by 4 blinded-reviewers. For MRI models, 0 
represented no enhancement, 1 mild, 2 moderate, and 3 extensive enhancement. For the EA maps, 
0 was considered healthy tissue (voltage > 1 mV), 1 was mildly decreased tissue voltage (> 0.1 mV 
and < 0.5 mV), 2 was moderate decreased tissue voltage (> 0.1 mV and < 0.5 mV) as well as fibrotic 
scar (< 0.1 mV), and 3 was extensively decreased tissue voltage (< 0.1 mV). The overall score was an 
average sum of all 18 regions. Using this method, 2 studies by the same investigators demonstrated 
a positive correlation between the overall score for the LA EA map and degree of enhancement 
(R2=0.57 and 0.61 respectively). 148, 149 However, this correlation was based on patients with prior LA 
ablation and does not confirm that regions identified as myocardial fibrosis on pre ablation LGE-MRI 
are reflective of low voltage myocardium, nor does it specify the absolute voltage reflected in 
regions of atrial enhancement.  
Two groups have studied the association between the presence of LA scar post-ablation and its 
association with AF recurrence. One study performed DE-MRI approximately 1-3 months following 
AF ablation and scored the extent of scarring around the ostium of each PV qualitatively (0 minimal, 
3 extensive and circumferential). No significant difference was found in the number of 
circumferentially scarred veins in patients with and without AF recurrence (35% vs. 55% 
respectively).150   
Another group studied patients undergoing PVI and “atrial debulking” for AF. LGE-MRI was 
performed approximately 3 months post ablation and 3D atrial renderings displaying regional 
enhancement were utilised to qualitatively assess how many PVs were circumferentially scarred per 
patient. They found that only 7% of patients had circumferential scarring of all four PVs on LGE, 11% 
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had 3, 13% had 2 and 31% of patients had 1 completely scarred PVs. The remaining 38% had no 
completely scarred PVs. Following the initial procedure, the patients with 4 completely scarred PVs 
were found to have 100% procedural success, whereas the patients with 3, 2 and 1 circumferentially 
scarred PVs had 77%, 84% and 73% freedom from AF respectively, and patients with no 
circumferentially scarred veins had only 54% freedom from AF.148 Unlike the previous study, these 
results would suggest that a greater number of circumferentially scarred veins per patient is 
associated with a better outcome from AF ablation. 
 
1.6.2 Assessing Atrial Substrate with LGE-MRI 
Atrial fibrosis is a common feature of clinical AF, both in patients with underlying organic heart 
disease and in patients with lone-AF. 151-153  Increased levels of collagen deposition are found in atrial 
biopsies of patients with lone-AF and patients with mitral valve disease when compared to control 
subjects in sinus rhythm.153 However, it is not clear from this study whether this is the cause or 
effect of AF. Several studies investigating LA substrate have suggested that AF may be a self-
perpetuating disease wherein chronic fibrillatory activation of the atria leads to progressive 
electrical and structural remodelling which facilitates ongoing arrhythmogenesis. Although at the 
cellular level these structural changes are complex, the electrical manifestation of the remodelling is 
that of a reduction in myocardial voltage and a decrease in the effective refractory period. 
 Several examples exist in the literature, from both cardiac surgeons and electrophysiologists, that 
the success of mechanical treatments for preventing AF is reduced by the presence of widespread 
low atrial voltage.154-157 In a large cohort of patients undergoing CPVA for AF, the presence of low-
voltage atrial myocardium on pre-ablation endocardial mapping was a powerful, independent 
predictor of procedural failure.156 There may be substantial gain therefore, in identifying a non-
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invasive method which can identify patients with widespread atrial remodelling prior to undertaking 
a course of ablative treatment for AF. 
Cardiovascular magnetic resonance imaging (MRI) is almost unique in its capability to reveal 
myocardial fibrosis through the use of late gadolinium enhancement imaging. For several years LGE-
MRI has been used to distinguish between reversible and irreversible ventricular myocardial 
ischemic injury and can also be used to predict whether regions of damaged ventricular myocardium 
will improve after revascularization in patients with coronary artery disease.158, 159 In addition, the 
presence of mid-wall fibrosis in patients with dilated cardiomyopathy is an independent predictor of 
sudden cardiac death, ventricular arrhythmias and cardiovascular hospitalisations.160  
The gold standard validation of atrial delayed enhancement would be histological sections. However, 
since this is not practicable in humans, numerous “next best” clinical correlates have been 
performed to help confirm the supposition that atrial delayed-enhancement does in fact represent 
myocardial fibrosis. Firstly, pre ablation LA enhancement has been shown to be predictive of 
arrhythmia recurrence following AF ablation. Pre ablation DE-MRI, performed in patients undergoing 
AF ablation and healthy volunteers, revealed minimal LA scarring in the healthy volunteers and a 
range of  enhancement levels in the AF patients. Furthermore, if AF Patients were grouped according 
to extent of atrial enhancement or “scarring” it was noted that 14% of patients with mild “scarring” 
had recurrent AF following ablation compared to 43% of patients with moderate “scarring” and 75% 
of patients with severe “scarring”. In addition, a highly significant increase in LA volume was found 
between groups with mild, moderate and severe “scarring” respectively.149, 161 This result supports 
the idea that atrial enhancement represents underlying fibrosis since it has previously been shown 
that atrial fibrosis and LA size are closely linked. 3, 162, 163 It also raises the possibility that patients may 
have a predetermined success rate from AF ablation and could be selected or counselled for the 
procedure on this basis. Alternatively, procedural strategy may be altered for patients who have a 
predicted lower ablation success rate with current standard AF ablation targets. 
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Pre ablation DE-MRIs were also performed to identify whether there was an association between 
levels of enhancement and patient risk factors for stroke, particularly CHADS2 score and history of 
previous stroke. The study population had a 9.3% prevalence of stroke. They noted an increase in 
percentage LA enhancement in patients with previous stroke compared to those without (24.4 ± 
12.4% vs. 16.2 ± 9.9%, p < 0.001).164 Furthermore, DE-MRI “fibrosis” was an independent predictor of 
cerebrovascular events (p=0.002) and significantly improved the predictive performance of the 
CHADS2 score (area under the curve 0.77). 
Local electrogram correlates in patients with AF have also been attempted. Global and regional 
scores of pre ablation LGE CMR atrial enhancement or “fibrosis” were identified by blinded expert 
observers in patients with PsAF who subsequently underwent endocardial mapping to identify 
regions of CFAE. Ablation of CFAE regions was performed and time to achieve sinus rhythm was 
recorded. A strong association was found between pre ablation global enhancement scores and both 
procedural and RF “time to terminate AF”. A weak correlation was found between global 
enhancement and CFAE surface area. Of note there was no correlation identified between regional 
enhancement score and extent of CFAE or extent of RF ablation of CFAE.165 This may be due to the 
difficulty of defining regions for comparison, problems defining the presence of absence of CFAE or 
current methods for identifying LA enhancement may not be spatially accurate or robust enough to 
identify an association. Alternatively, there may not be a direct correlation between the location of 
atrial “fibrosis” identified by LGE-MRI and CFAE. Several centres have questioned the definition and 
stability of CFAE and it remains to be seen whether novel algorithms for identifying CFAE can further 
elucidate the relationship between CFAE and the presence of atrial “fibrosis”. It is not clear for 
example why ablation of regions of fibrosis would lead to prolongation of the AFCL. Alternative 
theories linking CFAE with the autonomic nervous system may better explain the link between 
ablation of CFAE and a reduction in AFCL and subsequent improvements in freedom AF. 
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1.7 The Autonomic Nervous system as an alternative target for ablation 
The evidence for the involvement of the autonomic nervous system in AF arrhythmogenesis was 
discussed earlier in this chapter. Furthermore, the discrepancy between PV reconnection rates and 
AF recurrence implies that there may be a “second factor” involved in the prevention of AF 
paroxysms following PVI. The potential of the autonomic nervous system as a target for ablation to 
prevent AF has therefore also been investigated. Firstly, the effect of ablation of the ganglionated 
plexi on AF inducibility was studied in dogs. The result was that atrial fibrillation induction and 
maintenance was completely abolished following ganglionated plexi ablation.166 These results have 
led us to believe that adjunctive autonomic ablation may be a useful strategy in clinical AF ablation 
procedures.  
A significant challenge for the development of a strategy of autonomic modification is that there are 
few known endpoints for endocardial ablation of the autonomic ganglia. In 2000, Pappone reported 
on a cohort of 297 patients undergoing circumferential pulmonary vein ablation for AF. In 34.4% of 
patients, one or more vagal responses, including bradycardia, hypotension or AV block, were elicited 
by RF ablation close to the PV ostia. “Complete vagal denervation” was defined as abolition of this 
response to subsequent RF delivery.167 Patients with “complete vagal denervation” were significantly 
more likely to be free from AF post procedure than those that did not (99% vs. 85%, p < 0.002). From 
this he concluded that autonomic modification in addition to CPVA appeared to be beneficial in 
preventing AF recurrence. Although his success rates are significantly higher than many centres for a 
single procedure for PAF, with other centres having difficulty reproducing these success rates, the 
additive success seen with ablation of vagal responses may nonetheless be an important finding. In 
addition, the general experience of endocardial ablation is that the occurrence of an autonomic 
response to GP ablation is not common, which suggests that other endpoints are required to 
develop a reproducible, reliable method of autonomic modification. 
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1.7.1 Reduction in HRV parameters after AF ablation 
Several studies have investigated the effect of left atrial ablation on parameters of heart rate 
variability and would suggest that changes in HRV are reflective of autonomic modulation due to 
ablation of the ganglionated plexi.90, 168 The complexities of HRV measurement and the information it 
provides regarding activity of the autonomic nervous system are described in more detail in the 
methods section.  
Pappone was able to demonstrate a difference in parameters of heart rate variability between 
patients with and without AF recurrence following ablation. Heart rate, and time- and frequency-
domain HRV were measured on 24-hour Holter ECG before and after ablation (1 week, then 1, 3 and 
6 months). As the graphs below demonstrates, he noted a significant change in almost all 
parameters of HRV 1 week post ablation, compared with pre-ablation in all patients. Some 
parameters of HRV were significantly lower in patients without AF recurrence even at 1week post 
ablation.  At 1 month post ablation most HRV parameters were lower in patients without 
subsequent AF recurrence. The difference between patient groups persisted at 3 months, however 
at 6 months all HRV parameters had returned to pre-ablation levels. 
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Figure 1.7 The change over time from AF ablation in various parameters of heart rate variability in 
patients with and without AF recurrence. 
 Red line shows patients with recurrence of AF following ablation compared to the blue line showing 
patients who remain free from AF recurrence. Significantly higher mean heart rate and minimum 
heart rate was seen in patients free from AF recurrence, and significantly lower LF and HF 
parameters were also seen in this group compared to patients with recurrent AF. These changes 
remained significant for up to 3 months, with all parameters returning to baseline at 6 months. 167 
62 
 
 
Similar findings were noted in another study in which HRV parameters were analysed on 24hr Holter 
recordings pre and 24 hrs post AF ablation. Higher LF/HF ratio and lower HF parameters of HRV were 
found to be independent predictors of AF freedom.90 Given these results, HRV changes measured 
during AF ablation could potentially represent a feasible endpoint for autonomic modulation that 
could be predictive of freedom from AF.  
 
1.7.2 High frequency stimulation and ablation of Ganglionated Plexi 
Whilst HRV can be measured as a surrogate marker of GP injury following ablation, a method for 
endocardial identification of GP sites would be more clinically useful to target ablation and perhaps 
also as an endpoint for GP ablation. One such method is that of continuous high frequency 
stimulation (cont-HFS) and has been used by several groups to identify the location of activatable 
GPs. This method involves delivery of high-output pacing stimuli (5-15V at 20-50Hz) from an 
electrode placed at the presumed location of each ganglionated plexi and relies on identification of 
an AV nodal response, including RR interval prolongation or asystole. Ablation can be performed in a 
cloud around the stimulated GP site and some studies suggest that the response is typically 
abolished after 3-4 RF deliveries of 30secs each.169 The abolition of this response to stimulation has 
been suggested as an endpoint for autonomic ablation.169-174 
 Cont-HFS has also been used during open-heart surgery in humans for epicardial localisation of GP 
sites contained in the fat pads on the epicardial surface of the atria.170, 172 Ablation of the anterior 
right GP (ARGP) and inferior right GP (RIGP) during thoracoscopic surgical AF ablation has 
demonstrated promising single-procedure success rates in a small-non-randomised study and mixed 
AF population, however these results have yet to be reproduced in larger patient numbers.170 
63 
 
The effect of endocardial AF ablation on the activity of GP sites identified by cont-HFS has also been 
studied. In 20 patients, cont-HFS was performed prior to the AF ablation procedure. Approximately 
3-4 positive sites were identified per patient. Following antral PVI by an operator blinded to the GP 
locations, these sites were retested and all of the responses had been abolished.173 Similarly, 20 
patients undergoing a redo AF procedure underwent cont-HFS testing at presumed GP sites. No 
patients demonstrated positive vagal responses to GP site testing in this group. This led to the 
conclusion that vagal responses were eliminated by standard antral PVI ablation, and that these 
responses did not recur in patients presenting for repeat PVI, despite clinical recurrence of AF.173 
 A similarly designed study found that circumferential pulmonary vein ablation eliminated 30 of 34 
(88%) GP site AV nodal responses identified prior to ablation, and that remaining positive responses 
were all located at the crux GP.175 Following this, the effect of GP ablation on AF inducibility in 
humans was investigated. Endocardial cont-HFS was used to identified GP sites in 18 patients and 
with subsequent endocardial GP ablation. Additional epicardial stimulation was performed via 
pericardial access in 5 patients. GP ablation was performed until no further vagal responses could be 
elicited either epicardially or endocardially, however AF remained inducible in 17 out of the 18 
patients, from which they concluded that although vagal responses could be abolished via 
endocardial ablation, this did not appear to have a significant effect on the ability to induce and 
maintain AF in the catheter laboratory.176 
A small study was performed looking at the effect of GP ablation on AF recurrence in patients with 
and without identifiable GP sites. Endocardial and epicardial mapping for GP sites was performed in 
10 patients with a history of vagal AF symptoms. 7 of 10 of these patients had evoked vagal 
responses with cont-HFS, all of which were successfully eliminated. 3 patients had no elicited vagal 
response and underwent empirical CPVA. 2 of the 7 patients remained free from AF recurrence 
whilst the rest had recurrent symptoms. All 3 patients in whom CPVA was performed remained free 
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from AF recurrence.174  It was concluded that whilst vagal denervation may prevent AF in selected 
patients, it may not be a more effective strategy than CPVA.  
However, the findings of all 3 studies should be interpreted with caution in view of the findings of 
electrophysiological studies in dogs, demonstrating the interconnecting neural pathways between 
the left atrial GPs and the AV node.177 It was found that ablation of the right lower GP prevented the 
AV nodal response to stimulation of all other LA GP sites. If a similar network were to exist in 
humans, this would imply that RLGP ablation may prevent other GPs from being identified using the 
method of cont-HFS. 
Further studies have been performed to investigate whether ablation of the left atrial autonomic 
ganglia could be used for the purpose of treating AF in humans. A comparative study of anatomical 
vs. selective GP ablation was performed,  in which ablation was only performed at sites where GPs 
had been identified using cont-HFS in one group, whereas in the other group, ablation was 
performed at all presumed anatomical locations of GP sites without cont-HFS testing.171 A marked 
difference in outcome was found favouring anatomically guided GP ablation (42.5 vs. 77.5% patients 
free from AF at approximately 1 year). It is interesting to note that anatomical GP ablation produces 
similar success rates to that of CPVA, potentially suggesting that the additional areas of ablation 
encompassed by the CPVA may not have any additional effect over and above ablation at anatomical 
GP sites. It is not clear why anatomical ablation should be better than ablation of identifiable GP 
sites, however, it may be that the method of cont-HFS only identifies GP sites with connections to 
the AV node and is not the most effective method for identifying culprit GPs with connections to the 
pulmonary veins that may be responsible for AF initiation.  
More recently, a study was performed comparing PVI alone, with PVI plus additional anatomic GP 
ablation.178 The results demonstrated an significantly higher rate of freedom from AF in the group 
treated with additional GP ablation vs. PVI alone (78.8% vs. 45.5% after the first procedure and 
85.3% vs. 60.6% after the second procedure, p = 0.019). However, it is not clear from this study 
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whether PVI provides additional benefit over GP ablation alone. It is also possible that GP ablation is 
beneficial simply due to the additional PV ostial ablation lesions which may reduce rates of PV 
reconnection.  
An alternative method for GP identification in humans has been described by our group. HFS is 
delivered at presumed GP sites in short bursts synchronised to the atrial refractory period, to avoid 
direct atrial capture leading to AF initiation. This method has been shown to induce ectopic firing 
from within the pulmonary veins.179 The potential benefit of this method is that it does not rely on 
intact AV nodal connections. Instead it relies on intact connections to the pulmonary veins, which 
potentially make it a more relevant method for identifying culprit veins as a target for ablation. 
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1.8 Scope of Thesis 
 
Paroxysmal AF results from a combination of focal ectopic discharges originating from the 
pulmonary veins triggering fibrillation in the presence of a susceptible atrial substrate which retains 
the ability to self-terminate. Pulmonary vein isolation is associated with reasonable success rates for 
prevention of AF, however, despite a decade of technological advances aimed at achieving 
permanent pulmonary vein isolation, there remains a significant failure rate. Therefore, on the basis 
that PV isolation alone determined by current methods is inadequate, we hypothesised that: 
“ Identification of additional clinical endpoints beyond pulmonary vein isolation could improve 
success rates for AF ablation. “ 
This thesis attempts to address this hypothesis by the following approaches: (1) Investigating 
whether catheter stability and lesion duration affect antral ablation efficacy. (2) Developing a non-
invasive method for identifying the location and extent of left atrial scar after delivery. (3) 
Investigating the feasibility of targeting the autonomic trigger for AF using endocardial high 
frequency stimulation to identify and ablate culprit GP sites.  
Therefore in Chapter 3, we investigate the potential for new technologies for catheter navigation 
and ablation to improve the efficacy of ablation lesions. Without direct knowledge that the 
improvements in the current strategy of circumferential pulmonary vein isolation would lead to 
improved clinical outcomes, we opted for a surrogate measure of ablation efficacy which could be 
directly compared between current standard manual ablation and the newer robotically-assisted 
catheter navigation system. The surrogate measure was local electrogram attenuation in response 
to ablation and has been used before by our group in animal studies comparing robotic and manual 
ablation modalities. We therefore went on to apply this method in humans, comparing local 
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electrogram attenuation at current standard settings for robotic and manual ablation for multiple RF 
lesion deliveries during circumferential pulmonary vein isolation in patients with PAF. 
Outcome studies published during the course of this thesis, demonstrated equivalent outcomes 
between robotic and manually treated ablation groups. We considered that this may reflect the 
safety recommendation to reduce powers for robotic ablation compared to manual. We therefore 
went on to perform a further comparison between local electrogram attenuation from robotic 
ablation at increased RF settings (i.e. similar to standard manual settings). However, increasing the 
transmurality of ablation lesions without increasing the risk of damage to extra-cardiac structures 
remains a significant challenge. In order to address this, a non-invasive imaging modality able to 
identify the presence of durable atrial scar without significant extra-cardiac injury would be key to 
identifying optimal radiofrequency parameters for ablation.   
In Chapter 4, we set out to investigate the potential role of LGE-MRI in providing information about 
the efficacy of ablation lesions. Histological evidence for the efficacy of current ablative techniques 
to produce permanent, transmural atrial scar is limited to post-mortem and animal studies. A non-
invasive method for visualising atrial scar formation post-ablation may provide insights into the 
mechanisms of AF recurrence and facilitate improvements in ablation techniques. This thesis 
investigated the feasibility for identifying atrial ablation scar by performing pre and post-ablation 
DE-MRI, initially on patients undergoing cryoballoon ablation who would receive a predictable 
ablation lesion set. For validation of this method we performed voltage mapping in patients with and 
without prior LA ablation for correlation with the LGE-MRI performed prior to the procedure. We 
then applied our method to a broader range of patients undergoing cryoballoon or conventional 
ablation, and for this aspect of the study we recruited patients at both St Mary’s hospital and St 
Bart’s Hospital. Amounts of pre and post ablation enhancement on LGE-MRI were then compared 
with patient clinical characteristics and outcomes from AF ablation.  
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LGE-MRI may also have the potential to provide information about the underlying atrial substrate 
that is so far not evident from studying known patient risk factors such as age, AF duration, AF type, 
left atrial size, structural heart disease and other patient co-morbidities. If a single investigation 
were able to identify patients who were likely to have a higher success rate from pulmonary vein 
isolation, then this would at least in part allow us to better inform and select patients likely to have 
the greatest benefit from a single procedure.  
However, we hypothesised that if the target and electrophysiological endpoints for ablation were 
suboptimal, then improving ablation efficacy may have no effect on procedural outcome. Instead we 
considered the option that an alternative ablation target may exist.  There is mounting evidence that 
the intrinsic cardiac autonomic nervous system (ANS) may be such a target, with animal studies 
demonstrating its role in both the initiating trigger and generation of the susceptible atrial substrate 
sustaining paroxysms of AF. In chapter5 we investigated, using a parasympathetic blocking agent, 
whether the arrhythmogenic substrate changes seen following endocardial stimulation of GP sites 
are mediated via a parasympathetic or sympathetic mechanism.  
Human studies in which the ANS has been targeted for ablation have, however, produced 
disappointing clinical results so far. Potential limitations in current strategies for GP identification 
and endpoints for GP ablation may be responsible for these results. Chapters 6 investigated the 
potential for using heart rate variability as an intraprocedural end point marker for autonomic 
modulation. We measured HRV parameters at the start and end of the procedure and compared 
HRV reduction in patients with and without AF recurrence at 12 month follow up. In addition, we 
measured HRV changes after transeptal puncture and after each CPVA in a subgroup of patients to 
determine which procedural steps were associated with HRV reduction. 
In Chapter 7 we investigated the neural connections between GP sites around the human left 
atrium.  Hou et al described a neural network in dogs which, if present in humans, would imply that 
the strategy of GP identification through a bradycardic AV nodal effect may have significant 
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limitations when combined with GP ablation. Furthermore, we aimed to investigate whether the 
RUGP is the final common pathway to the SA node, as it has been shown in dogs. In order to do this 
we measured changes in heart rate variability (reflective of autonomic modulation of the SA node) 
before and after ablation at each GP site. Finally, we assessed the feasibility of synchronized HFS as a 
method for identifying GP sites producing ectopic activity within the pulmonary veins and 
determined whether local RF ablation could abolish this response. We identified sites producing PV 
ectopic activity in response to stimulation before and after pulmonary vein isolation with the 
cryoballoon, and subsequently investigated the effect of ablation on this response. 
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2 Methodology 
 
2.1 Patient Selection and Clinical Follow up 
Patients with symptomatic paroxysmal atrial fibrillation, resistant to at least one anti-arrhythmic 
agent, and referred for AF ablation were screened for inclusion in our studies. The cont-HFS study 
also included patients with persistent AF. All patients had stopped their anti-arrhythmic agent 5 half-
lives prior to the procedure, with the exception of amiodarone, and in all but the cont-HFS study, 
only those in sinus rhythm on the day of the procedure were recruited. All patients provided written 
informed consent for participation in the study, which was approved by the Local Research Ethics 
Committee.  Exclusion criteria included the following: heart failure (EF<35%), severe obstructive lung 
disease (COPD, asthma), liver impairment, renal failure. 
All study patients were followed at 3, 6 and 12 months with a clinical history and ECG, and a 24 hr 
Holter monitor was performed between 6 and 12 months post-procedure. After an initial blanking 
period of 6 weeks, the outcome measure of freedom from AF symptoms off all anti-arrhythmic drugs 
and 24 hour holter monitor with <30 secs of atrial arrhythmia was used to define procedural success. 
 
2.2 Catheter Ablation Protocols: 
2.2.1 Radiofrequency Ablation 
The procedures were performed in the fasted state, following trans-oesophageal echocardiogram to 
confirm the left atrial appendage was free of thrombus. Procedures were either under conscious 
sedation with morphine and midazolam or under general anaesthetic, according to operator 
preference. Arterial pressure monitoring was used in all patients from either a radial or femoral 
approach. Two 8 Fr sheaths were inserted into the right femoral vein and a 7 Fr sheath inserted into 
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the left femoral vein. Following transeptal puncture, unfractionated heparin was given to maintain 
therapeutic ACT (between 300 and 350s).  
Pulmonary venography was performed in all patients. An irrigated, 3.5mm tip bipolar mapping 
catheter (NavistarTM, Biosense Webster) was used for all patients. A steerable sheath was used for to 
provide stability to the mapping catheter in all cases. An electro-anatomic map of the left atrium was 
collected using CARTO-XPTM (Biosense Webster). Circumferential pulmonary vein ablation (CPVA) 
was performed guided by the CARTO-3D mapping system and the ablation catheter was kept still at 
each ablation point.  RF energy delivered at each site at 30W for 60 secs.  
2.2.2 Cryoballoon ablation 
Cryoballoon ablation has previously been described by our group in detail 141. Our pre-procedural 
management and venous access were the same as pre the previous section. Two separate transeptal 
punctures were performed. A circular mapping catheter was introduced to map the pulmonary vein 
via one transeptal sheath, and was placed at the ostium of each vein to confirm electrical connection 
prior to ablation.   Over an exchange length 0.035-inch guidewire introduced into the left superior 
PV, the second transeptal sheath was exchanged for a 15 Fr deflectable sheath (Flexcath, Medtronic, 
Minneapolis, Minnesota, USA) to allow introduction of a 28 mm cryoablation balloon (Arctic Front, 
Medtronic, USA). This was the only cryoballoon used for all cases. The cryoballoon was introduced 
over the wire into each pulmonary vein under fluoroscopic guidance and inflated in the left atrium 
before advancing to the vein ostium. A 50% contrast injection was performed, via the central lumen 
of the Arctic Front™ catheter, to demonstrate whether a good seal between the balloon and the PV 
ostium had been achieved. The balloon was repositioned via catheter flexion or guidewire 
repositioning until a good seal was achieved, at which point the refrigerant was injected into the 
cryoballoon aiming for trough temperatures of -40°C. Two 5 minute freezes were performed per 
vein. During the treatment of the right sided veins, the right phrenic nerve was captured via pacing 
in the superior vena cava (1500 ms CL, 20 mA output). The freeze was immediately terminated if any 
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reduction in the strength of right hemi-diaphragmatic contraction was felt by the operator. All PVs 
were checked for isolation using a circular pulmonary vein mapping catheter following ablation. Any 
residual PV sleeves were targeted using an RF catheter or focal cryoablation (Freezor Max, 
Medtronic, USA) according to operator preference.  
 
2.3 Robotically-assisted AF ablation 
The Hansen Sensei electromechanical robotic navigation system is capable of remotely steering a 
guide catheter to enable precise positioning and manipulation of any type of electrophysiological 
catheter within the heart for mapping and ablation. The Sensei system has been described in detail 
previously.131, 180  In brief, the system comprises three linked components: the physician’s 
workstation (Sensei™ robotic control system), remote catheter manipulator (RCM) and steerable 
guide catheter (Artisan™ Sheath) (See figure 1). The steerable guide catheter comprises an outer 
(14F) and inner (10.5F) steerable sheath through which any 8.5F or less ablation catheter can be 
placed. The outer guide can be inserted, de-inserted and can bend up to 90 degrees, whereas the 
inner guide is controlled by the 3D joystick and can be directed anywhere within the toroidal 
workspace.  The Artisan sheath maintains the catheter position by the tensile strength of four pull-
wires so that the shape adopted by the sheath is uniquely suited to the point of interest to which the 
catheter is being positioned.131 This is in contrast to the manual approach, where the operator has to 
dynamically apply torque and flexion to prevent the catheter displacing from the point of interest. 
The Sensei™ robotic control system also incorporates a pressure sensor (Intellisense™), which 
calculates the contact force at the tip of the catheter using the differential resistance when 
continuously dithering the catheter in and out of the Artisan sheath. This real-time pressure reading 
enhances the validation of tissue contact and also provides the ability to identify a pressure curve for 
optimal lesion production.131 
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The Sensei system is currently compatible with all 8.5F or less mapping and irrigated ablation 
catheters. The physician’s work station comprises 3 screens which can display any selected data 
including fluoroscopy, intracardiac echocardiography, electroanatomic mapping systems (Carto 
Biosense Webster, NavX St Jude Medical, Rotational Angiography imaging Philips ElectroNav etc.), 
and electrogram display systems (Bard Lab System Pro etc.)  The free standing physician’s work 
station and remote catheter manipulation system mounted on the patient table can be moved 
between laboratories and do not require any floor reinforcement such as that required for magnetic 
remote navigation systems. 
2.3.1 Animal studies 
The intended benefit of robotic catheter manipulation is that the catheter position is maintained 
once the physician has released the 3D joystick providing increased stability throughout the duration 
of RF delivery. In addition, the Intellisense system can confirm catheter contact during ablation. 
Several studies have been performed in animals to investigate whether the theoretical benefits of 
robotic ablation are translated into improved measurable parameters of lesion quality. In a study 
comparing robotic (Sensei) and manual ablation in 7 pig atria, robotic ablation reduced local 
electrogram amplitude to a greater degree than manual ablation (49+/- 2.6% vs. 29 +/- 4.5% signal 
reduction after one minute p=0.0002) The incidence of >50% signal reduction was also greater for 
robotic (37%) than manual (21%) (p=0.0001).181 Macroscopically, the robotic lesions were noted to 
be more consistently transmural compared to the manual lesions, with no evidence of charring or 
perforation with either modality. 
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Figure 2.1 (A) Comparison of robotic and manual ablation lesions collected on 3D electroanatomical 
mapping system corresponding to the (B) lesions demonstrated on the epicardial surface of a porcine 
atrium.181 
 
To evaluate the optimal contact force for robotic ablation, atrial ablation has previously been 
performed in 12 dogs with the Sensei system. ICE validation of contact was utilised with minimal 
contact correlating to an Intellisense measurement of 4.7 +/- 5.8 grams, consistent contact 9.9 +/- 
8.6 grams and tissue tenting produced 25.0 +/- 14.0 grams. A contact force of 10-20 and >20grams 
generated full thickness, larger volume ablative lesions compared to those created with <10grams 
force (98 +/- 69 and 89 +/- 70 vs. 40 +/- 42 mm3, p<0.05). However, the electroanatomic map / CT 
merge process was more distorted when mapping was generated at moderate or marked contact 
force. The investigators concluded therefore, that robotic mapping should be performed with only 
minimal contact force (i.e. <10grams) whereas optimal ablative lesion size is created using moderate 
(10-20grams) contact force.182 
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2.3.2 Feasibility and outcome studies 
Several studies demonstrating the feasibility of using the Sensei in humans have been performed. 
The feasibility and safety of performing PVI for paroxysmal atrial fibrillation using the Sensei system 
has been demonstrated by several centres, with additional linear lesion sets created in the 
treatment of persistent atrial fibrillation.129, 130, 183 Some centres have reported occasional difficulty in 
reaching the right lower pulmonary vein due to the lack of bend in the large bore outer sheath. This 
has however been improved by recommendations to make a more anterior transeptal puncture (as 
illustrated below) and also with the development of a thinner outer sheath.  
 
Figure 2.2 Hansen robotic simulator for circumferential ablation of the pulmonary veins used by our 
group, demonstrates the reachable and unreachable areas of the left atrium and pulmonary veins. 
(green = reachable and red = unreachable) The image on the left depicts a more anteriorly placed 
transeptal puncture compared to the image on the right, with reachable myocardium subsequently 
surrounding the right-sided pulmonary veins. 
 
 
76 
 
Initial studies demonstrating the early learning curve of working with remote navigation systems 
suggested longer procedure times using the Hansen system which may have been due to caution 
performing ablation with the increased stiffness of the Artisan catheter.131 However, as centres 
perform an increasing number of robotic procedures, it has been noted that setup time, fluoroscopy 
time and overall procedure time have reduced. Robotically-assisted ablation has proven to be both 
feasible and safe for performing atrial fibrillation ablation, and has the potential to improve lesion 
quality as seen in animal studies. However this is yet to be translated into improved clinical results. 
2.3.3 Robotically-assisted catheter ablation protocols 
The procedures were performed in the fasted state, following trans-oesophageal echocardiogram to 
confirm the left atrial appendage was free of thrombus. Procedures were either performed under 
conscious sedation with morphine and midazolam or under general anaesthetic, according to 
operator preference. Arterial pressure monitoring was used in all patients. Two 8 Fr sheaths were 
inserted into the right femoral vein and a 7 Fr sheath inserted into the left femoral vein. A long 14 
French sheath (30 cm) was inserted into the left femoral vein and advanced to the inferior vena cava 
(IVC) under fluoroscopic guidance. Following a single transeptal puncture, unfractionated heparin 
was given to maintain therapeutic ACT (between 300 and 350s).  
Pulmonary venography was performed in all patients. An irrigated, 3.5mm tip bipolar mapping 
catheter (NavistarTM, Biosense Webster) was used for all patients. The map catheter was placed 
inside the Artisan™ sheath and driven into left atrium alongside a J-wire placed within the left upper 
pulmonary vein, with the transeptal sheath and introducer withdrawn into the right atrium. An 
electro-anatomic map of the left atrium was collected using CARTO-XPTM (Biosense Webster). 
Circumferential pulmonary vein ablation (CPVA) was performed guided by 3D mapping and the 
ablation catheter was kept still at each ablation point.  RF energy delivered at each site at 25W for 
30 secs for (standard settings) or 25W for 60secs (increased settings). Using Intellisense pressure 
measurements, lesions were delivered using 10-20g pressure. All PVs were checked for isolation 
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using a circular pulmonary vein mapping catheter following ablation. Any residual PV sleeves were 
targeted at the ostium until PV isolation was achieved.  
 
2.4 Delayed-enhancement MR Imaging of left atrial scar 
MR scanning quality has improved and it may now be possible to visualise atrial myocardium, in 
particular looking for regions of pre-existing fibrosis and iatrogenic scar following catheter ablation 
procedures.184, 185  
The exact mechanism behind delayed enhancement of non-viable myocardium is not completely 
understood, however there is evidence to suggest that an increased volume of distribution, altered 
delivery and washout kinetics of gadolinium contrast agent (Gd-DTPA) result in its accumulation and 
prolonged presence in fibrotic myocardium.186, 187 Gd-DTPA is biologically inert and passively diffuses 
in the myocardium throughout the extracellular space, with a half-life in blood of approximately 
20mins. 188In acutely infarcted myocardium delayed-enhancement MRI may over-estimate the size 
of myocardial necrosis by enhancing both viable and non-viable myocardium due to the presence of 
tissue oedema and increased capillary permeability leading to an increased extracellular volume.189 
2.4.1 LGE CMR Protocol 
All imaging was performed using a 1.5 T Philips Achieva MR system and a 5 or 32 element phased 
array cardiac coil. The technique used for LGE imaging has been described previously.190 Initial 
survey and reference scans were performed to determine cardiac position and orientation followed 
by an axial white blood anatomy image. A vertical long axis and a horizontal long axis were also 
acquired to help with positioning.  A 50 phase 2D cine was acquired at the level of the 
atrioventricular groove to determine the time after the R wave with the least right coronary artery 
(RCA) movement and this time delay was used for subsequent ECG-gating.  
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Further anatomic detail of the left atrium (LA) and pulmonary veins (PVs) was obtained by using non-
ECG gated 3-D spoiled gradient echo contrast enhanced timing robust angiography (CENTRA) during 
the first pass of a 20 ml bolus of gadobenatedimeglumine contrast agent. This sequence was used at 
the time of the catheter ablation procedure for segmentation and registration with the mapping 
systems. A 3D left ventricular LGE breath hold sequence was acquired at approximately 9 minutes 
post-contrast. To further delineate LA anatomy and acquire a high resolution LGE image, an ECG 
triggered, free-breath navigator gated, whole-heart 3-D spoiled gradient echo sequence was 
acquired in an axial orientation, with an acquired resolution of approximately 1.5 x 1.5 x 4 mm and 
reconstructed to 1.25 x 1.25 x 2 mm. Complete LA coverage was obtained with 40-50 slices. Data 
were acquired within a window of 100-150ms within each R-R interval depending on heart rates, 
with a low-high k-space ordering and spectral pre-saturation with inversion recovery (SPIR) for fat 
suppression. The inversion recovery delay was determined from a Look-Locker sequence191, with an 
inversion time chosen to null myocardial signal.  
2.4.2 Image processing methods to identify atrial enhancement  
Interpreting 2D MR slices within a complex structure such as the left atrium and pulmonary veins is 
challenging and therefore most centres describe the generation of 3D atrial reconstructions to aid 
visualisation of atrial enhancement. This requires segmentation of the LA and PVs from the MRA 
with registration to the free-breathing, late-enhancement (LE) sequence, or manual slice-by-slice 
segmentation of the LE which is time-consuming and can be inaccurate. These steps introduce 
inherent inaccuracies to the process of visualising a thin-walled structure which is moving with the 
cardiac cycle and respiration. ECG-gating and respiratory navigation considerably improve the 
accuracy of the sequence,192 however, atrial fibrillation (particularly uncontrolled heart rates) and 
inconsistent breathing patterns remain significant challenges in producing high-quality LE images of 
the LA. 
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Following segmentation of the LE, current methods for identifying atrial enhancement include the 
analysis of pixel intensities within the LA wall. Peters et al describe a method of patient specific 
thresholding, in which the operator visually compares the results from multiple thresholding values 
and selects the minimum threshold which eliminates the majority of pixels within the left atrial 
blood pool.150 A second method illustrated in Figure 2.3 defines normal and abnormal myocardial 
tissue by identifying a bimodal distribution of pixel intensities within the LA wall. The first (lower) 
mode of pixel intensities is chosen as normal myocardium, the second (higher) mode of pixels as 
enhancing or abnormal myocardium (presumed to be scar) and the threshold for identifying 
abnormal myocardium is defined according to the following formula: 
 
Threshold for scar = (mean intensity scar – mean intensity normal myocardium) 
SD normal myocardium 
 
In practice, it is often difficult to identify the second peak, and groups have described manual 
selection of enhancing myocardium to identify a second distribution of pixel intensities. This can also 
be challenging, particularly in patients with very little enhancement, or in patients with diffusely 
enhancing atrial wall. In general a threshold of 2-4 SDs above the atrial wall mode is frequently 
selected at the discretion of the observer. 3D models of the LA are subsequently generated by either 
method with enhancing and non-enhancing regions visually identified according to a colour-look-up 
table.148  
2.4.3 A technique for Automatic atrial segmentation from the MRA sequence: 
Automatic segmentation of the LA was developed in collaboration between the Department of 
Computing and the Department of Cardiac Electrophysiology. Our software was written in C++. The 
algorithm performs an automatic Otsu-based region-growing within the MRA image for identifying 
the atrial chamber, followed by segmentation of PV using tubular shape models193. Segmentation 
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Figure 2.3 Illustration of the work flow of manual segmentation of a late-enhanced MRI of the left 
atrium. 
 
Following selection of the atrial wall (top row, middle and right) the distribution of pixel intensities 
within the wall is plotted (bottom right) and the threshold for identifying enhancing or scarred 
myocardium is calculated from the bimodal distribution. Detected enhancement is then overlaid on 
the LGE-MRI sequence (bottom row, middle and left). 
 
quality was confirmed by an experienced cardiac radiologist. Automatic segmentation depends on 
the quality of the MRA sequence and if suboptimal then manual segmentation or semi-automatic 
software including ITK-SNAP can be used. The method of producing the atrial segmentation is not 
critical to the automated process of atrial scar mapping however the quality of the anatomical 
surface is important for accurately displaying regional atrial enhancement. 
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The segmented atrial surface was used as the reference anatomy on which we compared the pre 
and post ablation enhancement levels and co-localised voltage readings. Rigid or non-rigid 
registration194 was performed depending on the degree of overlap between MRA and LGE 
sequences, with manual verification of registration quality prior to analysis of LGE regions.  
 
2.4.4 Novel methods for LGE Post-processing 
Current methods to identify regions with levels of enhancement defined as “scar” require operator 
selection of a region of myocardium with normal appearance within the LA wall. To remove operator 
bias, we used the LA blood pool as a non-enhancing region against which the LA wall enhancement 
could be compared and normalised. The blood pool was identified automatically by shrinking the LA 
segmentation using mathematical morphology, and the mean (MBP) and standard deviation (SDBP)   
intensity of the blood pool were calculated.  Intensity of the LA wall (ILA) was determined along the 
normal (ie at right-angles to) at each location or cell of the surface mesh. The value taken was the 
maximum intensity along this chord, 3mm inside and outside of the LA surface195 to allow for LA wall 
thickness and minor registration mismatch.  LA wall intensities (ILA) were compared to the blood pool 
mean (MBP) and expressed as multiples of SDBP  above the blood pool mean to provide a normalised 
LA wall intensity(NLA), such that:   
 
NLA= (ILA- MBP)/SDBP 
 
For comparison with co-localised voltage, normalised LA wall intensity was expressed as a 
categorical variable such that NLA was rounded to the nearest integer ie. 0 SD (NLA<0.5), 1 SD (NLA= 1 
± 0.5), 2 SD, 3 SD etc. 
 
To identify any change in enhancement levels between pre and 3-month post ablation scans, 
normalised intensities of the ostial regions and the body of LA in pre and post ablation scans were 
compared for all patients. Using paraview software, each PV ostial region was manually selected by a 
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blinded-observer asked to estimate and encircle the LA-PV junction on the post-ablation anatomy, 
and the ostial region was defined as extending 1cm proximal and distal to this estimated 
encirclement. 
As initial exploration of possible indicators of clinical relevance, baseline enhancement was 
correlated with CHADS2 score, as a composite measure of patient clinical characteristics.  LA surface 
area (%) identified as scar (defined as intensity >3SD above mean blood pool signal intensity) was 
compared in pre ablation scans for patients with and without CHADS2 risk factors including 
hypertension, diabetes, previous stroke, age > 65yrs and congestive heart failure. 
In order to determine whether an association exists between LGE and outcome from AF ablation, 
ostial and LA surface areas (%) identified as scar in pre and 3-month post ablation scans were 
compared for patients with and without AF recurrence at 12 months. To investigate whether 
outcome was associated with the number of PVs showing fully circumferential scar post-ablation, an 
observer blinded to patient outcome determined whether scar (defined as intensity >3SD above 
mean blood pool signal intensity) was continuous around the entire circumference of each vein in 
the 3-month scan, for correlation with both AF recurrence and the presence of electrical 
reconnection of each PV in those patients attending for redo ablation.  
 
2.4.5 Correlating Endocardial Voltage Maps with Delayed-Enhancement MRI 
An important validation is to compare regions of enhancement on LGE-MRI with the measured 
endocardial voltage at these sites. Patients undergoing initial and redo procedures are ideal for this 
assessment. Although blinded scoring systems have been used to show an association between the 
number of regions of the left atrium having low- or high-level enhancement and the number of 
regions having a low or high voltage,148 none has reported point-by-point correlation of co-localised 
enhancement and voltage, which is necessary for evaluation of both pre-existing and ablation 
related enhancement identified by LEG-MRI. Furthermore, a direct point-by-point method of allows 
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comparison of the two parameters as continuous variables, rather than predefined, binarised 
entities. 
Combining voltage and enhancement data 
The left atrial surface from the MR angiogram segmentation was imported in to Ensite NavX (St Jude 
Medical®) or Carto 3 (Biosense Webster®). The voltage mapping was performed in sinus rhythm 
prior to any ablation being performed. For each patient, the registered voltage map was exported 
for offline comparison with the free-breathing, LGE sequence registered to the same atrial anatomy. 
They were both represented on the reference left atrial surface.  Each endocardial voltage was 
assumed to represent a circular region of 2mm radius around the annotated point of endocardial 
contact, which would typically contain ~100 surface mesh cells each with a normalised intensity 
value (NLA). The mean normalised intensity value of the cells within the 2mm radius was used to 
compare with the co-located measured voltage. All areas of the atrium which did not have a 
measured voltage point within a 2mm radius were not included in the correlation analysis. 
 
2.5 Heart Rate Variability as an indicator of autonomic modification 
It was first appreciated in 1963 that fetal distress was preceded by alterations in inter-beat intervals 
before any appreciable changes occurred in the heart rate itself. Subsequent pioneering studies by 
Sayers and his associates introduced a computationally feasible analysis of heart rate variability 
(HRV) providing information about both cardiac sympathetic and parasympathetic modulations of 
heart rate.197, 198 A key finding has been that a reduced HRV was found to be a powerful and 
independent predictor of increased cardiovascular mortality in patients with heart disease and in the 
general population.199 
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 In addition to the statistical analysis of the beat-to-beat variations in heart rate from which the time 
domain measures of heart rate variability are derived, Akselrod introduced power spectral analysis 
of heart rate fluctuations to quantitatively evaluate beat-to-beat cardiovascular control.200 Using this 
method, the state of sympathovagal balance modulating sinus node pacemaker activity can be 
quantified in a variety of physiological and pathophysiological conditions.201 The attenuation of heart 
rate oscillations or impaired responsiveness to a given stimulus can also reflect altered function of a 
target organ, thus dynamic assessment of autonomic activity is essential. 
Many commercial devices now provide automated measurement of heart rate variability, a 
seemingly simple tool for both research and clinical studies. However, the interpretation and 
significance of the different measures of heart rate variability are more complex than generally 
appreciated and there is a potential for incorrect conclusions to be drawn about the underlying 
physiological conditions. It is therefore important to briefly discuss the various indices of heart rate 
variability and their physiological correlates. 
 
2.5.1 Measurement and interpretation of heart rate variability parameters 
Variable phenomena such as heart rate or arterial blood pressure can be described not only as a 
function of time (i.e. in the time domain), but also the sum of elementary oscillatory components, 
defined by their frequency and amplitude (i.e. in the frequency domain). The time domain analysis of 
RR interval variation is recommended to be performed on long duration ECG recordings, e.g. 24 
hours, whereas the frequency domain measures can be obtained from shorter 5-10min recordings. 
The analysis of HRV is usually performed off-line with computerized techniques. In a continuous ECG 
recording, each QRS complex is detected, and the normal-to-normal (NN) intervals (that is all 
intervals between adjacent QRS complexes resulting from sinus node depolarisations) are 
determined. Statistically-derived measures include the standard deviation of the NN interval (SDNN), 
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the standard deviation of the average NN intervals calculated over shorter periods, usually 5 minutes 
(SDANN) and the square root of the mean squared differences of successive NN intervals (RMSSD). 
Using the frequency domain analysis, the signal series can be represented by the sum of sinusoidal 
components of different amplitude, frequency and phase values, giving greater information about 
the periodicity of the signal. Various algorithms are used to evaluate the oscillatory components 
including fast Fourier transform (FFT) or autoregressive (AR) modelling. The FFT is easier to 
implement and usually requires selection of the number and frequency range of bands of interest. 
Spectral components of heart rate variability such as the very low frequency (VLF), low frequency 
(LF), and high frequency (HF) oscillations can be derived from short-term recordings (5- minute 
windows), whereas long-term recordings (24-hour window) allow the additional ultra-low frequency 
(ULF) oscillations to be determined.202 Power spectral density analysis provides the basic information 
of how power (variance) distributes as a function of frequency. The amplitude of LF and HF 
components is assessed by the area (i.e. power) of each component and, therefore, squared units 
are used for its absolute value. LF and HF may also be expressed as normalised units which represent 
the relative value of each power component in proportion to the total power, after subtraction of 
the VLF component.203  
Several studies have provided evidence that the respiratory component of heart rate variability, 
defined as HF spectral component, is a marker of vagal modulation.203-205 Furthermore, Mayer 
proposed that the LF component, present in RR and arterial blood pressure variability, is a marker of 
sympathetic modulation,206 however several groups argue that LF is more reflective of 
sympathovagal balance. Finally, in physiological conditions activation of either sympathetic or vagal 
outflow is accompanied by the inhibition of the other. Hence a reciprocal relation exists between the 
relative amplitude of these two rhythms, and the LF / HF ratio is thought to reflect this 
sympathovagal balance207 
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Table 1 Description of the standard measurements of heart rate variability in the time and frequency 
domain.  
Time Domain Measures of Heart Rate Variability 
Variable Units Description 
SDNN ms Standard deviation of NN intervals 
SDANN ms Standard deviation of the averages of NN intervals in all 5 min segments of 
the entire recording 
rMSSD ms The square root of the mean of the sum of the squared  differences between 
adjacent NN intervals 
SDNN index ms Mean of the standard deviation of all NN intervals for all 5-min segments of 
the entire recording 
SDSD ms Standard deviation of differences between adjacent NN intervals 
NN50 count Number of pairs of adjacent NN intervals differing by more than 50ms in the 
entire recording; 3 variants are possible counting all such NN intervals, pairs 
or pairs in which the first or second interval is longer 
pNN50 % NN 50 count divided by the total number of all NN intervals 
Frequency Domain measures of Heart Rate Variability 
Variable Units Description Frequency Range Physiological correlates 
Analysis of short-term recordings (5mins): 
VLF ms2 Power in VLF range <=0.04 Hz  
LF ms2 Power in LF range 0.04-0.15 Hz ?Sympathetic 
HF ms2 Power in HF range 0.15-0.4 Hz Parasympathetic  
LF/HF  Ratio LF [ms2]/HF[ms2] - Sympathovagal balance 
Analysis of Entire 24 Hours: 
Total power ms2 Variance of al NN intervals <=0.4 Hz  
LF ms2 Power in the ULF range <=0.003 Hz  
VLF ms2 Power in VLF range 0.003-0.04 Hz  
LF ms2 Power in LF range 0.04-0.15 Hz  
HF ms2 Power in HF range 0.15-0.4 Hz  
87 
 
2.5.2 Intra-procedural Short segment HRV measurement 
Measurement of HRV in the catheter laboratory, however, poses significant challenges. Frequent 
atrial ectopy caused by intra-cardiac catheter manipulation prevents HRV component analysis over 
the standard 10min recording window without unduly prolonging the procedure. For the purpose of 
identifying an endpoint for autonomic modification in the context of AF ablation, heart rate 
variability changes would need to be measured over shorter time durations than is currently 
recommended in the consensus document.  
Our group has developed a method of averaging multiple, 40 second ECG recordings to provide a 
measure of acute intra-procedural change in heart rate variability. HRV was averaged from 
sequentially shorter time windows from 5-minute ECG recordings in 15 healthy volunteers to 
identify the shortest duration that yielded valid values.  LF and HF averages from multiple 40-second 
recordings remained within the 95% confidence intervals of multiple 5-minute recordings.208 The 
figure below shows the reduction in both LF and HF immediately following AF ablation identified 
using this method, with no significant changes are seen following right atrial flutter ablation. It was 
proposed that such a method might be developed into an endpoint marker for adjunctive autonomic 
ablation and this was investigated in chapter 4 of this thesis.  
 
 
 
 
 
 
88 
 
Figure 2.4  Power spectral density plots and tachograms for patients undergoing left atrial catheter 
ablation for AF and right atrial catheter ablation for atrial flutter.  
 
No significant change in RR interval is noted following all types of catheter ablation. Significant 
changes in LF and HF parameters are noted only following left atrial catheter ablation.208 
 
 
2.6 Identification and ablation of the left atrial ganglionated plexi 
2.6.1 High frequency stimulation using the Grass Stimulator 
A Grass S48 stimulator with an SIU-V stimulus isolation unit (Astro-Med, RI, USA) was used in all 
cases to localize the ganglionated plexi. Consistent with other human studies the following 
stimulation parameters were used: Frequency 20Hz, pulse width 10ms, Voltage (at catheter tip) 10V, 
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voltage dialled on Grass stimulator 100V. Due to the potential for ventricular capture with high 
output atrial pacing, all sites were initial stimulated with a lower pacing rate (100 beats per minute). 
HFS was subsequently performed once the possibility of ventricular capture had been excluded. Our 
group has performed human validation work for this technique in both epicardial (surgical) and 
endocardial procedures.  
 
2.6.2 Continuous HFS 
The method of continuous high frequency stimulation (cont-HFS) has been used by several groups as 
a means to identify the location of activatable GPs in humans, and has also been validated by our 
group. A high-output, high frequency pacing stimulus is delivered from an electrode placed at the 
presumed location of each ganglionated plexi. The GP site location is identified by a vagal response 
to cont-HFS, defined as a prolongation of the RR interval by more than 50%. Asytole and AV-block 
frequently occur as a response to HFS, and local atrial capture, frequently inducing AF, is inevitable. 
Ablation can be performed in a cloud around the stimulated GP site and some studies suggest that 
the response is typically abolished after 3-4 RF deliveries of 30secs each.169 The abolition of this 
response to stimulation has been suggested as an endpoint for autonomic ablation.169-174 To 
investigate this further, we firstly investigated the effect of autonomic blockade on the response to 
HFS at known GP sites, and subsequently assessed the effect of ablation of GP sites in varying 
sequences. 
 
2.6.3 Synchronized HFS 
Synchronized HFS is a method that has been developed in animal studies209 and previously validated 
for use in humans by our group.70 The method of cont-HFS is limited by the fact that it results in 
atrial capture which frequently induces AF in the population of patients we are studying. Sync-HFS 
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delivers short bursts of HFS during the atrial refractory period in an attempt to stimulate epicardial 
GPs whilst avoiding direct atrial capture. This method allows us to investigate the effect of 
autonomic stimulation on the initiation of ectopy during sinus rhythm.  
The grass stimulator was programmed to perform fixed-rate pacing slightly faster than the patient’s 
intrinsic sinus rate, with pacing performed from the Map catheter placed at a presumed GP site. HFS 
was delivered at 20Hz for 100ms following a delay of 20-40ms after each pacing stimulus (dependent 
on the timing of the first local atrial depolarisation seen after the initial pacing stimulus). It has 
previously been demonstrated that the atrial refractory period at the PV ostia is 216±38ms22 
therefore the burst of HFS should fall within the local atrial refractory period, preventing local atrial 
capture.    
Animal studies have shown that autonomic activation using sync-HFS initiates rapid firing from the 
pulmonary veins leading to AF, and that autonomic denervation suppresses or eliminates those 
rapid firings.209 Our group has also previously shown that autonomic activation using sync-HFS 
initiates ectopic activity with the local PV.70 Following the results of this study, we sought to 
determine whether ablation of the ganglionated plexi in humans could abolish these effects. In 
addition we investigated the effect of pulmonary vein isolation on the ectopic firing initiated by 
autonomic stimulation as shown in Figure 2.5. 
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Figure 2.5 Example of synchronised HFS delivery. 
The method of Sync-HFS involves delivering short bursts of HFS (12V, 50Hz, 10ms pulse width), 
synchronized to the local atrial refractory period, through the map catheter. This aims to prevent 
local atrial capture which will inevitably result in AF induction.  
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3 Improving transmurality of lesions during antral ablation  
 
3.1 Introduction 
Achieving permanent pulmonary vein isolation with a single procedure is an ongoing challenge of 
atrial fibrillation (AF) ablation.23, 117, 124, 167 Conventional ablation catheters were designed to deliver 
radiofrequency energy to discrete sites such as the slow pathway to treat re-entrant arrhythmias 
with very high success rates. Catheter ablation for AF requires an extensive lesion set and has yet to 
achieve equivalent success rates, which may in part be due to the limitations of such catheters.5, 210 
Robotic catheter navigation has been developed to overcome some of the limitations of manual 
catheters such as precision movements for placing contiguous lesions and stable catheter position to 
maintain tissue contact throughout ablation delivery.131, 211, 212  
In animal studies, we demonstrated that at equivalent radiofrequency settings, there was more 
rapid and greater reduction in local electrogram amplitude during robotic ablation compared to 
manual. This was associated with more consistent transmurality on macroscopic examination of 
robotic lesions. 181 These findings suggest that robotic ablation could potentially improve the 
transmurality of ablation lesions in humans. However, this has not translated to improved success 
rates for robotic AF ablation in several non-randomised clinical studies compared to conventional 
manual approach. 130, 136, 137 A possible explanation is that many users reduced the robotic RF power 
and duration compared to manual settings due to concern about increased catheter stability leading 
to excessive energy delivery that increases the risk of perforation and oesophageal injury.183, 213 
In order to understand the discrepancy between the animal and human work, we investigated 
whether selection of the energy level or limitations of robotic manoeuvrability in the left atrium 
affect the lesion quality of robotic ablation in humans.  
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3.2 Methods 
Study patients 
Patients with symptomatic paroxysmal atrial fibrillation, resistant to at least one anti-arrhythmic 
agent, and referred for AF ablation were screened. All patients stopped their anti-arrhythmic agent 5 
half-lives prior to the procedure and only those in sinus rhythm on the day of the procedure were 
recruited. All patients provided written informed consent for participation in the study, which was 
approved by the Local Research Ethics Committee.  The 20 study patients were randomised to 
receive either robotic or manual ablation at our institution’s current standard RF settings of 30W for 
60 secs for manual ablation (M) and 25W for 30 secs for robotic ablation (R30). In a subsequent non-
randomised consecutive group of 10 patients, all undergoing robotic ablation, the duration of RF 
energy delivery was increased to 60 secs as for manual ablation, whilst maintaining the same 
reduced power setting of 25W (R60). All procedures were performed by experienced operators. 
Ablation procedure 
The procedure was performed in the fasted state, following trans-oesophageal echocardiogram to 
confirm the left atrial appendage was free of thrombus. Procedures were either performed under 
conscious sedation with morphine and midazolam or under general anaesthetic, according to 
operator preference. Arterial pressure monitoring was used in all patients. Two 8 Fr sheaths were 
inserted into the right femoral vein and a 7 Fr sheath inserted into the left femoral vein. For robotic 
procedures a long 14 French sheath (30 cm) was inserted into the left femoral vein and advanced to 
the inferior vena cava (IVC) under fluoroscopic guidance. Following a single transeptal puncture, 
unfractionated heparin was given to maintain therapeutic ACT (between 300 and 350s). Pulmonary 
venography was performed. An irrigated, 3.5mm tip bipolar mapping catheter (NavistarTM, Biosense 
Webster, CA, USA) was used. In robotic procedures the map catheter was placed inside the Artisan™ 
sheath and driven into left atrium alongside a J-wire placed within the left upper pulmonary vein, 
with the transeptal sheath and introducer withdrawn into the right atrium. An electro-anatomic map 
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of the left atrium was collected using CARTO-XPTM (Biosense Webster). Circumferential pulmonary 
vein ablation (CPVA) was performed guided by 3D mapping and the ablation catheter was kept still 
at each ablation point.  RF energy delivered at each site at 30W for 60 secs in manual ablation and 
25W for 30 secs for robotic ablation. For robotic procedures using Intellisense, lesions were 
delivered with a target of 10-20g pressure.   Pulmonary vein isolation was confirmed by a circular 
pulmonary vein mapping catheter. Robotic procedures were performed by one operator who had 
performed >50 cases at the start of the study. 
Catheter stability measurement 
In order to address the initial assertion that robotic navigation provides additional catheter stability 
compared to manual catheter manipulation, we needed to identify an intraprocedural measure of 
catheter stability that could be used to compare between the two modalities. Ideally we would 
measure the complete distance travelled throughout the duration of radiofrequency energy 
delivery. However, current electroanatomic mapping (EAM) systems do not easily release this data. 
An alternative method was to collect an ablation point marking the catheter position immediately 
prior to ablation starting and again immediately after ablation stopped. The Carto™ system has an 
automatic distance measurement tool allowing the calculation of distance between 2 selected 
points. We have previously validated the accuracy of this tool. 214 Additional annotation can be 
allocated manually to all markers collected at the end of ablation to allow for differentiation 
between the ablation start and ablation stop markers. Each collected point is automatically allocated 
a number via Carto™ and the number was manually logged on the Bard EP system to allow for 
correlation between the distance moved by the catheter and the degree of electrogram attenuation 
for each ablation lesion. The operators were instructed to maintain the ablation catheter at the 
same position. Lesions with complete catheter displacement were excluded. Clearly a limitation of 
this method is that the ablation catheter may move significantly during ablation but return to the 
initial location just before the ablation stops.  
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Signal reduction measurement 
The measurement of local electrogram voltage reduction has been used in several studies to 
monitor tissue injury during radiofrequency energy delivery.181, 215-217 The intracardiac electrogram 
recordings were stored on a Bard system (Lab system Pro EP, Bard, Lowell, MA) for offline 
measurement. The bipolar electrogram recording from the distal electrode of the mapping catheter 
was used for voltage amplitude measurement, from peak maximum to peak minimum. Signal 
amplitude is known to change with respiration and cardiac motion, therefore averaging the signal 
amplitude over 5 cardiac cycles prior to ablation start and after ablation stop may provide improved 
accuracy over a single measurement. The measurements were taken from the 5 atrial electrograms 
immediately prior to ablation start and the 5 atrial electrograms immediately following ablation stop 
(corresponding ablation time points are automatically logged on the Bard system). The voltage 
change between the mean pre and mean post ablation electrogram was calculated for each lesion. 
Percentage electrogram voltage change was calculated for each lesion and compared between 
robotic and manual modalities. Lesions which demonstrated an increase in voltage were defined as 
exhibiting catheter micromovement, since an increase in voltage can only be due to movement of 
the catheter and not due to RF delivery. The number of lesions demonstrating catheter 
micromovement during ablation were compared between robotic and manual modalities. These 
lesions were excluded from the overall calculation of voltage reduction for each modality. 
Evaluation of measurement reliability 
To prevent bias that may arise through un-blinded signal measurement, we assessed inter-observer 
variability in determination of voltages using the data from 2 patients from each of the three groups. 
The 2 additional observers were blinded to the findings of the first observer and each other, and to 
the modality of the procedure. Distance measurements were calculated automatically between 2 
selected points by the electroanatomic mapping system, therefore reproducibility testing was not 
felt to be necessary. 
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Comparison of ablation parameters for left and right-sided circumferential ablation 
Due to the relative inflexibility of the robotic inner and outer steerable sheaths, difficulty in reaching 
and maintaining stability at the right lower pulmonary vein has been noted by some operators. We 
compared signal attenuation during ablation for right and left sided veins in both robotic and manual 
groups to investigate whether there was a difference in ablation efficacy between left and right 
sided ablation for either modality.  
Statistics 
All variables are expressed as mean ± standard deviation. Statistical analysis of continuous variables 
was by unpaired t tests. Analysis of categorical variables was by Chi-square test. The association 
between distance moved during ablation and voltage reduction was analysed using Spearman’s rank 
correlation. Inter-observer, signal amplitude measurement reproducibility was determined using 
Pearson’s correlation co-efficient. A p value of <0.05 was considered statistically significant. 
 
3.3 Results: 
Patients were randomised to either manual (n=10) or robotic ablation (n=10). A further 10 
consecutive patients underwent robotic ablation at the increased lesion duration of 60s.  The patient 
demographics and procedural details are shown in Table 2. No significant differences in patient 
demographics or procedural details were noted between the 3 groups, with the exception of total RF 
time which was greater in the R60 group. There were three complications; two groin haematomas 
(minor) requiring no intervention, one in the manual group, one in the R60 group, and a 
retroperitoneal bleed (major) in the R30 group, given 2 units of blood transfusion and settled with 
no further treatment. These were not on the side of the robotic 14F sheath, and were all on the 
same side as the arterial sheath. Of note, there were no significant differences in patient 
demographics or procedural outcomes between procedures under general anaesthesia and 
conscious sedation.   
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Table 2 Patient Demographics and procedural details for manual and robotic groups 
 
 
* p – values comparing between groups using T-tests for normally distributed variables and Chi squared tests for binary variables.  
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Methodology Validation 
Voltage measurements were compared in 6 patients between the original observer (1) and two 
further observers (2 & 3). For observer 1 vs. 2, a good correlation was demonstrated between 
ablation start and stop measurements (R2=0.862 and 0.799 respectively, p < 0.001). The 
measurements were not significantly different between observer 1 and 2 (p=0.97 and 0.79 
respectively). For observer 1 vs. 3, a good correlation was demonstrated between ablation start and 
stop measurements (R2=0.87 and 0.856 respectively, p < 0.001). The measurements were not 
significantly different between observer 1 and 3 (p=0.41 and 0.39 respectively). This confirmed that 
there was accurate, reproducible and unbiased measurement of bipolar voltage electrogram 
amplitude. 
The importance of catheter stability for effective lesion formation is well established. We measured 
catheter stability using two time-points at the beginning and end of energy delivery. In order to 
confirm that this technique produces a valid marker of catheter stability, distance moved during RF 
was correlated with local electrogram reduction for all lesions (Figure 3.1). A significant negative 
correlation was identified between the distance moved during ablation and mean percentage signal 
reduction (Spearman’s rho -0.929, p<0.001).  
Voltage reduction for stable deliveries (<1mm moved during RF) was 46.1±30.8% compared to 
32.6±32.7% unstable deliveries (>1mm movement) (p=0.01). This finding confirms that our 
technique for assessing lesions in vivo is related to catheter stability. 
Lesions which produced an increase in local electrogram voltage were defined as episodes of 
catheter micromovement since this cannot be the result of ablation. We confirmed this by 
comparing the average distance moved for lesions demonstrating micromovement with those not 
demonstrating micromovement (4.5±3.5 mm vs. 3.1±2.6 mm respectively, p<0.001).   
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Figure 3.1 Correlation of signal amplitude reduction and distance moved during RF ablation. 
Signal amplitude attenuation (mean ±SEM) produced by both robotic and manual modalities reduces 
with increasing distance moved during RF ablation, demonstrating that greater catheter stability is 
associated with greater signal amplitude reduction following ablation. 
Catheter stability 
Catheter stability was analysed on each completed lesion; manual (M, n=347), robotic-30s (R30, 
n=406) and robotic-60s (R60, n=355). The average distance moved during RF delivery was 
4.3±3.0mm (M) vs. 2.9±2.3mm (R30) vs. 2.6±2.2mm (R60). Both robotic groups were more stable 
than manual ablation (p<0.001) (Figure 3.2 top panel).  
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Figure 3.2 Measures of catheter stability compared for Manual and Robotic modalities. 
(bottom panel) Distance (mean ±SEM) moved by catheter tip measured during Robotic and Manual 
RF ablation demonstrating greater catheter stability with Robotic ablation. (top panel) Episodes of 
micromovement (defined as an increase in local electrogram voltage during ablation) compared 
between Robotic and Manual ablation modalities.  
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The episodes of micromovement were 88/347 (25%) in the manual group, 46/406 (11%) in robotic-
30s and 50/355 (14%) in the robotic-60s groups (Figure 3.2 bottom panel). Again both robotic groups 
were more stable than manual (p=0.002 and p=0.01, for R30 and R60 respectively). 
The assertion that robotic catheter positioning is more stable than manual appears to be correct 
during CPVA in the left atrium and the duration of the RF delivery does not appear to influence this.  
Signal amplitude reduction 
The average signal voltage reduction was no different in the manual group 47.7±25.4% compared to 
the R30 group 45.9±21.3%, p=0.38. However, in the patients who underwent robotic ablation with 
increased RF duration (R60), there was a statistically greater voltage reduction 52.4±19.4% 
compared to manual ablation (p=0.012) and compared to R30 (p<0.001) (Figure 3.3).  
This confirms that increased catheter stability conferred by robotic navigation leads to greater signal 
attenuation compared to manual ablation. If both power and duration of radiofrequency energy are 
reduced (R30) then the benefits of robotic navigation can be lost. 
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Figure 3.3 Comparison of signal attenuation between Robotic and Manual Modalities. 
Significantly greater signal amplitude reduction (mean ±SEM) with Robotic ablation for 60 seconds 
compared to Manual (60s) and Robotic (30s) ablation at standard settings. 
 
The effect of general anaesthesia on catheter stability 
It has been suggested that the use of general anaesthesia can improve procedural outcomes and 
lead to lower rates of pulmonary vein reconnection.218 We studied the effect of GA across all groups. 
Measures of catheter stability were better in procedures under GA compared to conscious sedation 
(distance moved 2.8±2.3mm vs. 4.1±3.3mm, p < 0.001 and episodes of micromovement 12% vs. 18% 
respectively, p < 0.001) as were markers of ablation efficacy (signal attenuation 50.5±21.8% vs. 
46.8±22.4% respectively, p =0.03). 
* p – values comparing between Manual and Robotic 60s groups, using Student T-tests 
† p - values comparing between Robotic 30s and Robotic 60s groups using Student T-tests 
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 Figure 3.4 Comparison of signal attenuation between Robotic and Manual modalities for procedures 
with and without general anaesthesia. 
Local signal attenuation (mean ±SEM) compared for procedures conducted with and without general 
anaesthesia (GA), further separated into Manual and Robotic 30 and Robotic 60 groups. Significantly 
greater signal attenuation is seen in the Robotic 60 group with GA compared to both Manual and 
Robotic 30 groups with GA.   
* p – values comparing between Manual and Robotic 60s groups, using Student T-tests 
† p - values comparing between Robotic 30s and Robotic 60s groups using Student T-tests 
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The effect of GA on signal attenuation was non-significant in all groups (Figure 3.4). When 
procedures under GA alone were compared, there remained a greater signal amplitude reduction in 
the R60 group compared to manual (53.2±19.6% vs. 48.2±26.1%, p=0.02) and R30 (46.8±20.8%, p 
<0.001). 
 
 
 
Figure 3.5 Distance moved during robotic and manual ablation compared for procedures with and 
without general anaesthesia. 
Distance (mean ±SEM) moved by the catheter tip during RF delivery compared for procedures 
conducted with and without general anaesthetic, further separated into Manual and Robotic 30s and 
Robotic 60s groups. Significantly greater distances are seen with manual ablation compared to both 
robotic groups, in procedures with and without GA. 
* p – values comparing each of the Robotic 30 and Robotic 60 groups with Manual ablation, separately for GA and Non-GA 
procedures. 
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Similarly, there was significantly less distance moved during ablation under GA in the R60 group and 
R30 group compared to the manual group (2.5±2.1mm and 2.8 ±2.1mm  vs. 4.1±3.3mm, p<0.001 for 
both robotic groups) (Figure 3.5). 
Episodes of micromovement under GA were also fewer in both the R60 and R30 group compared to 
manual (11% and 9% vs. 18%, p=0.02 and p=0.001 respectively). These results suggest that although 
procedures under GA benefit from improved catheter stability, the effect is more marked during 
robotic ablation. 
Robotic navigation and location of CPVA 
We analysed each case by right or left sided circumferential ablation. The average signal amplitude 
reduction for the right vs. left CPVA was 46.5±25.3% vs. 48.8±25.5% for Manual (p=ns), 48.7±21.9% 
vs. 44.1±24.7% for R30 (p=ns) and 52.7±19.5% vs. 52.3± 19.5% for R60 (p=ns). There was no 
difference in ablation efficacy between right and left CPVA for each modality. 
Outcomes 
Our study was not powered to identify differences in outcome between robotic and manual 
ablation. However, 12 month follow up data (mean follow-up 22.2 ± 9.3 months) is available for the 
30 study patients and may provide preliminary insights into whether robotic ablation at higher 
powers has an effect on medium term outcomes. After an initial blanking period of 6 weeks, 
freedom from AF symptoms off all anti-arrhythmic drugs and 24 hour holter monitor with <30 secs 
of atrial arrhythmia, was used to define procedural success. 6 of 10 (60%) patients are free from AF 
recurrence at 12 months in the manual group, 5 of 10 (50%) patients in the robotic 30 group, 
whereas 8 of 10 patients (80%) in the robotic 60 group are free from AF recurrence at 12 months.  
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3.4 Discussion: 
Our study confirms that there is greater stability with robotically-assisted catheters during RF 
ablation compared to manual. However, at reduced power and duration of radiofrequency energy 
delivery (R30 group - our standard for robotic procedures), the signal amplitude reduction was not 
significantly different to manual ablation. This suggests that we may have lost the benefit of 
improved catheter stability of robotic ablation by reducing RF power and duration. Increasing the 
radiofrequency duration of robotic ablation to 60secs led to a significant increase in signal 
attenuation. If pulmonary vein reconnection is the result of insufficient ablation, signal attenuation is 
one of the few endpoints that can be used to monitor the acute effect of ablation and potentially 
improve the lesions delivered. This study provides important observations on the quality of lesions 
delivered during CPVA and how robotic guidance can be used to optimise signal attenuation. 
Previous studies comparing robotic and manual ablation have shown no significant difference in 
clinical outcomes. Although the primary aim of these studies was to prove safety and feasibility, it 
was generally anticipated that increased catheter precision and stability would lead to better clinical 
outcomes.  Whilst these studies used the same settings for both robotic and manual ablation (either 
45W for 20secs130 or 20-25W for 60s124) lesions, the reports comment on robotic ablation requiring 
shorter radiofrequency duration, implying that the operators adjusted power and time according to 
anatomical location and local signal attenuation. This would be considered standard practice at 
many centres where a target reduction in local electrogram of >80% is often quoted. 78, 85  However, 
we would argue that if a standardised change in local electrogram is used as an endpoint then it is 
likely that lesion quality will remain similar between manual or robotic approaches. Therefore, it 
may not be surprising that clinical outcomes remain similar. Furthermore, adjustment of RF 
parameters to achieve a desired level of local signal attenuation may not imply transmurality or the 
presence of a permanent lesion.  Even when adjunctive mapping is used to confirm conduction block 
in the CPVA, there remains a significant PV reconnection rate even though these pre-specified signal 
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attenuation targets have resulted in conduction block that presumably signifies a transmural effect. 
Therefore, our assumption is that the degree of signal attenuation needs to be increased to achieve 
permanent lesions.  This approach would need to be balanced against the potential increased risk of 
cardiac perforation, atrio-esophageal fistula formation and phrenic nerve injury.  
We have previously demonstrated in animal studies that at equivalent radiofrequency settings (25W 
for 60s, target pressure 20g), robotic ablation was superior to manual ablation. One in-vitro study 
looking at lesion transmurality and char formation with different RF powers, found that using 45W at 
20-30g for 40sec, 83% of lesions were transmural and 33% of lesions were associated with char 
formation. Using lower RF settings of 30W and 20-30g pressure, no lesions were associated with 
char formation, however only 16% were transmural. 219 These studies suggest that 25W for 60 secs 
should be a safe power and duration for robotic ablation. Following the preliminary results from our 
randomised series that our current settings were not producing statistically significant differences in 
signal attenuation, we felt that increasing RF duration to 60s would be a safe approach. Furthermore 
our previously published animal series suggested that these settings may be sufficient to produce 
transmural lesions 181.  
The current study also suggested a critical additive effect using general anaesthesia.  Robotic RF 
delivery was more stable than manual regardless of the type of anaesthesia, however, statistically 
significant changes in signal attenuation only occurred with robotic ablation conducted under 
general anaesthesia. On the basis of this pilot data, we would suggest that for any randomised 
comparison with manual ablation, the robotic ablation parameters should be 25W for 60s at 20g 
pressure under general anaesthesia. 
Limitations: 
Signal amplitude reduction has several limitations due to problems of combined local and far field 
signals. Catheter movement can produce both an increase and decrease in signal amplitude, and loss 
of local electrogram occurs with both effective ablation and poor tissue contact. Effective ablation 
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causing local tissue oedema may also lead to catheter movement and an increase in local 
electrogram voltage. Our methods do not enable us to differentiate between causes for local 
electrogram increase and catheter displacement. Our method for stability measurement is limited 
since it only measures the distance between the start and finish catheter locations. However, these 
limitations affect both manual and robotic ablation modalities equally. This was a pilot study only 
and not designed to power for clinical outcomes. 
 
3.5 Conclusions 
Robotically-assisted ablation using the Hansen system has the capability to produce greater local 
electrogram attenuation than manual ablation with appropriate RF parameter selection. The use of 
general anaesthesia appears to help achieve this benefit. Whilst randomised studies are required to 
assess clinical outcomes with increased RF power, a non-invasive method to assess durable lesion 
formation would be beneficial to achieve optimal ablation efficacy without increasing the risk of 
extracardiac damage.  
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4 Identification of left atrial scar using delayed-
enhancement cardiac magnetic resonance Imaging         
 
4.1 Introduction 
Several recent studies have shown that high-spatial-resolution late gadolinium enhancement (LGE) 
cardiovascular magnetic resonance (CMR) imaging can be used to visualise pre-existing left atrial 
fibrotic change and evaluate RF lesions.147, 149, 184, 185, 190, 192, 221  Current methods to identify atrial scar 
rely on operator judgement to define the level of enhancement assigned as scar. 147, 149, 184, 185, 190, 192    
One approach is to look for a bi-modal distribution of intensity to define the threshold of scar as the 
trough between the peaks.190 In many patients, however, the distribution of intensity is not bimodal, 
preventing this from being a universally applicable technique. An alternative approach is to manually 
select a region of scar and a region of non-scar tissue, to define a patient specific threshold above 
which enhancement is defined as scar.222 However in many patients scar may be patchy and 
different observers may choose different regions to define as scar.  Despite the operator 
dependence of these methods, visually appreciable correlations between regions identified as scar 
and areas of voltage <0.5mV in patients post AF ablation has previously been demonstrated.148, 223 
Furthermore, blinded scoring systems have been used to show an association between total scar in 
the atrium and the total burden of low-voltage electrograms in a given patient, but these measures 
lack the ability to co-localise scar and low voltage.148 
In this study we examine the use of the blood pool as an intensity reference in an automated 
process which expresses myocardial intensity as multiples of standard deviation above the blood 
pool mean intensity, combined with operator-independent segmentation.  We tested the hypothesis 
that these techniques will identify LGE with a level of consistency that will enable both point-by-
point correlation of co-localised enhancement and voltage, and correlation with procedural and 
patient characteristics.  
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4.2 Methods 
50 patients undergoing first ablation for paroxysmal AF were recruited from two centres: Bart’s and 
The London NHS Trust (N=25) and Imperial College Healthcare NHS Trust (N=25). LGE CMR scan was 
performed before and 3 months after either cryoballoon or conventional radiofrequency ablation. A 
subset of patients underwent endocardial voltage mapping during the ablation procedure. All CMR 
scans and voltage maps were performed in sinus rhythm. All patients were followed up at 3, 6 and 
12 months with an ECG and clinical history, and a 24 hr Holter monitor at 6 months. The study was 
approved by the local Research Ethics Committees (UK) and written, informed consent was obtained 
from all patients. All 50 patients included in the study had diagnostic quality images and completed 
12 months follow-up. 
LGE CMR Protocol 
All imaging was performed using a 1.5 T Philips Achieva MR system and a 5 or 32 element phased 
array cardiac coil. The technique used for LGE imaging has been described previously.190 A 50 phase 
2D cine was acquired at the level of the atrioventricular groove to determine the time after the R 
wave with the least right coronary artery (RCA) movement and this time delay was used for 
subsequent ECG-gating.  
Anatomic detail of the left atrium (LA) and pulmonary veins (PVs) was obtained by using non-ECG 
gated 3-D spoiled gradient echo contrast enhanced timing robust angiography (CENTRA) during the 
first pass of a 20 ml bolus of gadobenatedimeglumine contrast agent. This sequence was used for 
segmentation. A 3D left ventricular LGE breath hold sequence was acquired at approximately 9 
minutes post-contrast. The breath-hold scan was used to identify the optimal nulling time for the LV.  
 To further delineate LA anatomy and acquire a high resolution LGE image, an ECG triggered, free-
breath navigator gated whole-heart 3-D spoiled gradient echo acquisition was acquired in an axial 
orientation, with an acquired resolution of approximately 1.5 x 1.5 x 4 mm and reconstructed to 1.25 
x 1.25 x 2 mm. Complete LA coverage was obtained with 40-50 slices. Data were acquired within a 
window of 100-150ms within each R-R interval depending on heart rates, with a low-high k-space 
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ordering and spectral pre-saturation with inversion recovery (SPIR) for fat suppression. The inversion 
recovery delay, determined from a Look-Locker sequence191, was chosen to null myocardial signal. A 
leading navigator was used. Navigator inflow artefact was reduced by reducing the navigator rescale 
factor and by positioning the Navigator away from the right sided PVs. Free Breathing images were 
acquired about 12-20 min post injection depending on successful navigator placement aiming for a 
Navigator efficiency of over 30%. Example pre and post ablation LGE-CMR are shown in Figure 4.1. 
 
 
Figure 4.1 (top) pre ablation LGE-CMR transverse slice of LA and PVs (bottom) post ablation LGE-CMR 
of LA and PVs, red arrows demonstrating ostial ablation enhancement 
112 
 
Voltage Mapping 
21 patients had voltage maps during either the initial procedure (n=10) prior to any ablation being 
performed, or during the redo procedure for recurrent AF (n=11). The LA surface segmentation was 
imported into Ensite NavX (St Jude Medical®) or Carto 3 (Biosense Webster®). The LA geometry was 
collected using the duodecapolar A Focus catheter (St Jude Medical®) or 20 pole Lasso catheter 
(Biosense Webster). Regions including the PV ostia and left atrial appendage (LAA) were assigned as 
separate geometries to prevent interpolation between the 2 structures which often leads to the 
creation of false space in the LA-PV map. The electroanatomical geometry was registered to the 
imported LA segmentation using NavX surface registration. Peak to peak voltages were collected 
from the 10 bipoles of the 20 pole circular mapping catheter or the 2 distal poles of the mapping 
catheter, each bipole is 2mm apart from the centre of each recording electrode. Bipolar electrogram 
amplitudes are less affected by far-field signals, however are influenced by catheter orientation to 
the underlying tissue and the direction of wavefront propagation.196 We therefore performed 
additional unipolar recordings in 5 patients. A pentapole catheter placed was placed in the coronary 
sinus, and unipolar voltage data was collected between the distal pole of the map catheter and a 
single reference electrode within the inferior vena cava. Bipolar signals were acquired with high and 
low pass filter settings of 16-500Hz and unipolar 2-240Hz.  The operator collecting the voltage map 
was blinded to the offline left atrial enhancement map. 
 
Automated Method of Scar Mapping 
Automatic segmentation of the LA was performed using custom software, written in C++, similar to 
that used in a previous study by Knowles et al195. The algorithm performs an automatic Otsu-based 
region-growing within the MRA image for identifying the atrial chamber, followed by segmentation 
of PV using tubular shape models193. Removal of distal PV branches and the ventricular blood pool 
was performed manually. Segmentation quality was confirmed by an experienced cardiac 
radiologist. This surface was used as the reference anatomy, on which we compared the 
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enhancement levels and voltage readings. Rigid or non-rigid registration194 (depending on atrial wall 
overlap in the 2 sequences) was performed between the segmented MRA and LGE surfaces. Manual 
verification was carried out visually to ensure that the atrial wall was aligned correctly in the 2 
sequences by the registration process, prior to analysis of LGE regions.  
We used the LA blood pool as a non-enhancing region against which the LA wall enhancement could 
be compared and normalised. The blood pool was identified automatically by shrinking the LA 
segmentation using mathematical morphology, and the mean (MBP) and standard deviation (SDBP)   
intensity of the blood pool were calculated.  Intensity of the LA wall (ILA) was determined along the 
normal at each location or cell of the surface mesh. The value taken was the maximum intensity 
along this chord, 3mm inside and outside of the LA surface195 to allow for LA wall thickness and 
minor registration mismatch.  LA wall intensities (ILA) were compared to the blood pool mean (MBP) 
and expressed as multiples of SDBP  above the blood pool mean to provide a normalised LA wall 
intensity(NLA), such that:  NLA= (ILA- MBP)/SDBP.  An example of an automated scar map is 
demonstrated in Figure 4.2 For comparison with co-localised voltage, normalised LA wall intensity 
was expressed as a categorical variable such that NLA was rounded to the nearest integer ie. 0 SD 
(NLA<0.5), 1 SD (NLA= 1 ± 0.5), 2 SD, 3 SD etc.  
 
Comparison of voltage and enhancement data 
For each patient, the registered voltage map was exported for offline comparison with the free-
breathing, LGE sequence registered to the same atrial anatomy. They were both represented on the 
reference left atrial surface.  Each endocardial voltage was assumed to represent a circular region of 
2mm radius around the annotated point of endocardial contact, which would typically contain ~100 
surface mesh cells each with a normalised intensity value (NLA). The mean normalised intensity value 
of the cells within the 2mm radius was used to compare with the co-located measured voltage. All 
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areas of the atrium which did not have a measured voltage point within a 2mm radius were not 
included in the correlation analysis. These methodological steps are summarised in Figure 4.3.   
 
 
Figure 4.2 Example of atrial scar mapping of LGE-CMR after cryoballoon ablation, with colour look-up 
table denoting normalised intensity from SD 0 to SD10. 
 
Ablation Procedure 
Wide area PV encirclement using conventional radiofrequency ablation was performed in 25 of 50 
patients, with the other 25 undergoing cryoballoon ablation of all 4 PVs. These techniques are 
described in detail in the methods section. 
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Figure 4.3 Summary of method of automated intensity mapping and merging for correlation with 
voltage distribution. 
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(From top to bottom)  Intensity of the blood pool (MBP ±SDBP) determined from the area (blue) 
automatically selected as 1cm within the LA wall and used to normalise the LGE intensity of the LA 
wall (ILA), calculated as the maximum intensity along chords (red lines in second panel) perpendicular 
to the LA wall. The normalised intensity (NLA) was mapped onto the segmented 3D surface according 
to a colour look-up table (third panel).Measured endocardial voltage points were registered to the 
MRA segmentation (left first panel). Each endocardial voltage was assumed to represent a circular 
region of 2mm radius around the annotated point of endocardial contact. (Fourth panel) The 
segmented MRA was divided into cells from a surface mesh and cells within a 2mm radius of a 
voltage point were combined to provide a single mean intensity value (see text for discussion).  All 
points were grouped according to intensity value (expressed as a categorical variable) and plotted 
against the mean of all co-located voltage measurements. The correlation between mean bipolar 
voltage and normalised intensity from a single patient is demonstrated (bottom panel).  
 
Relationship between LGE, procedural outcome and clinical characteristics 
To identify any change in enhancement levels between pre and 3-month post ablation scans, 
normalised intensities of the ostial regions and the body of LA in pre and post ablation scans were 
compared for all patients. Using paraview software, each PV ostial region was manually selected by a 
blinded-observer asked to estimate and encircle the LA-PV junction on the post-ablation anatomy, 
and the ostial region was defined as extending 1cm proximal and distal to this estimated 
encirclement. 
As initial exploration of possible indicators of clinical relevance, baseline enhancement was 
correlated with CHADS2 score, as a composite measure of patient clinical characteristics.  LA surface 
area (%) identified as scar (defined as intensity >3SD above mean blood pool signal intensity) was 
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compared in pre ablation scans for patients with and without CHADS2 risk factors including 
hypertension, diabetes, previous stroke, age > 65yrs and congestive heart failure. 
In order to determine whether an association exists between LGE and outcome from AF ablation, 
ostial and LA surface areas (%) identified as scar in pre and 3-month post ablation scans were 
compared for patients with and without AF recurrence at 12 months. To investigate whether 
outcome was associated with the number of PVs showing fully circumferential scar post-ablation, an 
observer blinded to patient outcome determined whether scar (defined as intensity >3SD above 
mean blood pool signal intensity) was continuous around the entire circumference of each vein in 
the 3-month scan, for correlation with both AF recurrence and the presence of electrical 
reconnection of each PV in those patients attending for redo ablation.  
Statistical Analysis 
All normal variables are expressed as mean and standard deviation (SD) or standard error of the 
mean (SEM). One way analysis of variance was performed to analyse whether a difference exists 
between two or more sample means. Paired and unpaired T-tests were used when appropriate, with 
bonferoni correction for multiple tests. Categorical variables were compared with the chi-square 
test. Correlation of continuous variables was examined with Pearson’s and Spearman’s correlation 
coefficients for parametric and non-parametric data respectively. A probability of < 0.05 was 
considered significant. 
 
4.3 Results 
50 patients underwent LGE CMR prior to, and 3 months after their AF ablation procedure. Of these, 
21 had voltage mapping performed during either the initial (n=10) or redo (n=11) procedure. Patient 
characteristics are listed in Table 3. 3D surface reconstruction and scar map of normalised intensity 
were created for all patients (see examples in Figure 4.4 and Figure 4.5).  
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Table 3 Patient demographics of 50 patients undergoing LGE CMR before and after ablation with 
either Cryoballoon or conventional RF 
 
Voltage Correlation 
In 21 patients 4,386 bipolar voltage measurements were made (approx 200 per patient). A 
significant correlation was found between mean bipolar voltage for each patient and increasing 
enhancement (r=-0.561, R2=0.312, p<0.001) and similarly for unipolar voltage (r=-0.664, R2=0.441, 
p<0.001). A significant correlation was present between bipolar voltage and enhancement in 
patients with prior LA ablation alone (R2=0.395, p<0.001) and in patients without prior LA ablation 
alone (R2=0.162, p=0.003, Figure 4.6).  
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Figure 4.4 Pre ablation LGE CMR atrial enhancement maps with corresponding voltage maps. 
LGE CMR atrial enhancement mapping obtained pre ablation in 3 representative patients, with 
corresponding endocardial voltage maps registered to the MRA segmentation of the left atrium. 
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Figure 4.5 Post ablation LGE CMR atrial enhancement maps with corresponding endocardial voltage 
maps demonstrating a good correlation between regions of LGE identified scar and low voltage. 
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Figure 4.6 The mean voltage of all points at each whole number intensity level in each patient. 
This was correlated in 10 patients who had not had any prior ablation (top panel) and 11 patients 
who had had prior left atrial ablation (bottom panel). A significant correlation between voltage and 
intensity was demonstrated in both pre and post ablation LGE CMR scans, however this association 
was stronger in patients with prior ablation. 
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Figure 4.7 shows the relationship between mean (±SEM) voltage and normalised enhancement level 
for point-by-point data combined from all patients. One-way analysis of variance of the distribution 
of voltages at each normalised enhancement level (from SD 0 to SD 10) showed a highly significant 
difference (p < 0.001). Above 1SD, mean (±SEM) voltages significantly reduced for each increment in 
normalised enhancement level of intensity: 0SD = 1.18 ±0.03mV, 1SD= 1.19 ±0.03mV, 2SD = 1.02 
±0.04mV, 3SD = 0.78 ±0.05mV, 4SD = 0.57 ±0.05mV, 5SD = 0.45 ±0.05, 6SD = 0.38 ± 0.04mV, 7SD = 
0.35 ±0.04mV and >=8SD = 0.33 ±0.05mV. No significant differences were noted between SD 0 and 1 
(p=0.86), however significantly lower voltages were noted between SD 1 and 2 (p<0.001), SD 2 and 3 
(p<0.001), SD 3 and 4 (p<0.001) and SD 4 and 5 (p=0.048). No significant differences were noted 
between enhancement levels > 5SD. A similar association was found for unipolar voltage recordings, 
which were compared at regions of increasing enhancement in 5 patients with prior ablation, as 
shown in Figure 4.7. 
 In patients without prior LA ablation (N=10), one-way analysis of variance of the distribution 
voltages at each normalised enhancement level (from SD 0 to SD 10) showed a highly significant 
difference (p=0.007). Above 2SD, mean voltages significantly reduced for each increment in 
normalised enhancement level of intensity as shown in figure above. No patients without prior LA 
ablation (who underwent voltage mapping) had enhancement levels > 5SD above the blood pool 
mean. In patients with prior LA ablation (N=11), one-way analysis of variance of the distribution 
voltages at each normalised enhancement level (from SD 0 to SD 10) showed a highly significant 
difference (p<0.001). Above 1SD, mean voltages significantly reduced for each increment in 
normalised enhancement level of intensity, as shown in Figure 4.7. 
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Figure 4.7 The relationship between mean (±SEM) voltage and normalised enhancement level across 
all patents.  
124 
 
All surface points from all patients grouped according to their normalised intensity value (NLA, Figure 
below) and plotted against the mean of all co-located voltage measurements from endocardial 
mapping. (a) A significant reduction in measured bipolar voltage was seen with each increasing 
intensity level from 2SD above the blood pool mean up to 5SD. Above 5SD no further decrease in 
voltage was seen (N=22). (b) In a subset of patients unipolar voltage was measured. A similar 
reduction in unipolar voltage was seen with each increasing intensity level from 2SD above the blood 
pool mean up to 5SD (N=5). No patients displayed intensities above 5SD in this group. (c & d) Patients 
were divided into those who had prior LA ablation (12) and those who did not (10). A similar 
reduction in measured bipolar voltage with each increasing intensity level from 2SD up to 5SD was 
seen in patients with prior LA ablation. Above 5SD no further decrease in voltage was seen. In 
patients without prior ablation a significant difference in voltage measurements was seen above 
3SD. No patients without prior LA ablation displayed intensities above 4SD. 
 
Pre and post ablation LGE 
Given the predictable ostial lesion set with cryoablation, enhancement levels in the ostial and LA 
body regions were compared pre- and post-cryoablation (N=25). As shown in the graph below, there 
was a significant shift in the curve of % surface area above any given intensity threshold in the PV 
ostia post ablation compared with the PV ostia pre ablation and the LA body pre or post ablation. 
This would suggest that regardless of the intensity threshold chosen to compare pre and post 
ablation scans, a difference was detected in the post ablation PV ostia. Interestingly, there also 
appears to be a slight increase in the post ablation LA body intensities when compared with pre 
ablation scans. This may be due to the formation of atrial scar following ablation outside the 
manually identified ostial regions. Alternatively catheter manipulation within the atrium may cause a 
general inflammatory process within the atrium which can be detected on LGE-CMR. 
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Figure 4.8 Comparison of enhancement levels seen in the left atrial body and the pulmonary vein 
ostia in DE-MRI scans performed before and after cryo-balloon ablation for AF. 
 
A normalised enhancement level equivalent to 3SD above the mean blood pool signal was the lowest 
normalised enhancement level to demonstrate a significantly different voltage from normal 
myocardium in patients without prior LA ablation.  On this basis, we compared the percentage of the 
atrial surface >3 SD above the blood pool mean in pre-ablation scans As shown in Figure 4.9, in pre 
ablation LGE, there was no difference in the enhancement levels between ostial and LA body regions 
(p=0.183). In post ablation LGE, enhancement levels in the ostia were greater than in the LA body 
(p<0.001). Ostial enhancement was greater in post- than in pre-ablation scans (p<0.001).  
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Figure 4.9 Comparison between pre and post ablation left atrial scar detected on LGE CMR in the left 
atrial body and pulmonary vein ostial regions. 
Surface area (%) tissue with enhancement >3SD on post ablation LGE CMR is significantly higher than 
that detected on pre ablation LGE CMR in both ostial and LA regions. Amount of ostial tissue with 
enhancement >3SD on post ablation LGE CMR is significantly greater than that of the LA, whereas on 
pre ablation LGE CMR the amount of tissue with enhancement >3SD does not significantly differ 
between these regions. 
 
Relationship between LGE and patient risk factors for stroke 
We compared the percentage of the atrial surface >3 SD above the blood pool mean in pre-ablation 
scans between patients with a low (CHADS2=0), moderate (CHADS2=1) and high (CHADS2>1) risk of 
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stroke. As shown in Figure 4.10, patients with low, moderate and high risk had 3.2 ±3.2%, 4.4 ±3.4% 
and 7.1±7.4% (as % surface area of LA) atrial enhancement respectively (low vs. high p=0.035), 
demonstrating higher amounts of enhancement in patients with a high risk of stroke. The level of 
enhancement was greater in patients with hypertension than without (10.4 ± 9.9% vs. 5.8 ± 5.4%, p = 
0.04), and there was a significant correlation between patient age and levels of enhancement 
(Spearman’s rho = 0.363, p=0.009). 
 
*P value for T-test comparing CHADS2>1 vs. CHADS2 =0 
 
Figure 4.10  Association between pre ablation LA enhancement and CHADS2 score. 
Surface area (%) of left atrial tissue with enhancement >3SD on pre ablation LGE CMR is higher in 
patients with a high risk of stroke (CHADS2 >2) compared with patients at low risk of stroke 
(CHADS2=0). 
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A comparison was also made between left atrial size and the presence of LA scar >3SD. A 
significantly greater % LA scar was seen in patients with enlarged left atrial diameter (>=38mm) 
compared to patients with a normal LA diameter (<38mm), 7.5± 1.4% vs 3.5± 0.6%, p=0.018. (as 
shown in Figure 4.11. 
 
Figure 4.11 Comparison of pre-ablation scar detected on LGE CMR in patients with normal LA 
diameter and patients with enlarged LA diameter (>=38mm) 
 
Relationship between LGE and outcome from AF ablation 
Of the 50 patients who underwent AF ablation, 25 (50%) had recurrent AF documented. As shown in 
Figure 4.12, patients without AF recurrence had less pre-ablation atrial scar than those with AF 
recurrence (1.9 ± 1.7 vs 5.1 ± 4.3% p=0.033). Post ablation there was no difference in amount of 
atrial scar between patients with and without recurrence of AF (14.2 ±8.9 vs 12.3 ±7.0, p=0.675). 
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Figure 4.12  Comparison of pre ablation scar detected on LGE CMR in patients with and without AF 
recurrence after ablation.  
Surface area (%) of left atrial and pulmonary vein ostial tissue with enhancement >3SD  on pre 
ablation LGE CMR in 50 patients; 25 with and 25 without AF recurrence following AF ablation. 
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Figure 4.13 The number of circumferentially scarred veins as detected by DE-MRI was compared in 
patients with and without AF recurrence following AF ablation. No significant differences were noted 
between the 2 groups. 
Furthermore, as shown in Figure 4.13, no significant differences were found in the total number of 
veins per patient that showed enhancement throughout their entire circumference in patients with 
and without recurrent AF However as demonstrated in Figure 4.14, in the 21 patients who 
underwent redo procedures 63 of 84 PVs had reconnected and a significantly higher amount of 
enhancement was seen in veins which remained isolated compared to those that had reconnected 
(43.5 ±20.7%vs 21.8 ±19.5%, p<0.001).  
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 Figure 4.14 Post ablation enhancement detected in PV ostial regions on LGE CMR compared for veins 
that are isolated or reconnected at the redo procedure. 
Surface area (%) of pulmonary vein ostial tissue with enhancement >3SD  on post ablation LGE CMR 
compared in veins that are isolated and veins that are reconnected at the redo AF ablation procedure 
(N=21 patients). 
 
Enhancement levels following Cryoballoon vs. RF ablation 
To investigate whether different methods of creating tissue injury produced different levels of atrial 
tissue enhancement we compared post ablation enhancement >3SD between patients who had 
undergone cryo ablation and RF ablation. There was no difference in the amount of enhancement 
seen in patients following cryo or RF ablation (LA enhancement 16.5 ± 14.9% vs. 16.1 ± 11.0% p = 
0.93, ostial enhancement 23.5 ± 19.9%vs 25.8 ± 12.9% p = 0.81). 
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4.4 Discussion: 
We report the first point-by-point correlation of left atrial LGE CMR enhancement and co-located 
endocardial voltage, and have demonstrated the feasibility of a novel, objective, automated method 
of identifying left atrial enhancement. Enhancement levels on LGE CMR correlated with both bipolar 
and unipolar voltages, and this finding was consistent for patients both with and without prior LA 
ablation.  Significant associations were found between the amount of pre-ablation LA enhancement 
and patient risk factors for stroke. We also identified increased amounts of pre-ablation atrial scar in 
patients with recurrent AF following ablation.  These clinical correlates are, however, based on only 
50 patients with PAF and further studies are required to identify the relevance of these associations 
in broader populations with and without AF. 
 
LGE CMR and voltage 
In patients with and without prior LA ablation, increasing enhancement levels from 2 to 5SD 
correlated with significant reductions in both bipolar and unipolar voltages. There was no further 
reduction in measured voltage seen in regions with enhancement >5SD, indicating that 
enhancement of 5SD or greater may represent fully scarred atrial myocardium.  These objective 
point-by-point findings are broadly consistent with those reported in studies using blinded scoring-
systems to correlate regions of enhancement and low voltage.148, 149 Furthermore, a significant 
association has previously been demonstrated between overall ventricular LGE-MRI scar mass 
(>2SD) and endocardial voltage <1.5mV.224  
 
LGE CMR and stroke risk 
We used 3SD as the threshold for defining scar in patients without prior LA ablation, since this was 
the lowest enhancement level to demonstrate a significant difference in voltage from normal 
myocardium. We found significantly higher levels of scar in patients with high CHADS2 score, in 
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keeping with the findings of Daccarett et al, who also found LGE to be an independent predictor of 
cerebrovascular events.164 Patients with higher CHADS2 scores have also been found to have lower 
atrial voltages which further supports our findings.225 It is interesting to note that Daccarett found 
higher levels of fibrosis whilst studying patients with both paroxysmal and persistent AF, unlike our 
study population who only had PAF. It is not clear whether pre-existing atrial fibrosis is attributable 
to a single factor, such as AF burden, or multiple factors leading to atrial fibrotic change. The 
mechanism by which disparate pathological processes, such as hypertension and age, result in 
increased stroke risk may be by causing increasing atrial myopathy as the final common pathway. 
Further studies in larger and wider populations are required to ascertain the benefits of LGE CMR to 
guide anti-coagulation strategies. 
 
LGE CMR and procedural outcome 
Persistent AF and increased atrial size are the only current predictors of reduced procedural success 
from AF ablation.86, 220 In our paroxysmal AF population with relatively normal LA size, pre-existing 
atrial scarring detected by LGE CMR was able to identify patients with a worse outcome following 
AF ablation.   Although this finding requires further study in larger populations, it is consistent with 
those of Akoum et al, who found that patients with increasing levels of pre-ablation fibrosis, as 
denoted by Utah levels 1-4, had a higher chance of developing recurrent AF post ablation.   Verma 
reported that patients with LA scarring (defined as absence of electrogram in multiple sites on pre-
procedural voltage mapping) had a significantly higher rate of procedural failure than those without 
atrial scarring.156  There is therefore a growing body of evidence for LGE CMR as a non-invasive, pre-
procedural method to identify patients with extensive atrial scarring, unlikely to benefit from 
pulmonary vein isolation. LGE CMR may provide a tool for patient selection, for modification of 
ablation strategy or selection of alternative treatment options.  By eliminating inconsistency 
inherent in manual methods, the automated approach described may have the potential to provide 
a universally applicable tool to guide patient management. 
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LGE CMR and pulmonary vein reconnection 
Current techniques for AF ablation may achieve the immediate procedural endpoint of PV 
conduction block, without creating permanent circumferential full thickness lesions. A method which 
allows visualisation of atrial scar may identify sites consistently lacking permanent ablation scar and 
provide a tool with which to develop improved ablation techniques. Previous studies have shown 
that extent of PV antral LGE post procedure correlates well with lower rates of AF recurrence 150, and 
although circumferential enhancement in all 4 PVs was found in only 6% of patients, these patients 
had 100% freedom from AF. 148  
We found an increase in the amount of ostial scar in veins that remained isolated at the redo 
procedure compared to those which had reconnected. However, our study did not demonstrate any 
patients with circumferential enhancement of all 4 PVs and in addition we did not show an 
association between the amount of enhancement in post-ablation scans and the rate of recurrence. 
All patients requiring a redo procedure did have LGE CMR and electrical evidence of gaps in ablation 
lines leading to PV reconnection. However, not all patients with gaps had recurrence of AF. This is in 
keeping with several clinical studies which have identified the presence of reconnected veins in 
patients  free from AF who volunteered for a restudy following AF ablation.122  
The ability to objectively identify atrial scar may make it possible to explore in a multicentre study 
the extent and location of permanent scar and how this may translate into longer term freedom 
from AF. LGE-CMR may play a key role in assessing the efficacy of different ablation technologies to 
achieve circumferential scar without increasing the risk of the procedure. Alternatively, LGE-CMR 
may provide further insight into the mechanisms of arrhythmia recurrence following AF ablation and 
facilitate the identification of novel targets for catheter ablation.  
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Limitations 
Whilst experienced operators considered each data point to represent good myocardial contact, we 
were unable to confirm contact during all voltage measurements. This could lead to erroneous 
recordings of low voltage when in fact the myocardium at that location may be healthy. Future 
studies using pressure-sensing catheters will be more accurate in comparing voltage and atrial LGE. 
Acknowledging the limited spatial resolution of LGE CMR, we elected to assign enhancement levels 
based on the highest signal intensity on a cord through the atrial wall, with no attempt to 
differentiate transmural and partial thickness LGE.  
The manual selection of regions of interest around the pulmonary vein ostia used to calculate ostial 
scar adds an element of subjectivity to our methods. However, the identical region is used to 
compare pre and post ablation scans, which limits the influence of the selection on the results. 
 A degree of spatial error is inherent in the process of registering a non-gated MRA sequence with a 
cardiac and respiratory motion gated, free-breathing LGE sequence. Similarly a degree of registration 
error is present when registering the MRA sequence with the gated electroanatomic map collected 
during the AF ablation procedure. However, despite these limitations these methods represent a 
technique which may be readily implementable in most hospitals and provide objective, 
reproducible data on which further developments in the field can be based. 
 
4.5 Conclusions 
We have described a novel, operator-independent technique of atrial LGE CMR analysis which 
provides values for atrial scar that correlate with co-localised voltage measurements. The 
associations described between atrial LGE and clinical factors including CHADS2 score and AF 
recurrence highlight the potential clinical value for risk stratification and patient selection for 
ablation, however, the clinical applicability of the technique requires further validation. 
Furthermore, our LGE-CMR results suggest a high degree of asymptomatic PV reconnection which 
further supports our hypothesis that alternative endpoints for catheter ablation may exist. 
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5 The use of Heart Rate variability to monitor Autonomic 
Modification 
 
5.1 Introduction 
The intrinsic cardiac autonomic nervous system has been implicated in the initiation and 
maintenance of atrial fibrillation (AF). Animal studies have shown that autonomic stimulation leads 
to pulmonary vein ectopy 6 and increases susceptibility of the atria to develop AF in the presence of 
ectopic activity 226. In humans, modification of the autonomic nervous system has been suggested 
for prevention of AF 174, 227 by targeting presumed sites of dense atrial autonomic innervation during 
endocardial catheter ablation. 59 Currently, there are no established techniques to monitor 
autonomic modification during ablation, so adjunctive autonomic ablation is performed either by 
empirical ablation at predetermined anatomical sites 228 or by targeting sites that cause AV block  167, 
169, 174, 227. However, it is not possible to ascertain the extent of autonomic modification that has 
taken place in the context of the patient’s overall cardiac autonomic function.   
Heart rate variability (HRV), can provide information about both cardiac sympathetic and 
parasympathetic modulations of heart rate.197, 198, and might have potential for such monitoring. 
Power spectral analysis of heart rate fluctuations evaluates the state of sympathovagal balance 
modulating sinus node pacemaker activity and can be quantified in a variety of physiological and 
pathophysiological conditions.200, 201 Our group has developed a method of averaging multiple 40 
second ECG recordings to provide a measure of acute intra-procedural change in heart rate 
variability.229 Several studies have shown a reduction in HRV parameters following AF ablation. We 
sought to use our novel method of intra-procedural HRV measurement to identify preferential areas 
within the left atrium for HRV reduction. Furthermore, we investigated whether the degree to which 
HRV parameters reduced was associated with the outcome of AF recurrence at 12 months post-
ablation. 
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5.2 Methods: 
54 consecutive patients undergoing PVI, who met the inclusion criteria with none of the exclusion 
criteria (p70), were enrolled in the study. All patients had symptomatic PAF resistant to at least one 
anti-arrhythmic agent. All anti-arrhythmic agents were stopped 5 half lives prior to the procedure. 
Baseline characteristics are reported in table 4. The study was approved by the local Research Ethics 
Committee for St Mary’s hospital and St Bartholomew’s hospital, and all patients signed a written 
informed consent for the procedure. All patients were followed up at 3, 6 and 12 months with an 
ECG and clinical history, and a 24 hr Holter monitor at 6 months. 
Procedures were performed in the fasted state, under conscious sedation with morphine and 
midazolam or under general anaesthesia according to operator preference. Transoesophageal 
echocardiogram was performed to confirm the left atrial appendage was free of thrombus. Two 8 
French sheaths were inserted into the right femoral vein and a 7 French sheath inserted into the left 
femoral vein. A 14 French channel or artisan sheath was inserted into the femoral vein and advanced 
to the inferior vena cava (IVC) under fluoroscopic guidance. Following a single or double transeptal 
puncture, heparin was administered to maintain an ACT > 300s and pulmonary venography was 
performed. Wide-area circumferential ablation was performed using either robotic or manual 
catheter navigation as described in detail elsewhere.131, 230 Using a 3-D mapping system lesions were 
delivered via a 3.5mm thermocool ablation catheter to encircle the left and right pulmonary veins 
with residual sleeves mapped and targeted using a 20-pole circular mapping catheter.  
Procedures were defined as beginning at needle to skin and ending at catheter removal. All 
recordings were taken in the period between these events (i.e. intra-procedural). Sinus rhythm ECG 
recordings were taken for at least 5 minutes at the beginning and at the end of each procedure, with 
patients lying still on the operating table. The ECG recordings were stored on a Bard system (Bard 
EP, Lowell, MA) for offline analysis. The ECG with the largest R wave amplitude was visually 
inspected to exclude ectopic beats before exporting segments for analysis. Five 40s ectopy-free ECG 
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segments were exported from the recordings taken at the start and end of the procedure In a 
subgroup of 14 patients, HRV indices were assessed at intervals  to assess whether ablation at a 
particular site resulted in HRV changes. Five 40s ectopy-free ECG segments were exported at the 
following time points: baseline, after transeptal puncture, after right CPVA and after left CPVA. 
Seven of these patients underwent left CPVA followed by right (group 1), and 7 patients had right 
CPVA followed by left (group 2). An offline analysis was performed using MatLab to calculate heart 
rate variability parameters in the frequency domain; low frequency (LF, 0.04-0.15Hz) and high 
frequency (HF, 0.15-0.6Hz). 
During AF ablation patients may be required to undergo cardioversion to confirm pulmonary vein 
isolation in sinus rhythm. We therefore assessed whether cardioversion alone had an effect on 
indices of HRV. 10 patients undergoing elective cardioversion for persistent AF were studied. 
Continuous ECG monitoring was performed for 150 mins post cardioversion with the patient lying 
still in the recovery room. Five 40s ectopy free ECG segments were exported every 10 minutes 
during this period and HRV indices were calculated for each time point.  
General anaesthesia (GA) was used according to operator and patient preference. GA is known to be 
associated with a reduction in sympathetic tone. We compared LF and HF parameters of HRV 
separately in patients who underwent AF ablation with GA or conscious sedation, to identify 
whether these parameters were affected by the mode of sedation. 
Statistical analysis 
All normal variables are expressed as mean and standard deviation (SD). One way analysis of 
variance was performed to identify whether a difference was present between the groups. Paired 
and unpaired T-tests were used when appropriate, with bonferoni correction for multiple tests. 
Categorical variables were compared with the chi-square test. The power of each frequency band 
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was logarithmically transformed to normalize the distribution 167. A value of p<0.05 indicates 
statistical significance. 
 
5.3 Results 
All pulmonary veins were isolated at the end of the procedure in the 54 patients undergoing AF 
ablation. Patient characteristics are summarised in table 4. All patients were in sinus rhythm at the 
start and end of the procedure. 6 of 54 patients required cardioversion to restore sinus rhythm 
during the procedure. No patients experienced any acute complication during the procedure.  
 
 
Table 4 Patient characteristics for  measurement of changes in HRV  following AF ablation. Patient 
characteristics are also shown for the 2 subgroups of patients who underwent left or right CPVA first 
*p value comparing patient characteristics between group 1 and group 2. 
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with additional HRV recordings. No significant differences in patient characteristics or procedural 
duration are noted between these groups.  
 
HRV reduction following AF ablation 
HRV indices were calculated for all 54 patients at baseline and immediately following AF ablation. LF 
and HF HRV indices were both found to reduce following AF ablation. Log LF and HF reduction was 
0.96 and 0.73 respectively (n=54, p<0.001). There was no change in the mean RR interval (877±191 
to 843±220ms, p=0.26) or the LF/HF ratio. 
 
HRV indices following cardioversion 
In the 10 patients undergoing elective cardioversion only, one way ANOVA demonstrated no 
significant difference between LF and HF values from the ECG recordings taken at each of the ten 
minute intervals over 150minutes (p=0.99) following DC cardioversion as shown in Figure 5.1 The 
average RR interval also did not change over the 150min time period (p=0.97).  
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Figure 5.1 Change in LF and HF parameters of HRV over time following DC cardioversion. 
 
HRV changes following right and left CPVA 
14 patients undergoing AF ablation were studied for step-wise changes in HRV, as shown in Figure 
5.2. In group1 ( left CPVA first), Log LF was 2.32, 2.15, 1.95, 0.55 and log HF was 1.91, 1.47, 1.75, 0.68 
at baseline, after transeptal puncture, L CPVA and R CPVA respectively, demonstrating significant 
change after R CPVA only (p<0.001). In group 2 (right CPVA first), Log LF was 1.67, 1.82, 0.25, 0.28 
and log HF was 1.43, 1.55, 0.23, 0.25 at baseline, after transeptal puncture, R CPVA and L CPVA 
respectively, demonstrating significant change after right CPVA only (p<0.001), as shown in Figure 
5.2. 
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Figure 5.2 Changes in LF and HF parameters of HRV measured intraprocedurally. 
In 14 patients, log LF and log HF parameters of HRV were calculated at baseline, following transeptal 
puncture after the right CPVA and after the left CPVA. 7 patients underwent right CPVA followed by 
left (group 1), the other 7 patients underwent left CPVA followed by right (group 2). LF and HF 
parameters of HRV were seen to reduce significantly in both groups following the right CPVA only 
(p<0.001).   
 
HRV changes and freedom from AF 
48 patients completed 6 months follow up. 23 of these had recurrence of AF and 25 did not. As 
shown in Figure 5.3, no statistically significant differences in log LF and HF reduction were found 
between patients with AF recurrence and those without (LF; 0.92 vs. 1.02, p=0.76, and HF; 0.76 vs. 
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0.79, p=0.91) suggesting that HRV parameters are not associated with AF freedom following 
ablation. 
 
 
Figure 5.3 Reduction in LF and HF parameters of HRV compared in patients with and without AF 
recurrence following ablation.   
 
 
HRV changes and General Anaesthesia: 
We compared LF and HF parameters of HRV separately in patients who underwent AF ablation with 
GA or conscious sedation. Baseline HRV parameters were measured following induction of general 
anaesthesia. Patients under GA had lower HF parameters at baseline compared to under conscious 
sedation. (1.28 vs. 1.96, p=0.001). No difference was noted in LF parameters at baseline between 
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patients under GA or conscious sedation (1.72 vs. 2.08, p=0.08). We also compared the reduction in 
LF and HF parameters of HRV following ablation in patients under GA and conscious sedation. A 
significantly smaller reduction in HF parameters was noted in patients under GA compared to 
conscious sedation (0.95 vs. 1.39, p=0.03) whereas a similar reduction in LF parameters was seen 
following ablation in these 2 groups (1.37 vs. 1.59, p=0.28).  
 
5.4 Discussion 
Autonomic modulation of the sinus node causes physiological oscillations in heart rate leading to LF 
and HF HRV 202. Using a novel method to obtain HRV indices from multiple short segment ECG 
recordings, we have confirmed in this study that HRV parameters of LF and HF both reduce following 
AF ablation, which is in keeping with current reports in the literature in which HRV was measured 
from 24 hr Holter monitors. Furthermore, we have demonstrated that this reduction occurs only 
after ablation of the right sided pulmonary veins. It remains to be seen whether a specific area of the 
right CPVA is responsible for this reduction and this will be investigated in Chapter 7. 
 An important consideration when measuring changes in HRV is to ensure a constant RR interval, 
since any cause of reduced RR interval (i.e. sinus tachycardia) is necessarily accompanied by a 
smaller absolute amplitude of variability of the RR interval. We detected a significant reduction in HF 
and LF HRV following AF ablation, without a reduction in the RR interval, suggesting that the 
reduction is due to modifications of autonomic nervous activity. 
HF parameters are thought by some to reflect respiratory variations in heart rate which may explain 
our finding that HF parameters were significantly lower at baseline in patients following induction of 
GA compared to patients under conscious sedation. A smaller reduction in HF HRV parameters was 
seen following AF ablation in patients under GA, which is likely to reflect the lower baseline HF level. 
Since there were equal numbers of GA cases in the 2 groups of patients undergoing sequential CPVA 
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with serial HRV measurement, then it is unlikely that the effect of general anaesthesia on HF HRV 
will significantly influence our results. However, this effect could be considered a limitation for the 
use of HRV as an endpoint marker for autonomic modulation in cases under GA. 
Hou et al 177 showed in animal studies that a significant amount of sympathetic and parasympathetic 
input to the sinus node traverses the right anterior ganglionated plexus located in the antral region 
of the right superior pulmonary vein. We hypothesised that in humans, a similarly-sited ganglionated 
plexus is responsible for most of the nervous traffic to the sinus node and in turn can influence LF 
and HF variations in the heart rate. Our study showed HRV reduction occurred only following 
ablation around the right-sided pulmonary veins, which could conceivably disrupt autonomic 
nervous inputs into the sinus node. 
 This finding is of key importance to the potential use of HRV as an endpoint measurement for 
adjunctive autonomic ablation. HRV indices do not appear to reflect autonomic modulation of the 
autonomic ganglia associated with the left-sided pulmonary veins, therefore limiting the use of HRV 
as an endpoint for left atrial autonomic denervation. 
This result is in keeping with the second finding of our study, which is that the degree of HRV 
reduction is not associated with AF recurrence following ablation. The changes in HRV during AF 
ablation appear to be related only to right-sided circumferential pulmonary vein ablation. Ablation 
of autonomic ganglia in other regions of the heart (including adjacent to the left pulmonary veins), 
are not reflected by HRV changes, but may still affect ablation outcomes. The development of 
alternative methods to monitor autonomic modulation, reflecting of the activity of all left atrial 
ganglionated plexi, is likely to be required to establish clinical endpoints for autonomic modulation. 
Further studies may then be performed to identify whether greater autonomic modulation is 
associated with an improved outcome from AF ablation.   
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Limitations: 
Patients undergoing DC cardioversion for persistent AF did not demonstrate any significant change 
in HRV parameters in the 150minutes following cardioversion. We were unable to assess whether 
cardioversion resulted in a significant change in HRV from baseline since these patients were in AF 
prior to the cardioversion. Furthermore, it was not possible to study the effects of cardioversion 
intraprocedurally on paroxysmal AF patients undergoing ablation as this would prolong the total 
procedure duration beyond an acceptable time.  
 
5.5 Conclusion: 
Intra-procedural measurement of HRV is feasible and we demonstrate that right CPVA ablation 
preferentially reduces HRV. Canine studies suggest right anterior GP is a “gateway” to the sinus node 
and our study implies a similar functional network may exist in humans. HRV reduction following AF 
ablation does not appear to be associated with clinical outcome.  Further studies of the human 
autonomic nervous system are required to understand its influence on the AF substrate and to 
identify endpoints for autonomic modification. 
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6 Parasympathetic nervous system stimulation alters 
fibrillatory cycle length in human atrial fibrillation  
 
6.1 Introduction: 
Human studies have demonstrated that autonomic stimulation can trigger atrial fibrillation (AF) and 
also promote atrial substrate changes which allow for the maintenance of sustained periods of AF.71, 
231 In animal studies, direct application of acetylcholine to atrial and pulmonary vein (PV) 
preparations induced heterogeneous shortening in action potential duration, promoting 
maintenance of stable PV tachycardias 232. Human studies from our group have shown that 
endocardial stimulation at presumed sites of autonomic innervation produces a reduction in atrial 
fibrillation cycle length (AFCL) with decreasing effect across the left atrium from the site of 
stimulation.231 However, it has yet to be determined whether this effect is sympathetically or 
parasympathetically mediated. We tested the effect of parasympathetic blockade on AFCL changes 
in response to endocardial stimulation at sites of autonomic innervation.  
 
6.2 Methods: 
The effect of parasympathetic blockade on AFCL shortening was studied in 10 patients. Patients with 
persistent AF were recruited who were undergoing clinically indicated AF ablation procedures. All 
anti-arrhythmic agents were stopped 5 half lives prior to the procedure. The study was approved by 
St Mary’s Research Ethics Committee and all patients signed a written informed consent for the 
procedure. All patients were in a fasted state and underwent a trans-oesophageal echocardiogram 
on the day of the procedure to exclude left atrial thrombus. Either conscious sedation (morphine 
and midazolam) or general anaesthetic was used according to operator preference. Invasive arterial 
pressure monitoring was used in all patients. Following transeptal puncture, heparin was 
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administered to maintain an ACT > 300. An electroanatomic map of the left atrium and pulmonary 
veins was created using an electromagnetic navigation system (CARTO™, Biosense Webster Inc, 
USA). Quadripolar catheters were placed in the high right atrium (HRA) and coronary sinus (CS), and 
a 20-pole circumferential mapping catheter (Lasso, Biosense Webster, CA, USA) was placed at the 
ostia of the pulmonary vein.  
The mapping catheter (3.5mm irrigated tip) was placed at the presumed anatomical location of a GP 
site, with the circular mapping catheter placed in adjacent pulmonary vein. Continuous HFS was 
delivered endocardially using a Grass Stimulator (20Hz, 10ms pulse duration, 10V). A positive 
response was defined as >50% prolongation in the RR interval compared to the mean RR averaged 
over 10 beats prior to HFS (i.e. RR interval ratio, mean pre HFS : longest post HFS was > 2). Positive 
HFS sites were marked on the 3D map.  
 
Parasympathetic blockade 
To test the hypothesis that the AFCL changes were due to parasympathetic nervous system 
activation, we examined the effects of HFS on AFCL in the PV adjacent to the HFS site in the presence 
or absence of a vagal response. Electrogram recording segments 15 seconds prior and post HFS were 
exported for offline manual measurement of RR interval, HRA cycle length (CL), CS CL and PV CL. 
Following identification of all vagal responses within the presumed anatomical locations of the 4 GPs 
sites, a parasympathetic blocking agent was given. 0.04mg/kg body weight of atropine was given to 
achieve parasympathetic blockade. 233, 234 HFS was repeated at the same GP sites that previously 
provoked vagal responses, and the AFCL at the PV adjacent to this site was again calculated. If the 
effects of HFS were due to direct local atrial capture, then the changes recorded in AFCL would be 
expected to be similar, irrespective of a vagal response or parasympathetic blockade.  
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AFCL measurements 
AFCL measurements were obtained from the HRA, CS, PV and Map catheter recordings. The AFCL 
was measured, using callipers on the Bard EP system at 50mm/s sweep speed, over 30 cycles prior 
to HFS, 10 cycles immediately following HFS and the subsequent 50 cycles post HFS. Continuous or 
fragmented activity or a potential interval < 50ms was counted as a single activity. AFCL was 
averaged for every 10 cycles and plotted consecutively to look for temporal AFCL changes in 
response to HFS.  
Statistical methods 
Pre-HFS and post-HFS AFCL were compared with the paired t-test. A value of p<0.05 was considered 
statistically significant.  
 
6.3 Results: 
10 patients were enrolled. Patient characteristics are listed in table 5. Prior to atropine 
administration, there were 35 sites with positive vagal responses recorded, ([max RR/pre RR] of 
3.3±1.3).  31 of these sites were positive on retesting after relocation of the catheter at the identical 
site on the electroanatomic map, suggesting that our method of identifying positive sites was 
reproducible. Following atropine administration, all vagal responses to HFS were abolished ([max 
RR/pre RR] of 1.4±0.3). 
 
 The effect of HFS on the PV AFCL adjacent to sites with and without a vagal response to HFS and 
following atropine administration was studied. The mean AFCL was measured over 30 cycles prior to 
HFS, 10 cycles immediately following HFS and the subsequent 50 cycles post HFS. The results are 
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demonstrated in Figure 6.1. The AFCL was also measured at the same time points in the CS and HRA 
catheter sites. Table 6 demonstrates the results.  
 
 
Table 5  Patient characteristics of 10 patients enrolled to study the effects of parasympathetic 
blockade on AFCL change in response to autonomic stimulation. 
 
HFS at positive vagal sites produced a reduction in the PV AFCL from 160±28 to 144±26ms, p<0.0001. 
After atropine administration the reductions in PV AFCL adjacent to the sites of HFS were no longer 
observed (164±30 to 165±33ms, p=0.34) (Table 6) Similarly, the mean AFCL in the HRA reduced from 
177±34 ms to 169±31 ms (p=0.005) and at CS from 169±29 ms to 159±28 ms (p=0.013). These 
reductions in CL were not observed following atropine administration; the HRA CL remained 
constant at 181±34 ms (p=0.95) and at CS 172±32ms and 170±34ms (p=0.92). 
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Figure 6.1 Measurement of atrial fibrillation cycle length over time in the pulmonary vein adjacent to 
site of autonomic stimulation, before and after administration of a parasympathetic blocking agent. 
Each column represents cycle length averaged over 10s before HFS (pre 1 – pre 3) and after HFS (post 
1 – post 6). Significant reduction in PVCL is noted following HFS at positive vagal sites (left). This 
reduction is abolished following administration of atropine (right).  
 
It is interesting to note however, that a reduction in PVCL was also seen following HFS at sites 
without a “vagal” or AV nodal response, from 176±30ms to 162±28ms (p=0.001). These sites were 
not retested following atropine administration since only sites producing an AV nodal response to 
HFS were retested. The reduction in AFCL following HFS at sites with and without a vagal response 
and again following atropine administration are shown for each recording location in Figure 6.2. 
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Table 6  Atrial fibrillation cycle length measured at the coronary sinus (CS), high right atrium (HRA) 
and pulmonary vein (PV) before and after high frequency stimulation. 
A significant reduction in AFCL following a vagal response to HFS is demonstrated at all recording 
locations at sites.(middle 3 rows) A significant reduction in AFCL is also measured in the local PV 
following HFS at sites without a vagal response.(top 3 rows) This reduction in AFCL in response to HFS 
is abolished after administration of a parasympathetic blocking agent – Atropine (bottom 3 rows). 
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Figure 6.2 AFCL reduction following HFS at sites with and without vagal responses and following 
parasympathetic blockade. 
Atrial fibrillation cycle length reduces significantly at the coronary sinus (CS), high right atrium (HRA) 
and pulmonary vein (PV) in response to high frequency stimulation at sites with a vagal response, 
and only in the PV following HFS at sites without a vagal response. Reduction in AFCL is not seen at 
any site in response to HFS after administration of a parasympathetic blocking agent (Atropine). 
 
6.4 Discussion: 
We have shown that HFS at positive vagal sites produces a shortening of the AFCL in all 3 areas 
studied; the HRA, CS and local PV. This effect was abolished following atropine administration to 
achieve complete parasympathetic blockade. This provides direct evidence that the AFCL shortening 
measured at these sites in the left atrium is mediated via the parasympathetic nervous system. 
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We have also demonstrated that HFS performed at sites not eliciting a vagal response can also 
produce significant shortening of the local PVCL. This effect was not seen in more distant areas of 
the atrium such as the HRA or CS catheters. This would suggest that whilst the mechanism of PVCL 
shortening is likely to be due to parasympathetic stimulation, this effect is not dependent on 
producing an AV nodal response. This highlights important limitations of the use of continuous HFS 
to identify GP sites. It is perhaps the case that not all GP sites have connections to the AV node 
despite connections to the local PV. Alternatively endocardial HFS may not sufficiently stimulate the 
GP to produce a detectable AV nodal response despite the proximity of the mapping catheter, and 
yet on occasion the level of stimulation may be enough to effect the electrophysiology of the local 
PV. Further studies are required to elucidate the autonomic pathways around the left atrium and 
how they respond to high frequency stimulation. 
Limitations 
Our definition of autonomic activation relies on AV block with (max RR/pre RR interval) > 1.5. 
However, we recognize that there is likely to be a continuous spectrum of responses to GP 
activation, which may be independent from the observed effect on the AV node. This would be in 
keeping with our observation in which there was a reduction in PV AFCL even in the absence of 
defined vagal response.  
 
6.5 Conclusion: 
Atrial refractory period shortens following endocardial stimulation of GP sites. GP sites producing a 
remote autonomic response appear to have an effect on both remote and local myocardial 
refractory periods, whereas HFS sites that do not produce a remote autonomic response only have 
an on effect the local refractory period. The shortening of the atrial refractory period is abolished by 
parasympathetic blockade and therefore mediated by parasympathetic activity.  The 
parasympathetic nervous system may therefore have a role in facilitating maintenance of AF in 
human atria and could be an effective adjunctive target in AF ablation.  
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7 Identification and ablation of left atrial ganglionated plexi 
 
7.1 Introduction: 
Animal and human studies have demonstrated that autonomic stimulation can trigger atrial 
fibrillation (AF) and also promote atrial substrate changes which allow for the maintenance of 
sustained periods of AF.71, 231 Interestingly in the canine studies, epicardial ganglionated plexi (GP) 
ablation was able to completely abolish both AF induction and maintenance.166 Although clinical AF 
ablation has focused on pulmonary vein isolation (PVI), there is a high PV electrical reconnection rate 
even in patients who remain symptom-free.124 This raises the possibility that ablation near the PVs 
may reduce ectopic triggering and inadvertent modification of GP sites has been proposed as an 
explanation for both this and the superior outcomes from wide area circumferential pulmonary vein 
ablation compared to ostial segmental PVI alone.235 
This has led to studies attempting to specifically target GP sites. The GPs are part of a neural network 
located on the epicardial surface of the heart, which comprises multiple ganglia with interconnecting 
neurons and axons, including afferent sensory fibres and sympathetic and parasympathetic 
efferents.236 177 Two techniques have been used to locate GP sites. Continuous high frequency 
stimulation (cont-HFS) with endocardial stimulation at 10V, 20Hz for several seconds identifying GP 
sites which induce bradycardia at the AV node.175, 227 This technique invariably leads to AF induction 
as a result of high rate local atrial capture. A second method is synchronised high frequency 
stimulation (sync-HFS) which involves current delivery only during the local atrial refractory period, 
thereby avoiding AF induction by high rate atrial capture and identifies GP sites that trigger ectopy 
(both PV and non PV).  We have shown that approximately 50% of GP sites that produce ectopic 
triggering by sync-HFS do not produce an AV nodal response by cont-HFS, however 90% of sites with 
an AV nodal response will trigger ectopics.71 Canine studies suggest that the network has a common 
pathway into the AV node via the right lower GP and ablation here abolishes the AV nodal effects 
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from other left atrial GP sites177.  Similarly, a common input to the SA node via the right upper GP 
has been identified in dogs, whereby ablation at the RUGP significantly attenuates sinus rate slowing 
in response to left atrial GP stimulation.177 These studies illustrate the complexities of the neural 
pathways that are still not well understood. Therefore, it may not be surprising that endocardial 
ablation of GP sites identified by the AV nodal response to cont-HFS has had mixed results for 
preventing AF in humans.237, 238  Autonomic modification for AF may be more effective if sites with 
connections to the PVs can be identified and targeted. We hypothesized that the effects of GP 
stimulation could be prevented by ablation at either the stimulation site or proximal to the effector 
site by transection of the neural pathway. We investigated the pathways between the left atrium 
and the AV node by identifying GP sites that produce an AV nodal response to cont-HFS and then 
assessed the effect of ablation at each GP site (in particular the right lower GP) on the  AV nodal 
response from non-ablated GP sites.  The neural inputs to the PVs were studied by assessing the 
effect of sync-HFS after GP site ablation and ostial PV isolation. Additional assessment of the neural 
inputs to the SA node was made using heart rate variability as a measure of autonomic modulation 
of SA nodal activity. 
 
7.2 Methods: 
Patients were recruited who were undergoing clinically indicated AF ablation procedures. All anti-
arrhythmic agents were stopped 5 half lives prior to the procedure. All patients were in a fasted 
state and underwent a trans-oesophageal echocardiogram on the day of the procedure to exclude 
left atrial thrombus. Either conscious sedation (morphine and midazolam) or general anaesthetic 
was used according to operator preference. Invasive arterial pressure monitoring was used in all 
patients. Following transeptal puncture, heparin was administered to maintain an ACT > 300. An 
electroanatomic map of the left atrium and pulmonary veins was created using an electromagnetic 
navigation system (CARTO™, Biosense Webster Inc, USA). HFS was performed prior to any ablation 
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being performed. The study was approved by St Mary’s Research Ethics Committee and all patients 
signed a written informed consent for the procedure. 
Cont-HFS protocol 
Endocardial high frequency stimulation was performed in patients undergoing catheter ablation for 
AF (Paroxysmal or Persistent). Following transeptal puncture, quadripolar catheters were placed in 
the high right atrium (HRA), coronary sinus (CS) and a 20-pole circumferential mapping catheter 
(Lasso, Biosense Webster, CA, USA) was placed initially in the left upper PV (LUVP). Arterial access 
was obtained for invasive blood pressure monitoring and the blood pressure waveform trace was 
recorded on the Bard Lab System Pro (Bard EP, Lowell, USA) amplifier and recording system. This 
enabled accurate measurement of the RR interval during episodes of HFS, since all other intracardiac 
and surface ECG channels are saturated due to the stimulation artefact. A 3.5mm irrigated tip 
catheter (Biosense-Webster, CA, USA) was positioned at the presumed anatomical location of the 
left upper GP (LUGP) site. Cont-HFS (20Hz, 10ms pulse width, 10V) was applied at this site for up to 8 
seconds or until a positive response was achieved, whichever was the earliest. Positive sites were 
identified during the procedure (via visual interpretation of the RR interval) and both positive and 
negative sites were marked distinctly on the electroanatomic mapping system. This process was 
repeated for all 4 GP sites (left upper, left lower, right upper and right lower) with the lasso 
positioned in the PV adjacent to the GP site being tested. 
Determining RR interval ratio 
To determine the response to cont-HFS, the RR interval was measured offline on Bard Lap System 
Pro, using callipers to measure 10 cardiac cycles prior to HFS and dividing by 10 to produce a mean 
CL, and subsequently measuring the longest post HFS RR interval following the onset of HFS. The 
post HFS RR interval was divided by the mean pre HFS RR interval was to determine the RR interval 
ratio in response to HFS: 
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  RR Interval ratio  =    Longest Post HFS Cycle Length 
                    Mean pre HFS Cycle Length 
 
 
 
 
Figure 7.1 Example of offline RR interval ratio measurement to identify response to HFS. 
Mean pre HFS RR interval measures 9.2s over 10 cycles, i.e. 920ms. Longest post HFS RR interval is 
4.224s. RR interval ratio = 4.2 / 0.92 = 4.56, i.e. positive response to HFS. 
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Assessment of neural pathways from the left atrium to the AV node:  
In dogs the RLGP acts as the final common input to the AV node and ablation at the RLGP abolishes 
all AV nodal response to HFS stimulation from other active GP sites. We tested this phenomenon in 
humans. 8 patients undergoing left atrial ablation were enrolled. After completing the 
electroanatomic map of the left atrium (LA), the mapping catheter (3.5mm irrigated tip) was placed 
at the presumed anatomical location of a GP site, with the circular mapping catheter (20 pole) 
placed in adjacent pulmonary vein. Continuous HFS was delivered endocardially using a Grass 
Stimulator (20Hz, 10ms pulse duration, 10V). A positive response was defined as >50% prolongation 
in the RR interval compared to the mean RR averaged over 10 beats prior to HFS (i.e. RR interval 
ratio, mean pre HFS : longest post HFS was > 2). Positive HFS sites were marked on the 3D map as 
illustrated in Figure 7.2.  
Figure 7.2 Sites of positive and negative responses to high frequency stimulation marked on 
electroanatomic map of the left atrium 
 
 
Patients were divided into two groups; the RLGP group and other GP group. The RLGP group had a 
cluster of RF lesions placed over positive HFS sites at the RLGP followed by retesting of all previously 
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positive unablated sites. The “other GP”  group had a cluster of RF lesions placed over positive sites 
at the RUGP, LUGP or LLGP followed by retesting of all previously positive unablated sites and then 
went on to have RLGP ablation with further retesting of the remaining previously positive unablated 
sites. In both groups the RR interval ratio (mean pre HFS : longest post HFS) was calculated to 
identify AV nodal response before and after ablation of the index GP. The flow chart in Figure 7.3 
summarises the different procedural groups. 
 
Figure 7.3 Flow chart demonstrating the different patient groups, the numbers of patients in each 
group, the type of HFS testing and the intervention performed in each study arm. 
 
Assessment of neural pathways from left atrium to the pulmonary veins: 
A separate group of patients were recruited who were in sinus rhythm at the time of the AF ablation 
procedure. After completing the left atrial electro-anatomic map, catheters were placed in the PV, 
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coronary sinus and high right atrium. PV connection was confirmed with a 20 pole circular mapping 
catheter. The mapping catheter (3.5mm irrigated tip) was placed at the presumed anatomical 
location of the GP site adjacent to the PV. Short bursts of HFS (12V, 50Hz, 10ms pulse width), 
synchronized to the local atrial refractory period, were delivered through the map catheter. A 
positive site was defined by initiation of PV ectopy (earliest activation seen within the PV - see 
example in Figure 7.4) and these were recorded distinctly from negative sites on the LA geometry. 
Patients were randomly allocated as control, PVI or GP ablation group. 
 
 
Figure 7.4 Pulmonary vein ectopic response to sync-HFS. 
Sync-HFS performed from the map catheter placed at a GP site can be seen here to initiate  ectopic 
activity in the local pulmonary vein, with the earliest activation seen on the PV mapping catheter 
bipoles PV 13-14. This was defined as a positive response to HFS.  
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Control Group: Patients underwent GP localisation with synchronized HFS. Positive sites were 
identified and documented on the 3D geometry. These sites were then retested with synchronised 
HFS by moving the mapping catheter away and then back to the positive site guided by the location 
on the 3D map. This control study was designed to prove the reproducibility of PV ectopy generation 
by stimulation of positive GP sites. 
PVI group: Synchronized HFS was performed and sites producing PV ectopy were marked as positive 
on the 3D map. Once all positive left atrial sites had been identified, PVI was performed using the 
Arctic Front™ Cryoballoon. In brief, the 28mm Arctic Front Balloon was inflated at the ostium of each 
PV in turn. Occlusion of the vein was confirmed with contrast injection and two 5 minute freezes 
were subsequently applied to each vein. Radiofrequency energy or Freezor Max was applied to any 
remaining PV sleeves. PV isolation was confirmed using a 20 pole circular mapping catheter.  
Synchronized HFS was repeated at the previously marked positive sites following confirmation that 
all PVs were isolated. Fixed rate pacing was initially performed to confirm local atrial capture, with 
HFS delivered in the refractory period as per the protocol described pre-ablation.  
GP ablation group: After completing the 3D electroanatomic map, synchronized HFS was performed 
from the mapping catheter placed at a single presumed GP site. A positive site was defined as one 
producing ectopic activity within the vein. A range of responses was seen from a single ectopic 
response to atrial arrhythmia lasting >30secs. All were defined as positive responses and marked on 
the electroanatomic map, followed by the application of 4-5 minutes of RF in a cluster surrounding 
the GP site. Further retesting with synchronized HFS was then performed at and around the ablated 
GP site, and if any further ectopy was induced another 2-3 mins of additional ablation surrounding 
this site was performed, followed by HFS re-testing. This process was repeated for all 4 pulmonary 
veins. The patient subsequently underwent PVI using the operator’s method of choice and no 
further HFS testing was performed.  
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Assessment of neural pathways from left atrium to the sino-atrial node: 
In the same patients recruited in sinus rhythm for assessment of neural pathways from the left 
atrium to pulmonary veins, multiple 40sec ECG recordings were taken at several time points during 
the procedure and exported for offline analysis using MatLab to assess low frequency (LF) and high 
frequency (HF) parameters of heart rate variability. This method has previously been validated by 
our group.208  
PVI group: Five 40 sec, ectopy free, ECG segments were exported at the following 5 time points: 
Baseline, after sequential cryoballoon ablation of the left upper pulmonary vein (LUPV), left lower 
(LLPV), right upper (RUPV) and finally the right lower pulmonary vein (RLPV). Pulmonary veins were 
ablated in the same order in all patients. 
GP ablation group: Five 40 sec, ectopy free, ECG segments were exported before and after the 
ablation of each positive GP site (using sync-HFS to identify sites initiating PV ectopy). Patients 
remaining in AF after GP site stimulation were excluded from HRV analysis. 
Statistics: 
All normal variables were expressed as mean and standard deviation.  Normal variables were 
compared using paired and unpaired Student-T tests where appropriate. Paired, categorical 
variables were compared using McNemar’s test. Comparison of patient demographics across more 
than 2 or more groups was with the Chi-square test for categorical variables and Mann-Whitney U 
test for continuous variables. Fisher’s Exact test was used for small patient numbers. A significant 
result was defined as p <0.05. 
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7.3 Results: 
Left atrium to AV node: 
10 patients were recruited and underwent identification of GP sites using continuous HFS. The 
patient demographics are shown in table 7. HFS was performed at GP sites and 38/60 (63%) were 
positive for AV nodal response. Patients were then randomly allocated to two groups receiving 
either RLGP ablation or another site.   
Table 7 Patient and procedural characteristics of 10 patients enrolled for autonomic stimulation and 
ablation using continuous HFS. 
 
 
 
 
*P – value comparing RLGP and Other GP group 
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Figure 7.5 Change in RR interval ratio produced by HFS before and after ablation of selected GP sites. 
(a) Significant reduction in RR interval ratio is seen in response to HFS at previously positive GP sites 
following ablation of the right lower GP alone compared to the pre ablation response. (b) No change 
in the RR interval ratio is seen in response to HFS following ablation of either the right upper, left 
upper or left lower GP sites. (c) HFS was performed before and after ablation of the GP site 
undergoing stimulation. A significant reduction in the RR interval ratio was seen in response to HFS 
following ablation compared to the pre ablation response. 
166 
 
In the “other GP” group (N=5) all 19 unablated GP sites remained positive after ablation of the target 
GP site (post : pre HFS RR interval ratio 4.33 ± 1.65 pre ablation vs. 4.44 ± 2.15 post ablation of RU, 
LU or LL GP sites p=0.78, Figure 7.5b). In the RLGP group (N=5) 2 of 15 sites remained positive 
following ablation of the RLGP. 4 patients in the “other GP” group went on to have RLGP ablation 
followed by testing of any remaining unablated positive sites. 0 of 7 sites remained positive after 
RLGP ablation. In total, 2 of 22 sites remained positive after RLGP ablation (post : pre HFS RR interval 
4.47 ± 1.46 pre ablation vs. 1.43 ± 0.29 post ablation of RLGP, p <0.001, Figure 7.5a). For both 
groups, 1 of 14 ablated GP sites remained positive despite ablation (post : pre HFS RR interval ratio 
4.56 ± 1.57 pre-ablation vs. 1.67 ± 0.65 post ablation, p<0.001, as shown graphically in Figure 7.5c). 
 These results demonstrate that ablation at each local GP sites renders them unable to produce a 
distant vagal response at the AV node. In addition, ablation of the RLGP alone abolishes the AV nodal 
response to HFS produced by all left atrial GP sites, whereas ablation at other GP sites does not 
affect the AV nodal response of unablated GP sites.  
 
Left atrium to pulmonary vein 
20 patients were recruited, 3 were in the control group, 8 in the PVI group and 9 in the GP ablation 
group. The patient characteristics for all groups are detailed in table 8. 41 of 123 sites tested were 
positive for a PV response (33%). 
Control group: In the control group (N=3), 17 sites were tested with HFS, 8 positive sites initiating PV 
ectopy were identified and recorded on the electroanatomic map. The catheter was moved away 
from the site of stimulation and back before retesting to determine reproducibility of the method. 
Retesting was subsequently performed without any RF ablation being delivered. All 8 sites remained 
positive for PV ectopy on retesting (p = 1.0) (Figure 7.6a).  
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PVI group: In the 8 patients in the HFS and PVI group, 17 positive sites were recorded on an electro-
anatomic mapping system out of 52 tested sites. Cryoballoon ablation of all four pulmonary veins 
was subsequently performed. GP sites were not specifically targeted or avoided during ablation and 
no ablation in addition to PVI was performed. Synchronized HFS was repeated at the 17 positive sites 
and none produced ectopy or AF despite evidence of local atrial capture proving no evidence of local 
myocardial damage (p < 0.001) (Figure 7.6b). 
 
Table 8  Patient and procedural characteristics of 20 patients undergoing autonomic stimulation 
using synchronised HFS, with either pulmonary vein isolation or GP ablation prior to retesting. 
 
 
*P – value comparing distributions of variables across all 3 groups  
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Figure 7.6 Number of sites initiating PV ectopy in response to sync HFS (a) in the control group, (b) 
before and after PV isolation, and (c) before and after ablation at the local GP site. 
 
GP ablation group: In the HFS and GP ablation group (N=9), 54 presumed GP sites were tested, 16 of 
these initiated PV ectopy. In two patients, the first HFS site produced AF which did not terminate 
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spontaneously, therefore no further testing was possible in these patients. In the remaining patients, 
RF ablation was performed in a cluster around the positive site and then further testing was 
performed. 3 of 14 sites were positive on retesting (p < 0.001) (Figure 7.6c). After additional RF 
ablation around the GP site, no further ectopy could be initiated on retesting. In one case, ablation 
at the LUGP site resulted in LUPV isolation, however in all other cases the local PV remained 
connected after the cluster ablation of the GP.  
 
Left atrium to SA node: 
In the 17 patients recruited to assess the neural pathways from the LA to PVs (control group not 
included) who presented in sinus rhythm and were undergoing PVI ± GP ablation, LF and HF HRV 
parameters were calculated at each procedural stage. 
PVI group: In the 8 patients of the PVI group, LF HRV parameters at the start of the procedure and 
after  cryoballoon ablation of each pulmonary vein are shown in the figure below, with a reduction in 
LF seen only after cryoballoon ablation of the RUPV (p<0.001). Similarly, HF HRV parameters were 
also seen to reduce only after RUPV ablation as shown in Figure 7.7 (p<0.001). 
GP ablation group: In the 9 patients undergoing GP ablation LF parameters at the start of the 
procedure and after ablation of each identified GP site are show in figure below, with a reduction in 
LF HRV seen only with ablation at the RUGP compared to ablation at all other GP sites (p=0.02). 
Similarly, HF HRV parameters were also seen to reduce only after RUGP ablation as shown in Figure 
7.8 (p=0.01). 
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Figure 7.7 LF and HF HRV changes with stepwise cryoballoon ablation of each pulmonary vein. 
Significant reduction in both LF and HF HRV parameters are seen only with ablation at the right 
upper pulmonary vein. 
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Figure 7.8 LF and HF HRV parameters measured after ablation of individual left atrial GPs. 
Significant reduction in LF and HF parameters are seen only with ablation of the right upper GP.  
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7.4 Discussion: 
In this study we investigated the feasibility of GP site identification and ablation using cont-HFS. We 
confirmed the presence of a left atrial neural network that has a common entry to the AV node via 
the RLGP. Therefore, if cont-HFS induced bradycardia (AV nodal response) is to be used as a method 
for identifying GP sites for autonomic modulation then the RLGP should be targeted last.  
We subsequently investigated the feasibility of GP site identification and ablation using sync-HFS. In 
patients in sinus rhythm, we have demonstrated that sync-HFS can be used to identify GP sites 
producing PV ectopy and ablation at these sites abolishes the PV response to stimulation. Antral 
cryoballoon ablation also prevents sync-HFS induced PV ectopy, suggesting that neural inputs to the 
PVs are disrupted during PVI. What is not clear, however, is the extent to which this disruption is 
permanent given the high rate of electrical reconnection of pulmonary veins. 
Further evidence for the existence of atrial neural networks in humans is demonstrated in this study 
as ablation at the RUGP alone produces significant reductions in the low frequency and high 
frequency oscillations of HRV, suggesting that the RUGP is the final common neural pathway to the 
SA node. Antral cryoablation at the RUPV also produces significant reductions in heart rate variability 
parameters whereas ablation of all other PVs does not, suggesting that neural inputs from the RUGP 
to the SA node may be transected during RUPV ablation. This implies that heart rate variability 
changes immediately post AF ablation do not reflect the extent of left atrial denervation, but instead 
reflect disruption of neural inputs to the SA node, precluding the use of HRV as an endpoint marker 
of adjunctive autonomic ablation. 
Implication of Neural Networks for adjunctive autonomic ablation: 
Studies performing endocardial GP stimulation and ablation in patients with AF have provided mixed 
evidence regarding the role of adjunctive autonomic ablation. In 2 studies, GP sites identified using 
cont-HFS prior to antral PVI or circumferential pulmonary vein ablation (CPVA), were noted to be 
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almost entirely absent on retesting following ablation.173, 175 Similarly, patients undergoing a redo AF 
procedure underwent cont-HFS testing at presumed GP sites and no patients demonstrated positive 
vagal responses. This led to the conclusion that vagal responses were eliminated by standard antral 
PVI ablation, and that these responses did not recur in patients presenting for repeat PVI, despite 
clinical recurrence of AF.173 Following this, the effect of GP ablation on AF inducibility in humans was 
investigated. Endocardial cont-HFS was used to identified GP sites, with subsequent endocardial and 
epicardial GP ablation performed until no further vagal responses could be elicited. However AF 
remained inducible in 17 out of the 18 patients, from which it was concluded that although vagal 
responses could be abolished via ablation, this did not appear to have a significant effect on the 
ability to induce and maintain AF in the catheter laboratory.176 
The findings of both studies should be interpreted with caution in view of the findings of our study 
demonstrating the interconnecting neural pathways between the left atrial GPs and the AV node.177 
We found that ablation of the right lower GP prevented the AV nodal response to stimulation from 
all other LA GP sites, suggesting that without an intact RLGP other active GPs may not be identified 
using the method of cont-HFS. Neither study reported performing RLGP ablation last in their 
methods, therefore RLGP ablation may have prevented the identification of any remaining active GP 
sites in these studies.  
Our findings may also have implications for outcome studies using cont-HFS to identify GP sites for 
adjunctive autonomic ablation to prevent AF. A comparative study of anatomical vs. selective GP 
ablation (GP sites identified using  cont-HFS in the latter group), found a marked difference in 
outcome favouring anatomically guided GP ablation (77.5% vs. 42.5% patients free from AF at 
approximately 1 year).171 These results suggested that the use of cont-HFS to identify GP sites did 
not improve outcomes over ablation at all presumed anatomical GP sites. It is interesting to note 
that anatomical GP ablation produces similar success rates to that currently quoted for CPVA220, 
which may prompt speculation that ablation of the non-GP areas encompassed by the CPVA may not 
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provide any additional outcome benefit. However, studies performing a direct, randomised 
comparison between the 2 methods would be required to confirm this. The investigators went on to 
demonstrate an improvement in outcome with anatomical GP ablation in addition to PVI vs. PVI 
alone (73.5% vs. 45.5%).178 However, again it is not clear from this study whether PVI provides 
additional benefit over GP ablation alone. 
We propose a functional method, potentially able to identify and ablate culprit GPs, some of which 
may not be at the expected anatomical locations. In our study, we have demonstrated the use of 
sync-HFS to identify connections between the GP and local pulmonary vein which can generate PV 
ectopy, likely to be responsible for AF initiation. We have subsequently demonstrated that ablation 
at these GP sites can prevent ectopy initiation within the local PV, without the need for PV isolation. 
Our study did not find any evidence of ectopic firing within the pulmonary veins following PVI, 
however it may be in this series that antral PV ablation using the large 28mm cryoballoon had 
transected neural inputs to the PVs in addition to ablating the myocardial sleeves. There are, 
however, reports in the literature of ongoing firing within isolated PVs which can be terminated by 
ablation at the presumed local GP sites.239   
Importantly, we found that sites targeted on an anatomical basis, only produced a positive response 
63% of the time using continuous HFS and 33% of the time using synchronized HFS, therefore 
localization and ablation of GP sites by anatomy alone, without functional testing, may result in 
unnecessary ablation. The use of functional testing in areas of the LA not traditionally expected to 
contain GP sites may lead to identification of culprit GPs, potentially producing PV and non-PV 
ectopic triggers responsible for AF initiation. Ablation of all sites initiating ectopy may be a potential 
strategy to prevent paroxysmal AF at the neural trigger and possibly overcome the problem of PV 
reconnection and AF recurrence. 
175 
 
Limitations: 
The method of sync-HFS described in the study is only applicable to patients in normal sinus rhythm, 
and therefore the results of the second part of the study, in which the PV ectopic response to GP 
stimulation was abolished by ablation, can only be applied to patients was paroxysmal AF. It is 
possible that patients with persistent AF may be cardioverted in order to use this method, however, 
we did not attempt this during our study. 
Furthermore the effect of PVI was only studied using the 28mm cryo-balloon in our cohort. This 
result may not necessarily be extrapolated to patients undergoing conventional ostial PV isolation. 
The complication of phrenic nerve injury is seen more frequently with cryo-balloon ablation than 
with conventional ostial RF ablation,141, 220, 240, 241 which may have implications for other neural 
connections on the epicardial surface of the PVs. The effect of conventional ostial PV isolation on GP 
sites initiating PV ectopy remains to be elucidated.  
 
7.5 Conclusion: 
We have demonstrated the atrial neural network of autonomic ganglia in patients undergoing 
ablation, in which the RLGP acts as the final common pathway for neural inputs to the AV node and 
the RUGP acts as the final common input to the SA node. An understanding of atrial neural networks 
is essential if endocardial stimulation is used to identify GP sites for the purpose of adjunctive 
autonomic ablation. 
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8 Conclusions 
Current strategies for catheter ablation of paroxysmal atrial fibrillation aim to achieve electrical 
conduction block between all pulmonary veins and the left atrium. Despite a decade of technological 
advances aimed at achieving permanent pulmonary vein isolation, there remains a significant rate of 
pulmonary vein reconnection. Consistently achieving transmural atrial ablation scar without 
increasing the risk of cardiac perforation or damage to neighbouring extra cardiac structures such as 
the phrenic nerve or oesophagus, remains a significant challenge for novel ablative technologies. 
Lack of robust methods to assess the achievement of permanent circumferential scar is also likely to 
be hindering the development of novel ablative technologies able to address this challenge.   
Novel technologies are usually compared to the conventional approach of PVI using the primary 
outcome measurement of AF freedom without anti-arrhythmic drug therapy. Since all technologies 
target the same immediate procedural endpoint of electrical pulmonary vein isolation as defined by 
loss of pulmonary vein potentials on a duodecapolar circular mapping catheter, it is perhaps not 
surprising that these technologies frequently achieve a similar rate of AF freedom. However, it has 
been noted that there is a high PV electrical reconnection rate even in patients who remain 
symptom-free, which would suggest the lasting isolation of all pulmonary veins may not be a 
necessary endpoint in these patients.123 It may be that ablation near the PVs can reduce ectopic 
triggering despite the return of pulmonary vein conduction. Animal studies have demonstrated that 
the autonomic ganglia adjacent to each pulmonary vein can induce pulmonary vein ectopic firing 
when stimulated. Inadvertent modification of GP sites during catheter ablation of AF may therefore 
reduce ectopic triggering and explain the superior outcomes from wide area circumferential 
pulmonary vein ablation compared to ostial segmental PVI. [2] On the other hand, strategies 
targeting autonomic ganglia alone have so far shown disappointing results. This may be due to a lack 
of transmurality achieved by ablation or may be due to inappropriate clinical endpoints for 
autonomic modification  
177 
 
We addressed the failure of current catheter ablation strategies to achieve permanent pulmonary 
vein isolation by investigating the use of robotically-assisted ablation, which has previously been 
shown to produce more consistently transmural lesions in animals. Without direct knowledge that 
improvements in the current strategy of circumferential pulmonary vein isolation would lead to 
improved clinical outcomes, we opted for a surrogate measure of local electrogram attenuation to 
compare ablation efficacy between current standard manual ablation and the newer robotically-
assisted catheter navigation system. Outcome studies have so far demonstrated equivalent 
outcomes between robotic and manually treated ablation groups. We considered that this may 
reflect the recommended reduction in power settings for robotic ablation and therefore performed 
a comparison of local electrogram attenuation between manual ablation and robotic ablation at 
both standard and increased RF settings.  
Robotically-assisted ablation was designed to improve catheter stability during ablation to achieve 
improved ablation efficacy, therefore we designed our study to assess both catheter stability and 
electrogram attenuation. We were able to demonstrate a correlation between catheter excursion 
during RF delivery and local electrogram attenuation, which would suggest that efforts to improve 
catheter stability should lead to greater local electrogram attenuation. We went on to demonstrate 
that the robotic catheter did in fact achieve a greater stability during ablation compared to the 
manual catheter. We would therefore expect to see a greater electrogram attenuation with robotic 
ablation when compared to manual. However this was not seen in the robotic group with reduced 
RF duration and power, and was only achieved in the robotic group with RF duration the same as the 
manual group, despite the radiofrequency power cut off remaining lower than that of the manual 
group. From this we could conclude that whilst robotic ablation does confer additional catheter 
stability over manual ablation, the improvement in ablation efficacy is lost if both the power and 
duration of RF energy is reduced.  Our study only compared 60sec lesion duration between manual 
and robotic modalities, but it is feasible that robotic lesions of 30Watts and 30secs may have similar 
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ablation efficacy as 25Watts and 60secs. Further studies would be required to confirm this and may 
be clinically useful in an effort to reduce fluoroscopy and procedure times for AF ablation.  
In a subgroup analysis, we found that general anaesthesia at the time of the procedure also conveys 
additional benefits of catheter stability with concomitant increases electrogram attenuation. These 
findings are in keeping with other evidence in the literature that manual AF ablation procedures 
performed using a steerable sheath for additional stability, are more successful than those without. 
However, both robotic ablation and procedures under GA have been shown to result in greater risk 
of oesophageal ulceration. 128, 135 
Therefore, the ongoing challenge for improving the efficacy of radiofrequency ablation lesions is to 
produce consistently transmural lesions without increasing the risk of perforation or injury to extra-
cardiac structures. Histological evidence for the efficacy of current ablative techniques to produce 
permanent, transmural atrial scar is generally limited to post-mortem and animal studies. Ostial PV 
biopsies taken during surgical Cox-maze procedures from patients who had previous endocardial 
PVI, demonstrated full thickness myocardial scar in only 50% of biopsies. The other 50% had either 
partial thickness or fully viable myocardium or both, and were more frequently associated with 
electrically reconnected PVs, suggesting that anatomic gaps or non-transmural lesions following 
catheter ablation were likely to be the cause of pulmonary vein reconnection.117 A non-invasive 
method for visualising atrial scar formation post-ablation would allow a direct assessment of current 
ablation techniques and their efficacy in creating durable, circumferential pulmonary vein scar. Such 
an assessment may facilitate improvements in ablation techniques and potentially provide insights 
into the mechanisms of AF recurrence.  
LGE-MRI is a well established tool for identifying and quantifying post-infarction ventricular scar, and 
as scanning quality and resolution improves there is significant potential to apply this technique to 
the atrium. Significant imaging challenges include the thin walled left atrium, cardiac and respiratory 
motion and long scanning times required particularly for patients with irregular heart rates and 
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unpredictable breathing patterns. Furthermore, current methods to allow 3D visualisation and 
quantification of atrial enhancement on LGE-MRI are highly operator dependent, many requiring 
operator selection of “normal” and “abnormal” myocardium in order to determine the 
enhancement level that denotes atrial scar.  In order to assess the feasibility of LGE-MRI to 
objectively determine the presence of atrial scar we developed an automated method for identifying 
regions of atrial enhancement on LGE-MRI to remove the potential for operator bias. We tested our 
method on pre and post ablation LGE-MRIs of patients undergoing Cryoballoon ablation, as this 
technique would deliver a predictable lesion set. Quantitative comparison of pre and post ablation 
atrial enhancement, on the same patient anatomy, demonstrated a significant increase in amount 
(surface area) of atrial scar (enhancement >3SD above the blood pool mean intensity) in the PV ostia 
compared to the rest of the left atrium. To validate our method, a subgroup of patients with and 
without prior LA ablation underwent endocardial voltage mapping for correlation with co-localised 
enhancement levels. A significant association was identified between voltage and normalised 
intensity for levels of enhancement 3SD or more above the blood pool mean intensity, with 
increasing levels of enhancement reflecting significantly lower endocardial voltages. LGE-MRI 
therefore has the potential for non-invasive evaluation of ablation related atrial scar, and may 
facilitate improvements in ablative technologies striving to achieve durable pulmonary vein 
isolation. 
A significant association was also noted between patient clinical characteristics and pre-ablation 
atrial enhancement. CHADS2 score was used as a composite measure of stroke risk, and we found 
that surface area identified as scar (>3SD above blood pool mean) was significantly greater in 
patients with high stroke risk compared to low. In addition, we found that the quantity of pre-
ablation scar was greater in patients with AF recurrence vs. no recurrence following ablation and 
was the only predictor of freedom from AF in this PAF population with relatively normal LA size. This 
finding needs to be tested in a larger patient population, however LGE-MRI appears to have the 
potential to identify pre-existing atrial scar or fibrosis which may help select appropriate patients for 
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PVI and lead to further improvements in procedural success rates. Alternatively, LGE-MRI may 
identify patients who require additional ablation targeting atrial substrate rather than simply 
preventing the AF trigger.  
However, if the ablation target and endpoints for ablation are suboptimal, then improving ablation 
efficacy may have no effect on procedural outcome. The current literature suggests that durable 
pulmonary vein isolation is achieved in approximately 90% of patients undergoing laser balloon 
ablation. However there remains a 60% recurrence rate of atrial fibrillation in these patients. We 
have performed LGE CMR and atrial scar mapping in a single patient undergoing pulmonary vein 
isolation with the laser balloon and the result would suggest that the laser balloon produces a more 
ostial lesion set than either the cryoballoon or wide area circumferential RF ablation. Although only 
demonstrated in a single patient, our results, coupled with the current clinical outcomes for laser 
balloon ablation, raise the hypothesis that additional arrhythmogenic substrate may be present in 
the antral regions of the pulmonary veins which is important for AF maintenance. Furthermore, 
these results suggest that clinical endpoints in addition to PVI need to be identified  if outcomes 
from AF ablation are to be improved.  
There is mounting evidence that the autonomic nervous system located in the antral regions 
adjacent to each pulmonary vein may contribute to the arrhythmogenic substrate in human atrial 
fibrillation, with studies demonstrating its role in both the initiating trigger and generation of the 
susceptible atrial substrate sustaining paroxysms of AF. We demonstrated using a parasympathetic 
blocking agent that endocardial stimulation of GP sites produces a reduction in the local PV cycle 
length (CL) via a vagally mediated mechanism. The reduction in AFCL can also be seen in distant 
areas of the atrium, suggesting parasympathetic activation may facilitate the maintenance of 
paroxysms of AF. 
Human studies in which the ANS has been targeted for ablation have, however, produced 
disappointing clinical results so far. Potential limitations in current strategies for GP identification 
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and endpoints for GP ablation may be responsible for these results. We have demonstrated that an 
interconnecting GP network is present in humans, similar to that described by Hou et al in dogs.  This 
implies that the strategy of GP identification through a bradycardic AV nodal effect, when combined 
with GP ablation, may not identify all GP sites unless the RLGP is ablated last. Furthermore, we found 
that heart rate variability (a measure of autonomic modulation of the sinus node) reduces following 
AF ablation but only following ablation of the RUGP, confirming that the RUGP acts as the final 
common input to the sino-atrial node in humans. This finding precludes the use of HRV as an 
endpoint marker for adjunctive autonomic ablation as changes are only reflective of ablation at the 
RUGP site. We confirmed this by demonstrating that there were no significant differences in HRV 
reduction following AF ablation in patients who had AF freedom or AF recurrence at 12 months post 
ablation. 
Finally, we investigated the feasibility of using synchronized HFS as a method of identifying GP sites 
that initiate ectopic activity within the pulmonary veins and assessed the response to both PVI and 
local RF ablation at the GP site. We demonstrated the acute loss of the stimulated PV ectopic activity 
following cryoballoon PVI suggesting that PVI may transect the neural inputs to the pulmonary vein. 
We went on to demonstrate that localised RF ablation applied at GP sites initiating PV ectopic 
activity also abolished the response to GP stimulation, suggesting that ablation at the neural trigger 
may be sufficient to prevent episodes of PAF initiated by ectopic activity.  It is not clear therefore 
why recurrent paroxysms of AF occur despite the apparent transection of all neural inputs to the PV 
following PVI in our study. There have been reports of ongoing neural connections to the PV despite 
PVI, which have been successfully abolished following ablation at the nearby GP site. It may be that 
autonomic nerves retain the ability to re-innervate the pulmonary vein given the finding that heart 
rate variability parameters invariably return to pre-ablation levels of following AF ablation. 
Furthermore one may speculate that ablation at the GP site itself may be more likely to prevent re-
growth compared to more distal ablation, as this is often the case in axonal injuries to the rest of the 
body. More importantly, however, the strategy of targeting the neuronal trigger for AF removes the 
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need for extensive empirical ablation targeting all 4 pulmonary veins, many of which may not be 
responsible for AF paroxysms. Efforts can then be focused on improve transmurality and ablation 
efficacy without causing unnecessary damage to surrounding left atrial structures.   
However, GP ablation may also have potential unwanted side-effects. There is one case report in the 
literature of a patient treated with endocardial and epicardial vagal denervation for the treatment of 
PAF who represented with symptoms of gastroparesis. Gastric hypomotility was later confirmed on 
CT and gastric emptying scintigraphy. The patient’s symptoms were however transient and he made 
a complete recovery. 242 A potentially more serious unwanted effect of GP ablation is an alteration in 
ventricular electrophysiology. Despite the inability to perform a standard assessment of ventricular 
refractoriness using extra-stimulus pacing due to AF, unpublished data by our group suggests that 
vagal activation from cont-HFS at a GP site both decreases the APD90-RR interval slope recorded 
from the base of the left ventricular and increases the nAPD90 recorded from the base of the left 
ventricle. 
Furthermore, as previously mentioned, significant reductions in heart rate variability are noted 
following AF ablation, which appear to return to baseline at 6 months.167 Several published series in 
patients with myocardial infarction suggest that reduced heart rate variability post infarction is a 
poor prognostic indicator in terms of mortality.243 Whilst this has only anecdotal links to HRV 
reduction after AF ablation, further studies are required to elucidate the mechanism via which heart 
rate variability is reduced in either setting. The mechanism by which it leads to an increased 
mortality following myocardial infarction is not well defined, however further investigations into the 
effect of atrial autonomic modification on ventricular electrophysiology are clearly required.  If the 
use of autonomic modification were to become widespread then the prevalence of unwanted side 
effects as listed above should be carefully monitored. 
In conclusion, improvements in ablation efficacy and the achievement of consistent transmurality, 
combined with specific targeting of the neural trigger for AF using appropriate neuro-
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electrophysiological endpoints, may potentially improve the success rates of catheter ablation for 
paroxysmal AF. Patient selection using pre-procedural LGE-MRI may enable identification of patients 
requiring ablation of the ectopic trigger alone, allowing alternative therapeutic strategies to be 
employed in patients with a more advanced underlying atrial substrate. 
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Limitations 
The use of signal amplitude reduction measurement as a marker of ablation efficacy has several 
limitations due to problems of combined local and far field signals. Catheter movement can produce 
both an increase and decrease in signal amplitude, and loss of local electrogram occurs with both 
effective ablation and poor tissue contact. Effective ablation causing local tissue oedema may also 
lead to catheter movement and an increase in local electrogram voltage. Our methods do not enable 
us to differentiate between causes for local electrogram increase and catheter displacement. Our 
method for stability measurement is limited since it only measures the distance between the start 
and finish catheter locations. However, these limitations affect both manual and robotic ablation 
modalities equally. This was a pilot study only and not designed to power for clinical outcomes. 
Despite the our development of an automated method of LGE-MRI analysis which requires minimal 
operator input, our study was not performed in a blinded fashion which limits the conclusions that 
can be drawn. Furthermore, it should be noted that the method of LGE-MRI scanning of the left 
atrium has yet to be validated in animals or in a large number of normal human subjects. Whilst 
there is some data pertaining to the low level of LGE identified in normal human control subjects, 
this is from a single centre only and has yet to be replicated in multiple centres.  
During voltage mapping, experienced operators considered each data point to represent good 
myocardial contact, however we were unable to confirm contact during all voltage measurements. 
This could lead to erroneous recordings of low voltage when in fact the myocardium at that location 
may be healthy. Future studies using pressure-sensing catheters will be more accurate in comparing 
voltage and atrial LGE. Acknowledging the limited spatial resolution of LGE CMR, we elected to 
assign enhancement levels based on the highest signal intensity on a cord at right angles to the atrial 
wall, with no attempt to differentiate transmural and partial thickness LGE.  
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The manual selection of regions of interest around the pulmonary vein ostia used to calculate ostial 
scar adds an element of subjectivity to our methods. However, the identical region is used to 
compare pre and post ablation scans, which limits the influence of the selection on the results. 
 A degree of spatial error is inherent in the process of registering a gated MRA sequence and a non-
gated, free-breathing LGE sequence. Similarly a degree of registration error is present when 
registering the MRA sequence with the gated electroanatomic map collected during the AF ablation 
procedure. However, despite these limitations these methods represent a technique which may be 
readily implementable in most hospitals and provide objective, reproducible data on which further 
developments in the field can be based. 
The method of sync-HFS described in the study is only applicable to patients in normal sinus rhythm, 
and therefore the results of the second part of the study, in which the PV ectopic response to GP 
stimulation was abolished by ablation, can only be applied to patients was paroxysmal AF. It is 
possible that patients with persistent AF may be cardioverted in order to use this method, however, 
we did not attempt this during our study. 
Furthermore the effect of PVI was only studied using the 28mm cryo-balloon in our cohort. This 
result may not necessarily be extrapolated to patients undergoing conventional ostial PV isolation. 
The complication of phrenic nerve injury is seen more frequently with cryo-balloon ablation than 
with conventional ostial RF ablation,141, 220, 240, 241 which may have implications for other neural 
connections on the epicardial surface of the PVs. The effect of conventional ostial PV isolation on GP 
sites initiating PV ectopy remains to be elucidated.  
Our definition of autonomic activation following Cont-HFS relies on AV block with 
(max RR/pre RR interval) > 1.5. However, we recognize that there is likely to be a continuous 
spectrum of responses to GP activation, which may be independent from the observed effect on the 
AV node. This would be in keeping with our observation in which there was a reduction in PV AFCL 
even in the absence of defined vagal response. 
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Patients undergoing DC cardioversion for persistent AF did not demonstrate any significant change 
in HRV parameters in the 150minutes following cardioversion. We were unable to assess whether 
cardioversion resulted in a significant change in HRV from baseline since these patients were in AF 
prior to the cardioversion. Furthermore, it was not possible to study the effects of cardioversion 
intraprocedurally on paroxysmal AF patients undergoing ablation as this would prolong the total 
procedure duration beyond an acceptable time.  
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